text
stringlengths 65
123k
| url
stringlengths 25
420
| crawl_date
timestamp[us, tz=UTC]date 2022-04-01 01:00:57
2022-09-19 04:34:04
|
|---|---|---|
Law reduced prison time for man tied to Sacramento shooting
SACRAMENTO, Calif. (AP) — A suspect arrested in connection with last weekend’s mass shooting outside bars in Sacramento served less than half his 10-year sentence because of voter-approved changes to state law that lessened the punishment for his felony convictions and provided a chance for earlier release.
Smiley Allen Martin was freed in February after serving time for punching a girlfriend, dragging her from her home by her hair and whipping her with a belt, according to court and prison records.
Those count as nonviolent offenses under California law, which considers only about two dozen crimes to be violent felonies — such as murder, rape, arson and kidnapping.
Martin, 27, was arrested Tuesday on suspicion of possession of a firearm by a prohibited person and possession of a machine gun. He is among the 12 people wounded during Sunday’s shooting, which killed six others.
Police have said the violence was a shootout between rival gangs in which at least five people fired weapons, including Martin’s brother, Dandrae Martin, who also was arrested. No one has yet been charged with homicide in the shooting.
Smiley Martin typically would have remained behind bars until at least May after serving a minimum of half his time for his previous arrest in 2017, but prison officials evidently used a very expansive approach to applying lockup time credits to his sentence, said Gregory Totten, chief executive officer of the California District Attorneys Association and a former Ventura County district attorney.
“They’ve been given very broad authority to early release folks and to give them additional credit and all kinds of considerations for purposes of reducing the length of sentence that somebody serves,” Totten said.
Corrections officials did not dispute that Martin was among thousands of inmates who received additional credits that sped up their releases under state law. But the officials said their policy prohibits disclosing what prison time credits Martin received.
They cited credits through Proposition 57, the 2016 ballot measure that aimed to give most of the state’s felons a chance of earlier release. Credits were also broadly authorized in California to lower the prison population during the pandemic.
Proposition 57 credits include good behavior while behind bars, though corrections officials declined to release Martin’s disciplinary report. Good conduct credit is supposed to be reserved for inmates who follow all the rules and complete their assigned duties.
The state “has implemented various credit-earning opportunities to incentivize good behavior and program participation for incarcerated individuals, including those created in furtherance of Proposition 57— which was overwhelmingly approved by voters,” state corrections spokesperson Vicky Waters said in a statement.
Supporters of the credits, including former Gov. Jerry Brown, who pushed for Proposition 57, have said it’s important to give inmates a second chance. The opportunity for earlier release encourages inmates to participate in education and other rehabilitative programs and helps to reduce mass incarceration.
“The most recent reforms in California are seeking to change a culture that has been churning out recidivism problems for generations,” said Will Matthews, spokesperson for the Californians for Safety and Justice group, which backed the changes. “The question we need to be asking ourselves is, how are we engaging in behavior change?”
Under Proposition 57, credits are granted for completing rehabilitative or educational programs, self-help and volunteer public service activities, earning a high school diploma or higher education degree and performing a heroic act. Officials added credits during the coronavirus pandemic, including 12 weeks of credit that applied to most inmates.
Martin was denied parole in May 2021 under California’s process for nonviolent offenders to get earlier parole, after a letter was sent from the Sacramento County District Attorney’s Office. Prosecutors said they objected to his parole based on his lengthy criminal record and asserted that Martin “clearly has little regard for human life and the law.”
Six months after he turned 18, Martin was caught in January 2013 with an assault rifle and two fully loaded 25-bullet magazines, prosecutors said. Months later, he pushed aside a Walmart clerk to steal computers worth $2,800, they said. In 2016, he was arrested as a parolee at large. And less than six months after that was the assault that sent him back to prison.
It’s not clear if Martin has an attorney who can comment on his behalf.
Martin pleaded no contest and was sent to prison on charges of corporal injury and assault likely to cause great bodily injury in January 2018 under a plea deal in which prosecutors dismissed charges of kidnapping — considered a violent felony — and intimidating a witness or victim.
The sentencing judge awarded Martin 508 days of credits for time he spent in Sacramento County jail before his conviction, based on a California law that allows judges to double the actual time in jail, which in Martin’s case was 254 days.
Martin also had “a variety of additional post-sentencing credits,” which corrections department spokesperson Dana Simas said were awarded for time served while awaiting transfer to state prison from county jail.
Before Proposition 57, he would have qualified for 20% “good time” credits — meaning he could reduce his time served by one-fifth — but corrections officials used their authority under the ballot measure to bump those to 50%. Pending regulations opposed by most of the state’s district attorneys would further increase good time credits to two-thirds of a sentence for such repeat offenders.
Sacramento Mayor Darrell Steinberg, a progressive Democrat who formerly led the state Senate, was among those upset when he learned of Martin’s record.
“If people have a history of committing violent acts, and they have not shown a propensity or willingness to change, I don’t think they should be out on the streets,” he said at an event where officials requested more than $3 billion from the state to expand crime prevention programs.
Republican state Sen. Jim Nielsen, who once headed the state parole board, said “good time” credits are generally awarded automatically, without inmates having to do anything to earn them.
“It gives them enormous opportunity to free up beds,” said Nielsen, an opponent of earlier releases.
The state has relied on such efforts, particularly its powers under Proposition 57, to keep the prison population below the level required by a panel of federal judges who ruled that inmate crowding had led to unconstitutionally poor conditions.
Martin was released to the supervision of the Sacramento County Probation Department in February. County probation officials wouldn’t provide the terms, saying their records are not public documents.
Without discussing Martin’s case, Karen Pank, executive director of the Chief Probation Officers of California association, said generally someone coming out of prison under the state’s Post Release Community Supervision program with an extensive and violent criminal history would likely have been treated on a “high-risk” caseload.
That would subject the person to more intensive supervision, including a requirement to check in with a probation officer more frequently and in person, although individualized determinations on risks and needs would be made and treatment and services would continue to be offered.
Hours before Sunday’s shootout, Martin posted a live Facebook video of himself brandishing a handgun, a law enforcement officials told The Associated Press. The official was not authorized to public discuss details of the shooting investigation and spoke on condition of anonymity.
Pank said if there is evidence of a felon in possession of a firearm, that can be grounds for a violation, which may result in time in jail. However, it’s unlikely anyone from law enforcement could have acted in time even if they had seen the video.
“The big if is would they have known about it,” said Totten. But in this case, “it didn’t matter — it was so close to the time” of the shooting.
___
Associated Press writers Adam Beam, Stefanie Dazio and Michael Balsamo contributed to this story. Dazio reported from Los Angeles and Balsamo from Washington, D.C.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/04/08/mass-shooting-suspect-served-less-time-due-california-law/
| 2022-04-08T18:50:48Z
|
North America to experience total solar eclipse on April 8, 2024
Published: Apr. 8, 2022 at 11:38 AM EDT|Updated: 3 hours ago
(Gray News) - A total solar eclipse will cross North America two years from today on April 8, 2024.
With a total solar eclipse, the moon passes between the sun and the Earth, completely blocking the face of the sun.
NASA says 13 U.S. states will be within the path of totality: Texas, Oklahoma, Arkansas, Missouri, Illinois, Kentucky, Indiana, Ohio, Pennsylvania, New York, Vermont, New Hampshire and Maine. Parts of Mexico and Canada will also be within the path of totality.
For exact times on when the eclipse will occur in each area, visit NASA’s website.
Copyright 2022 Gray Media Group, Inc. All rights reserved.
|
https://www.whsv.com/2022/04/08/north-america-experience-total-solar-eclipse-april-8-2024/
| 2022-04-08T18:50:55Z
|
Officials find 6 human skulls in shipment at Chicago airport
Published: Apr. 8, 2022 at 1:29 PM EDT|Updated: 1 hour ago
CHICAGO (CNN) – U.S. Customs and Border Protection agents working at the Chicago O’Hare International Airport discovered human skulls in a shipment at the end of March.
In total, agents found six skulls that were shipped from the Netherlands and headed to Iowa. Three separate packages sent from the same person were seized, each containing two skulls.
The shipments were inspected after X-rays showed anomalies.
The skulls were sent to the Centers for Disease Control and Prevention for further evaluation.
Officials are investigating the incident but did not provide further details.
Copyright 2022 CNN Newsource. All rights reserved.
|
https://www.whsv.com/2022/04/08/officials-find-6-human-skulls-shipment-chicago-airport/
| 2022-04-08T18:51:01Z
|
Price of stamps to increase starting in July
Published: Apr. 8, 2022 at 12:38 PM EDT|Updated: 2 hours ago
(Gray News) - The cost of stamps will be increasing in July.
According to the U.S. Postal Service, a first-class mail Forever stamp will cost 60 cents, a 2-cent increase from its current price of 58 cents.
Other mailing services will also cost more, including:
- Letters (metered 1 ounce) will cost 57 cents, up from 53 cents.
- Letters additional ounce(s) will cost 24 cents, up from 20 cents.
- Domestic postcards will cost 44 cents, up from 40 cents.
- International letters will cost $1.40, up from $1.30.
The proposed increases are scheduled to take effect July 10. The Postal Regulatory Commission will review and approve the prices before they take effect.
The U.S. Postal Service says the increased prices are a result of inflation and increased operating expenses.
Copyright 2022 Gray Media Group, Inc. All rights reserved.
|
https://www.whsv.com/2022/04/08/price-stamps-increase-starting-july/
| 2022-04-08T18:51:08Z
|
Proud Boys member pleads guilty to conspiracy in Jan. 6 riot
WASHINGTON (AP) — A North Carolina man on Friday became the second member of the extremist group Proud Boys to plead guilty to conspiring with other group members to stop Congress from formally certifying Joe Biden’s 2020 election victory.
Charles Donohoe, 34, pleaded guilty during an appearance in federal court in Washington to charges of conspiracy to obstruct an official proceeding and assaulting or impeding federal officers. His plea agreement includes a provision to cooperate in the ongoing Justice Department cases against other Proud Boys members.
Federal sentencing guidelines call for a prison term of about six to seven years, although terms of his sentence will be up to a federal judge.
The indictment against Donohoe and other members of extremist groups, such as the Proud Boys and Oath Keepers, have been a focus of the Justice Department’s sprawling investigation of the Jan. 6, 2021 insurrection. Donohoe — who had been president of a local Proud Boys chapter in North Carolina — has close ties to the group’s leader, Enrique Tarrio.
More than three dozen people charged in the Capitol siege have been identified by federal authorities as Proud Boys leaders, members or associates.
Tarrio pleaded not guilty this week to charges that he remotely led a plot to stop Congress’ certification of Biden’s 2020 victory in the presidential election. Though he wasn’t at the Capitol during the Jan. 6 riot, prosecutors say Tarrio organized encrypted chats with Proud Boys members in the weeks before the attack, had a 42-second phone call with another member of the group in the building during the insurrection and took credit for the chaos at the Capitol.
A New York man, Matthew Greene, became the first Proud Boys member to plead guilty to conspiracy in December. He agreed to cooperate with authorities as part of a plea agreement.
On the morning of Jan. 6, Proud Boys members met at the Washington Monument and marched to the Capitol before President Donald Trump finished addressing thousands of supporters near the White House.
Around two hours later, just before Congress convened a joint session to certify the election results, a group of Proud Boys followed a crowd of people who breached barriers at a pedestrian entrance to the Capitol grounds, according to one of the indictments. Several Proud Boys also entered the Capitol itself after the mob smashed windows and forced open doors, the indictment says.
Since Jan. 6, 2021, more than 775 people have been arrested in nearly all 50 states for crimes related to the breach of the U.S. Capitol, officials said.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/04/08/proud-boys-member-pleads-guilty-conspiracy-jan-6-riot/
| 2022-04-08T18:51:15Z
|
Death row inmate asks S.C. judges to halt firing squad or electrocution
COLUMBIA, S.C. (AP) — A South Carolina inmate set to die either by a firing squad or in the electric chair later this month is asking the state Supreme Court to halt his execution.
Lawyers for 57-year-old Richard Moore say he shouldn’t face execution until judges can determine if either method is cruel and unusual punishment. Moore is set to die on April 29 unless a court steps in.
He has until next Friday to choose between the South Carolina’s electric chair, which has been used twice in the past 30 years, or being shot by three volunteers who are prison workers in rules the state finalized last month.
South Carolina corrections officials finished updating the death chamber to prepare for executions by firing squad.
Moore has spent more than two decades on death row after he was convicted of killing convenience store clerk James Mahoney in Spartanburg.
Moore could face a choice between the electric chair and the firing squad, two options available to death row prisoners after legislators altered the state’s capital punishment law last year in an effort to work around a decade-long pause in executions, attributed to the corrections agency’s inability to procure lethal injection drugs.
The new law made the electric chair the state’s primary means of execution while giving prisoners the option of choosing death by firing squad or lethal injection, if those methods are available.
The state corrections agency said last month it had finished developing protocols for firing squad executions and completed $53,600 in renovations on the death chamber in Columbia, installing a metal chair with restraints that faces a wall with a rectangular opening 15 feet (4.6 meters) away.
In the case of a firing squad execution, three volunteer shooters — all Corrections Department employees — will have rifles loaded with live ammunition, with their weapons trained on the inmate’s heart. A hood will be placed over the head of the inmate, who will be given the opportunity to make a last statement.
South Carolina is one of eight states to still use the electric chair and one of four to allow a firing squad, according to the Washington-based nonprofit Death Penalty Information Center.
Moore is one of 35 men on South Carolina’s death row. He exhausted his federal appeals in 2020, and the state Supreme Court denied another appeal this week.
Lindsey Vann, an attorney for Moore, said Thursday she will ask the court to stay the execution.
The state last scheduled an execution for Moore in 2020, which was then delayed after prison officials said they couldn’t obtain lethal injection drugs.
During Moore’s 2001 trial, prosecutors said Moore entered the store looking for money to support his cocaine habit and got into a dispute with Mahoney, who drew a pistol that Moore wrestled away from him.
Mahoney pulled a second gun, and a gunfight ensued. Mahoney shot Moore in the arm, and Moore shot Mahoney in the chest. Prosecutors said Moore left a trail of blood through the store as he looked for cash, stepping twice over Mahoney.
At the time, Moore claimed that he acted in self-defense after Mahoney drew the first gun.
Moore’s supporters have argued his crime doesn’t rise to the level of heinousness in other death penalty cases in the state. His appeals lawyers have said that because Moore didn’t bring a gun into store, he couldn’t have intended to kill someone when he walked in.
South Carolina’s last execution was in 2011, when Jeffrey Motts, on death row for strangling a cellmate while serving a life sentence for another murder, abandoned his appeals and opted for the death chamber.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/04/08/s-carolina-schedules-1st-execution-with-firing-squad-ready/
| 2022-04-08T18:51:26Z
|
S.C. man who livestreamed sexual assaults against toddler receives prison sentence
BLUFFTON, S.C. (WCSC/Gray News) - A 33-year-old man has received a decades-long prison sentence for the production of child pornography.
WCSC reports David James Allison of Bluffton, South Carolina, was sentenced to 30 years in prison and a lifetime term of court-ordered supervision on Friday by U.S. District Judge Bruce Howe Hendricks.
The Beaufort County Sheriff’s Office responded to a call in January 2020 after a family member of a 22-month-old child accused Allison of sexually assaulting the toddler.
Authorities said Allison admitted to deputies that he assaulted the victim approximately five times between September and December 2019 and livestreamed the assaults over Skype.
Investigators said the Skype communications were tied to an IP address of a 52-year-old man from Littlehampton, West Sussex, United Kingdom. Sussex police said Andrew McPherson-Young admitted to directing Allison and watching the assaults on Skype.
The Department of Justice said McPherson-Young is currently being prosecuted in the United Kingdom.
The South Carolina 14th Circuit Solicitor’s Office said Allison was sentenced by both state and federal courts, and he will serve his sentences concurrently in federal prison.
Copyright 2022 Gray Media Group, Inc. All rights reserved.
|
https://www.whsv.com/2022/04/08/sc-man-who-livestreamed-sexual-assaults-against-toddler-receives-prison-sentence/
| 2022-04-08T18:51:36Z
|
Trans kids, parents fight wave of legislation in red states
MONTGOMERY, Ala. (AP) — Ninth grader Harleigh Walker, 15, spends her time after school like many girls her age: doing homework, listening to Taylor Swift, collecting records and hanging out with friends.
But this year, her spring break also included trying to persuade members of the state House and Senate to reject legislation banning gender-affirming medications for transgender kids like her under 19. She was unsuccessful. On Thursday, Alabama lawmakers passed the measure. If Gov. Kay Ivey signs it into law, Harleigh will no longer be able to take testosterone-blocking drugs.
“Honestly, I’m a little scared now,” she said Thursday after learning the bill had passed. “But we’re still going to fight no matter what.”
Harleigh said she is holding out hope the governor will veto the bill or it will be blocked by a court. Ivey has not indicated whether she plans to sign it.
Alabama is among multiple states with Republican-controlled legislatures that have advanced bills not only to block medical treatment but to ban transgender children from using school restrooms or playing on sports teams that don’t correspond with their sex at birth. The Alabama medication bill is one of the most far-reaching: It would put doctors in prison for up to 10 years for prescribing puberty blockers or hormonal treatment to trans kids under 19.
Conservative lawmakers say the measures are needed to protect children and parental rights.
“We regulate all kinds of things that are harmful for minors — alcohol, cigarette smoke, vaping, tattoos — because their minds aren’t ready to make those decisions about things that can affect them long term,” said Rep. Wes Allen, the sponsor of the House version of the Alabama legislation. Allen cited public hearing testimony from a woman who said she regretted taking hormone therapy to try to transition to being male.
“With these powerful medications that have detrimental effects on their body long term, we just want to put a pause on it ... give them a chance to develop and grow out of that,” Allen said.
But opponents say transgender health is being used as a deliberate political wedge issue to motivate a voting base — in the same way they say bills about critical race theory have been employed. Critical race theory is a way of thinking about America’s history through the lens of racism. Numerous Republican-controlled legislatures have proposed bills to block its teaching in public schools.
The measures involving trans youth have prompted swift backlash from medical experts, Democratic President Joe Biden’s administration, the U.S. Department of Justice and the families of trans youth. Last month, the Justice department sent a letter to all 50 state attorneys general, warning them that blocking transgender and nonbinary youth from receiving gender-affirming care could be an infringement of federal constitutional protections.
“My child is not a political tool. This is not a fair fight to pick on vulnerable children,” said Vanessa Finney Tate, the mother of a 13-year-old trans boy in Birmingham, Alabama, after testifying at a public legislative hearing on bill that would block students from using bathrooms corresponding to their gender.
Harleigh’s father, Jeff Walker notes that many of the same Alabama lawmakers who supported the ban on gender-affirming medical treatment recently argued, ‘It’s your body and your choice’ regarding coronavirus vaccinations. He said the family is now scrambling to find another state where it can continue Harleigh’s medical care.
“We just don’t want people meddling in our medical care,” he said.
Medical groups including The American Academy of Pediatrics have publicly opposed efforts to outlaw gender-affirming care.
“Gender-affirming care benefits the health and psychological functioning of transgender and gender-diverse youth,” the Endocrine Society said in a statement. “When an individual’s gender identity is not respected and they cannot access medical care, it can result in higher psychological problem scores and can raise the person’s risk of committing suicide or other acts of self-harm.”
The organization notes that only reversible puberty blockers are recommended for younger adolescents, while older adolescents might qualify for hormone therapy.
Harleigh received the medication — which stops her from going through male puberty — only after consulting with a team of doctors for years. She said it’s “weird” to see lawmakers with no medical experience call her medication “child abuse,” when six doctors have agreed she should have it.
Angus, a 16-year-old trans teen who requested that his last name not be used because of the bullying he has received in his north Alabama town, said he knew at puberty that the mirror reflected “a body that wasn’t my own.”
After coming out to his mother, he began slowly testing the waters: dressing as a man, changing his name. Only after years of talking to a team of doctors, was he able to recently get medications to stop his periods. The next step, which he is eager to start, would be a small dose of testosterone.
“I have been waiting for seven years to finally become a man, the man that I’ve always known I am,” Angus said.
He said bills to block such treatments are harming, not protecting trans youth.
“The government is saying, ‘Oh, parents are abusing their children by letting them transition,’” he said. “Actually, it’s more child abuse to not let them transition if they come out. What these bills really are doing is putting trans youth lives at risk because these suicide rates will spike exponentially. And a lot of families will lose their children.”
Similar bans are moving forward in other states.
In Texas, Republican Gov. Greg Abbott has ordered the state’s child welfare agency to investigate as abuse reports of gender-confirming care for kids. And a law in Arkansas bans gender-affirming medications. That law has been blocked by a court, however.
Trans youth in many red states say they feel attacked, angry, betrayed and scared by the wave of legislation aimed at them.
“It feels like a back-stab,” Harleigh said. “I’ve lived in this state my whole life. For them to just say, ‘Well, you know what, this is an issue that’s really popular on my side of the aisle so I’m just going to raise it up and support it because it’ll help me win my election’ — It just hurts to see them do that.”
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/04/08/trans-kids-parents-fight-wave-legislation-red-states/
| 2022-04-08T18:51:42Z
|
Warner and Kaine announce $232 million in federal funding for Virginia transit
HARRISONBURG, Va. (WHSV) - U.S. Sens. Mark R. Warner and Tim Kaine (both D-VA) announced the designation of $232,426,060 in federal funds for Virginia transit systems.
This largest-ever investment in Virginia transit was authorized by the Infrastructure Investments and Jobs Act, negotiated by Sen. Warner and supported by Sen. Kaine.
The funding will be awarded through the U.S. Department of Transportation’s Federal Transit Administration formula programs and distributed to transit systems throughout the Commonwealth.
“Thanks to the bipartisan infrastructure law, Virginia continues to receive funding for much-needed transportation upgrades,” the senators said. “This investment in the Commonwealth’s public transit will make lives easier for every Virginian who relies on public transportation while creating good-paying jobs for workers.”
Because of this record investment in transit, Virginia is set to receive a 28.7 percent increase in funds over last year’s total apportionment.
Much of this funding will be distributed not by locality, county, or city, but by “Census-designated Urbanized Area” (UZA). UZAs are urban community clusters that often include urban centers and surrounding areas. Maps of all UZAs are available here.
The Harrisonburg area is expected to receive $3,038,232. The Staunton-Waynesboro area is expected to receive $1,028,479.
Areas that are more rural will still receive funding, but that funding will be awarded directly to Virginia to be allocated, at the discretion of the state.
In addition to the $232 million guaranteed for Virginia, the Commonwealth is expected to receive a portion of the $280,270,139 in funding designated to the D.C. Metro Area, which includes Northern Virginia, D.C., and Maryland. This funding will be divided across transit agencies and localities within the area.
Copyright 2022 WHSV. All rights reserved.
|
https://www.whsv.com/2022/04/08/warner-kaine-announce-232-million-federal-funding-virginia-transit/
| 2022-04-08T18:51:53Z
|
NEW YORK, April 8, 2022 /PRNewswire/ -- 5WPR, one of the largest independently-owned PR firms in the U.S., is pleased to announce their work for client Carparts.com has been chosen as a finalist in the 2022 SABRE North America Awards within the E-Commerce consumer goods category.
CarParts.com offers an e-commerce platform that is changing the way drivers shop for auto parts. To reinforce the brand's position and establish executive leadership as visionary innovators within the industry, 5W Public Relations launched an all-encompassing strategy focused on establishing the company CEO and CFO as thought leaders while simultaneously building brand awareness among business media and retail investors.
"Within an overcrowded e-commerce space, our technology team has continually engaged national media and drawn unprecedented attention to our client's business," said 5WPR CEO, Matthew Caiola. "We appreciate working with partners who trust us to tell their story and even expand into new channels, like the social app Clubhouse, to pioneer a new strategy to reach retail investors and consumers in the digital age."
The 2022 North American SABRE Awards includes around 350 campaigns on its shortlist, selected from among more than 2,000 entries. The campaigns were evaluated by a jury of industry leaders.
Winners will be unveiled at the North American SABRE Awards ceremony on Wednesday, May 4, in New York City.
5W Public Relations is a full-service PR agency in NYC known for cutting-edge programs that engage with businesses, issues and ideas. With more than 250 professionals serving clients in B2C (Beauty & Fashion, Consumer Brands, Entertainment, Food & Beverage, Health & Wellness, Travel & Hospitality, Technology, Nonprofit), B2B (Corporate Communications and Reputation Management), Public Affairs, Crisis Communications and Digital Marketing (Social Media, Influencer, Paid Media, SEO). 5W was awarded 2020 PR Agency of The Year and brings leading businesses a resourceful, bold and results-driven approach to communication.
Media Contact
Matthew Caiola
mcaiola@5wpr.com / 212.999.5585
View original content to download multimedia:
SOURCE 5W Public Relations
|
https://www.whsv.com/prnewswire/2022/04/08/5wpr-named-finalist-e-commerce-campaign-2022-sabre-awards/
| 2022-04-08T18:51:59Z
|
The complete cannabis growing system took home two awards from Spannabis, Europe's premier cannabis event.
BARCELONA, Spain, April 8, 2022 /PRNewswire/ -- Advanced Nutrients, the global leader in cannabis nutrients, was voted the Best Cannabis Nutrient Brand 2022 from the growers at Grow Diaries, a popular cannabis cultivation website. Big Bud®, their No.1-selling product, was named the Best Nutrients 2022 by Spannabis.
Both awards speak to the fertilizer company's commitment to science and innovation; they're responsible for more than 53 cultivation breakthroughs, and were one of the first three entities in the world to receive a government-issued license to grow cannabis for research purposes. Today, growers in 110+ countries rely on Advanced Nutrients to cultivate clean, safe, potent cannabis that succeeds in even the most saturated marketplaces.
"When I founded Advanced Nutrients in 1999, I was determined to develop cannabis-specific, science-backed products that growers in our community could trust," says CEO Michael 'BigMike' Straumietis. "Twenty-three years later, I'm proud to say this vision has come to fruition tenfold. Innovating the best nutrients possible for every type of grower remains our top priority, and I'm excited for what we've got planned over the next several years."
In addition to the awards, Advanced Nutrients debuted their latest innovation at Spannabis; the Sensi Professional Series. Designed for commercial growers, it's the only water-soluble powder that Hits the Shift, meeting the phase-specific nutritional requirements of cannabis to unlock its true genetic potential.
About Advanced Nutrients
Founded by Michael "BigMike" Straumietis, Advanced Nutrients is widely regarded as one of the world's most influential nutrient brands. In 1999, the company revolutionized the industry by developing the first and only complete growing system for cannabis that optimizes all phases of the vegetative and bloom cycles to bring the plant to its true genetic potential. With 39 years of experience overseeing the cultivation of millions of plants, BigMike has brought 53 innovations to cannabis science. For additional information, please visit: www.advancednutrients.com
View original content to download multimedia:
SOURCE Advanced Nutrients
|
https://www.whsv.com/prnewswire/2022/04/08/advanced-nutrients-named-best-cannabis-nutrient-brand-2022/
| 2022-04-08T18:52:07Z
|
Amerant furthers its commitment to Houston's economy and long-term growth
HOUSTON, April 8, 2022 /PRNewswire/ -- Amerant Bank, with a presence in South Florida and Houston, TX, announced today that Francisco Rivero, Texas Market President, has been appointed to the Greater Houston Partnership Board of Directors. Rivero's appointment furthers Amerant's dedication to serving the greater Houston community and the businesses it relies on.
Founded in 1840, The Greater Houston Partnership is a gathering place for community-minded business leaders who want to be involved in Houston's economic growth. Alongside other members of the Board, Rivero will work to address Houston's unique challenges and champion the growth and success of the city.
"We are pleased that Francisco has become a member of the Greater Houston Partnership's Board of Directors," said Jerry Plush, Vice Chairman, President & CEO of Amerant. "The Houston market is a key area of focus for Amerant, and we believe that, by working together with the Greater Houston Partnership, we can add value to the Houston economy."
As EVP Houston Market President, Rivero is responsible for leading and managing Amerant's Houston team as well as developing Amerant's footprint in Texas. He has been with the bank for over 20 years.
"Houston is one of the greatest, most diverse cities in the United States, and I am honored to serve on the Partnership's board among some of the most esteemed business leaders in the region," said Rivero. "I look forward to representing Amerant in Houston and making the city one of the best places to live, work and do business."
About Amerant Bank
Amerant Bank is one of the largest community banks headquartered in Florida, with 17 banking centers in South Florida and 7 in Houston, TX. The bank has been serving clients for over 40 years, both domestically and abroad, and comprises subsidiaries Amerant Investments and Amerant Mortgage. Rooted in the communities it serves, Amerant Bank supports numerous non-profit, charitable and arts organizations. For news and updates, visit the Amerant Newsroom.
About Greater Houston Partnership
The Greater Houston Partnership works to make Houston one of the best places to live, work and build a business. As the economic development organization for the region, the Partnership champions growth across 12 counties by bringing together business and civic-minded leaders who are dedicated to the area's long-term success. Representing more than 900 member organizations and approximately one-fifth of the region's workforce, the Partnership is the place companies come together to make an impact. Learn more at Houston.org.
Media Contacts:
Victoria Verdeja
Amerant Bank
mediarelations@amerantbank.com
View original content to download multimedia:
SOURCE Amerant Bank
|
https://www.whsv.com/prnewswire/2022/04/08/amerant-banks-francisco-rivero-joins-greater-houston-partnership-board-directors/
| 2022-04-08T18:52:15Z
|
-- ACLX-002 completely regresses multiple cell line and patient-derived AML xenografts --
-- Company plans to initiate ACLX-002 Phase 1 clinical trial in AML/MDS in 2H'22 --
FOSTER CITY, Calif., April 8, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the presentation of preclinical data utilizing its novel ARC-SparX platform for ACLX-002, a CD123-targeted universal CAR-T cell therapy for relapsed or refractory Acute Myelogenous Leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The data show that ACLX-002 completely regressed disseminated MOLM14 and MV4-11 tumors in a schedule and dose-dependent manner without the aid of alloreactivity and performs similarly to a traditional CD123-targeting D-domain based CAR. Additionally, ACLX-002 completely regresses multiple cell line and patient-derived AML xenografts.
"There are limited treatment options for AML and MDS patients as heterogeneity is known to be a major challenge for targeted therapeutics in this patient population," said Rami Elghandour, Arcellx's chairman and chief executive officer. "Our ARC-SparX platform is designed to allow for controllability and adaptability, to potentially reduce toxicities that are often associated with serious dose-limiting adverse events and to overcome tumor heterogeneity. These ACLX-002 preclinical data provide the scientific rationale to move forward with initiating a Phase 1 clinical trial and our ambition to deliver a meaningful treatment option for these patients. We look forward to starting this study in the second half of this year."
The data are being presented at the American Association of Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022. Presentation details are as follows:
The poster can be accessed through the AACR Annual Meeting program or the company's corporate website www.arcellx.com/pipeline-focus-area/#scientific-publications
About the ARC-SparX Platform Technology
The ARC-SparX platform is designed to allow for controllability and adaptability, to potentially reduce toxicities that are often associated with serious dose-limiting adverse events and to overcome tumor heterogeneity. It is a modular therapy which utilizes a universal ARC-T cell combined with an off the shelf SparX protein to separate the tumor-recognition and tumor-killing functions. SparX (soluble protein antigen-receptor X-linkers) proteins utilize our D-Domain technology engineered to recognize antigens on the surface of diseased cells and flags those cells for detection by the ARC-T (Antigen Receptor Complex-T) cells. ARC-T cells express a D-Domain-based CAR engineered to specifically recognize a unique TAG in the SparX protein. ARC-T cells are dosed separately and only activated to kill the target cell when they encounter a SparX protein bound to the target antigen thus are controlled through SparX dose modulation. Arcellx has developed a collection of SparX proteins that bind different antigens on the surface of diseased cells. Multiple SparX proteins with different antigen specificity can be administered to potentially address antigen heterogeneity or antigen escape that contribute to relapsed and refractory disease.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Visit www.arcellx.com for more information.
Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing of clinical trials for its product candidates. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part I, Item 1A (Risk Factors) of Arcellx's Annual Report on Form 10-K and in other reports, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, that Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor and Media Contact:
Myesha Lacy
Arcellx, Inc.
ir@arcellx.com
View original content:
SOURCE Arcellx, Inc
|
https://www.whsv.com/prnewswire/2022/04/08/arcellx-presents-pre-clinical-data-aclx-002-novel-cd123-targeted-universal-car-t-cell-therapy-relapsed-or-refractory-acute-myeloid-leukemia-american-association-cancer-research-annual-meeting/
| 2022-04-08T18:52:21Z
|
Leading Provider of Tax-Advantaged Savings and Related Services Will Serve More Than 15 million Savers with Expanded Technology, Solutions, and Expertise
DRESHER, Pa., April 8, 2022 /PRNewswire/ -- Ascensus—whose technology and expertise help millions of people save for retirement, education, and healthcare—and Newport, the Walnut Creek, California-based retirement services provider—announced today that the two companies have closed their previously announced merger, the first step in their journey together as a combined organization.
The union combines the capabilities and talents of two market leaders in tax-advantaged savings and related services, serving more than 15 million savers and overseeing more than $745 billion in assets under administration as of December 31, 2021. Together, the unified company employs more than 5,400 employees across the U.S.
David Musto, president and chief executive officer of Ascensus, will serve as CEO of the combined company. Laura Ramanis, who has served as interim CEO of Newport since the announcement of the transaction last fall, and Kurt Laning, executive vice president of Newport Non-Qualified and Insurance Solutions, will join the Ascensus executive leadership team, reporting to Musto.
"With today's announcement, Ascensus and Newport have taken an important step in our journey towards a stronger, unified company," said Musto. "Clients across our lines of business will benefit from our expanded capabilities—accelerated investments in technology, data analytics, and user experiences—and broadened expertise. And both Ascensus and Newport associates can look forward to new opportunities for personal growth and enhanced career development."
"Ascensus and Newport share a passion for helping people save for their futures and supporting the growth and success of our partners," said Ramanis. "We look forward to continuing that mission as a combined company."
With industry-leading qualified and non-qualified retirement plan services, corporate and bank-owned life insurance (COLI and BOLI) practices, fiduciary and trust solutions, and other total rewards capabilities, Newport expands the services and expertise Ascensus provides to its clients and advisor partners. Newport's clients will benefit from greater access to unique tax-advantaged savings solutions across retirement, education, and health provided by Ascensus. The combined company's investments in technology, digital capabilities, and analytics will deliver enhanced value to clients, expand client relationships, and create even better outcomes for savers.
Both the Ascensus and Newport brands remain in use at closing, with the Ascensus brand representing the unified company.
"Our goal over the next several months is the successful unification of our company—built on the principle of 'best of the best' and our shared cultural attributes, and executed with the interests, quality, and stability of our client relationships foremost in mind," added Musto. "As a unified organization, Ascensus and Newport share a strong commitment to serving our clients and offering more—across the tax-advantaged retirement, education, and health savings expertise for which Ascensus is known, and capitalizing on Newport's well-established qualified and non-qualified retirement services, and fiduciary and COLI/BOLI capabilities as well."
Evercore acted as exclusive financial advisor to Newport in connection with the transaction.
Goldman Sachs Bank USA, SPC Financing Company LLC, and KKR Capital Markets LLC led the financing consortium.
Simpson Thacher & Bartlett LLP acted as transactional counsel to Ascensus and Kirkland & Ellis LLP acted as financing counsel to Ascensus. Morgan Lewis & Bockius LLP acted as legal counsel to Newport.
Ascensus helps millions of people save for what matters—retirement, education, and healthcare. Through co-branded, private-labeled, and other governmental partnerships, our technology, market insights, and business knowledge enhance the growth and success of our partners, their clients, and savers. Ascensus is a leading recordkeeping services provider, third-party administrator, and government savings facilitator in the United States. For more information, visit ascensus.com.
Headquartered in Walnut Creek, California, Newport is a leading retirement services provider that helps employers—and the advisors who serve them—prepare employees for a more financially secure retirement. The company has more than $150 billion in retirement assets under administration and more than $300 billion in corporate retirement and insurance assets. Newport maintains investment objectivity, fee transparency and a commitment to flexible, responsive service. Staffed by an exceptional team of nearly 1,500 retirement, insurance, and consulting professionals, the company provides retirement solutions tailored to the needs of employers of every size, from small businesses to the Fortune 1000. Visit newportgroup.com.
View original content to download multimedia:
SOURCE Ascensus
|
https://www.whsv.com/prnewswire/2022/04/08/ascensus-closes-newport-merger-agreement/
| 2022-04-08T18:52:28Z
|
PRINCETON, N.J., April 8, 2022 /PRNewswire/ -- Multi-millionaire Princeton landlord, Jack Morrison, has filed papers to evict his tenant, Princeton Professor Arno J. Mayer, from Morrison's "Witherspoon House", a rental building in the heart of downtown Princeton, New Jersey.
Princeton Professor Emeritus Arno J. Mayer is a world-renowned historian and World War II hero.
Professor Mayer is also a beloved member of the Princeton community and Princeton University faculty. Professor Mayer's official biography at Princeton University describes Professor Mayer as "a legendary teacher and mentor of students throughout his long career at Princeton…He has earned the respect and affection of undergraduates, graduate students, and colleagues in and outside the Department of History."1
Professor Mayer is also a World War II veteran and war hero. After escaping just two hours ahead of Nazi troops that invaded his native Luxembourg on May 10, 1940, Professor Mayer and his parents and grandparents made a two-year journey to the United States, fleeing across Europe and North Africa.
As soon as Professor Mayer was of age, he joined the U.S. Army where he was trained at Fort Dix, New Jersey and Fort Knox, Kentucky.
Because of his high IQ and fluency in German, Professor Mayer was recruited to join an elite unit of U.S. Army military intelligence that ran a top- secret, highly classified military installation not far from the Pentagon known only as: "Post Office Box 1142." At that facility, Professor Mayer helped guard and interrogate America's highest value Nazi war prisoners, including the Nazis' top rocket scientists. Professor Mayer was personally charged with guarding Wernher von Braun, the leading Nazi rocket scientist.
A Netflix documentary on Professor Mayer's wartime service was recently released titled: "Camp Confidential: América's Secret Nazis."2 The documentary was shortlisted for an Academy award. It shows how the intelligence gathered by Professor Mayer and his fellow intelligence officers led to the American Air Force bombing Peenemunde: the secret Nazi rocket facility that launched attacks on thousands of troops and civilians throughout Europe. The intelligence gathered by Professor Mayer and his colleagues saved thousands of lives.
Professor Mayer has filed a class action lawsuit on behalf of all the tenants of Witherspoon House asking for monetary damages and injunctive relief for the unlawful living conditions in Morrison's building. A copy of Professor Mayer filed complaint is available to the press upon request.
The complaint details:
- There is an ongoing rodent infestation in Witherspoon House.
- Morrison pled guilty in 2019 to violating Princeton's noise ordinance by bringing jackhammers inside Witherspoon House that were the same decibel level as commercial airliners.
- Elderly tenants in Witherspoon House were evacuated over a dozen times because of fire code violations in Morrison's restaurant kitchen, located in Witherspoon House.
- The building had a defective intercom and telephone system that made it extremely difficult for Professor Mayer's health aides to communicate and care for him.
- Morrison did not follow Covid procedures and safeguards in Witherspoon House and refused Covid relief to his tenants, including Professor Mayer.
Professor Mayer's legal defense is being coordinated by his son, Carl J. Mayer, Esq. Carl Mayer served as an elected member of the Princeton Township Committee and runs the Mayer Law Group LLC, a class action law firm that represents, consumers, senior citizens and workers. Carl Mayer has been profiled on Sixty Minutes for his public interest legal work.3
1 See Professor Mayer's full official Princeton University biography:https://dof.princeton.edu/about/clerk-faculty/emeritus/arno-j-mayer
2 https://decider.com/2021/11/03/camp-confidential-netflix-review/
3 https://en.wikipedia.org/wiki/Carl_J._Mayer
View original content:
SOURCE Carl Mayer
|
https://www.whsv.com/prnewswire/2022/04/08/attorney-carl-mayer-challenges-multi-millionaire-landlord-jack-morrison-attempts-evict-95-year-old-disabled-princeton-university-professor-world-war-ii-hero-holocaust-survivor/
| 2022-04-08T18:52:35Z
|
WASHINGTON, April 8, 2022 /PRNewswire/ -- Four private astronauts are in orbit following the successful launch of Axiom Mission 1 (Ax-1), the first all private astronaut mission to the International Space Station. Axiom Space astronauts lifted off at 11:17 a.m. EDT on Friday, April 8, from Launch Complex 39A at NASA's Kennedy Space Center in Florida.
A SpaceX Falcon 9 rocket propelled the Dragon Endeavour spacecraft carrying Ax-1 crew members Michael López-Alegría, Larry Connor, Mark Pathy, and Eytan Stibbe into orbit. The crew will spend more than a week conducting scientific research, outreach, and commercial activities on the space station.
"What a historic launch! Thank you to the dedicated teams at NASA who have worked tirelessly to make this mission a reality," NASA Administrator Bill Nelson said. "NASA's partnership with industry through the commercial cargo and crew programs has led our nation to this new era in human spaceflight — one with limitless potential. Congratulations to Axiom, SpaceX, and the Axiom-1 crew for making this first private mission to the International Space Station a reality."
Beginning at 5:30 a.m. on Saturday, April 9, NASA will provide live coverage of the Endeavour docking, hatch opening, and a ceremony to welcome the crew. The events will run on NASA Television, the NASA app, and the agency's website.
Endeavor will autonomously dock to the space-facing port of the station's Harmony module around 7:45 a.m. The welcome ceremony is expected to start shortly after the Dragon hatch opens at about 9:30 a.m. Saturday. Live mission coverage will end with the conclusion of the ceremony. The mission also will be covered by Axiom on its website.
"I first want to congratulate Michael, Larry, Eytan, and Mark," said Michael Suffredini, president and CEO of Axiom Space. "We will usher in a new era in private human spaceflight when they cross the threshold to enter the International Space Station. This journey is the culmination of long hours of training, planning, and dedication from the crew and the entire Axiom Space team, our partners at SpaceX, and of course, a credit to NASA's vision to develop a sustainable presence in low-Earth orbit."
Once aboard the station, the Axiom crew will be welcomed by Expedition 67 crew members, including NASA astronauts Thomas Marshburn, Raja Chari, and Kayla Barron, ESA (European Space Agency) astronaut Matthias Maurer, and Roscosmos cosmonauts Oleg Artemyev, Sergey Korsokov, and Denis Matveev.
Axiom Space astronauts are expected to spend about 10 days in orbit before a return to Earth and splashdown at one of seven landing sites off the coast of Florida. NASA and Axiom will release separate advisories to preview the Ax-1 farewell event and return coverage.
Learn more about how NASA is supporting a space economy in low-Earth orbit:
https://www.nasa.gov/leo-economy
View original content to download multimedia:
SOURCE NASA
|
https://www.whsv.com/prnewswire/2022/04/08/axiom-private-astronauts-headed-international-space-station/
| 2022-04-08T18:52:41Z
|
From Fade to Finish, the New Bevel Pro All-in-One Clipper + Trimmer Tool with Bevel Power Fade™ Gap Control, Bevel Pivot Lock™ Magnetic Guards, and Bevel Dial™ LED Display Is A Cut Above the Rest
ATLANTA, April 8, 2022 /PRNewswire/ -- The pioneering men's grooming brand Bevel is changing the industry yet again. Following the success of the Bevel Trimmer, the world's most advanced trimmer, comes the all-new Bevel Pro All-in-One Clipper + Trimmer, an all-in-one tool designed for both the professional barber and home consumer alike. Designed with feedback from everyday hair enthusiasts and barbers, the Bevel Pro is packed with technologically advanced features such as the world's first leverless electronic gap adjustment and Pivot Lock Magnetic Guards, making it a first of its kind, essential tool for the best cut ever.
Walker & Company – makers of Bevel – CEO and Founder Tristan Walker shared, "Eight years ago, I launched Bevel to deliver first-class solutions to the grooming needs of Black men. Year after year, with every product drop - from our very first Shave Kit to our groundbreaking Hair & Beard Trimmer and beyond - we've done that. Today, with the new Bevel Pro All-in-One Clipper + Trimmer, we're raising the bar again. The Bevel Pro was built for you (barbers, amateurs, and every one that cuts their own hair) and we're bringing the full power of the Clipper and the Trimmer, combined with cutting-edge technology & features, into a single device. We've built on our award-winning foundation and took it to the max: leverless electronic gap adjustments, LED display, double the battery life of the competition, and guards that snap & hold no matter the cut. I'm tremendously proud of the work that we've done and can't wait for everyone to get their hands on the Bevel Pro."
What Makes The Bevel Pro All-In-One Clipper + Trimmer Different
The Bevel Pro is packed with industry-leading, professional grade features required by master barbers as well as the home consumer.
Technological Advancements
- Bevel Power Fade™ Gap Control – First of its kind technology allows you leverless control with electronic gap adjustments at the touch of a button. Close the gap on the blade every time with precise, repeatable results.
- Bevel Dial™ LED Display: All-new LED Display delivers precise gap adjustments from 0.0-2.5mm at 0.1mm increments. A blue battery indicator ring lets you know how much juice is left so you're never caught off guard.
- Bevel Pivot Lock™ Magnetic Guards: Powerful patented design enables guards to snap on with magnets and securely stay on for the duration of your cut. Security, ease, and retention at the convenience of the click. Traditional spring clip guards are a thing of the past. Out the box, the Bevel Pro comes with five guards (#0, #1, #2, #3, and #4), with a #5-8 large guard set sold separately.
- Bevel Snap Lock™ Modular Blades (Tool-Free): Easily go from clipper to trimmer by simply snapping on/off the included black graphite-coated clipper and trimmer blades. Never any tools required.
Unsurpassed Quality
- Industry-Leading Battery Life: A single charge delivers up to 4+ hours of consistent, cordless power. That's twice the power of the competition
- Graphite Coated Stainless Steel Blades: This powerful combination delivers blades that reduce friction, repel buildup, and prolong blade life. Keeping your blades cooler and sharper longer. Every Bevel Pro comes with a Trimmer (square) Blade and a Clipper (fade) Blade.
- 360 Degrees of Non-Slip Handling: Features a 360o non-slip, soft touch grip for superior control and comfort.
- Ease of Use: Advanced user interface makes this tool perfect for right-handed, left handed and ambidextrous users. No matter which hand you use, from fade to finish, you'll get the best cut with the Bevel Pro.
Unparalleled Precision
- No Tools Required: No screwdriver or hardware needed. Snap your Clipper (fade) or Trimmer (square) blade to the Bevel Pro and use the Power Fade™ gap control buttons to dial in your preferred gap setting. With the Bevel Dial™ LED Display, you'll get precise 0.1mm readouts and always know where you stand.
- Fully Guarded: The Bevel Pro All-in-One Clipper + Trimmer come with some of the most requested guards: #0 (1/16in), #1 (1/8in), #2 (1/4in), #3 (3/8in), and #4 (1/2in) for precision cuts. An additional set with guards #5-8 will be available later this spring for purchase at getbevel.com, for $24.95.
Integral to Bevel's design process is working with/liaising with the Bevel barber community. From the beginning of development, every piece/feature of the Bevel Pro was tested by Master Barber's Marcus Harvey (@themarcusharvey) and Lauren Owens (@laurenthelegend) and used on a cross-section of their clients and hair textures.
Marcus Harvey, Celebrity Barber & Owner of The Musa Lair Gallery & Barbershop (Atlanta), "I used to need two tools (a clipper and a trimmer) to create a haircut, but with the Bevel Pro, I only need one tool. The Bevel Pro is perfect for everyone, whether you're a first-time barber learning to be quicker, more efficient, and more effective to cut more heads and make more money, or you are lining yourself or your kid up at home."
Lauren Owens, Celebrity Barber & Owner of Legends Only Barbershop (Atlanta), "The LED display and Power Fade Gap Control are my favorite things about the Bevel Pro. It makes it so I can go from a 0mm to a 2.5mm with a quick glance and a touch of a button. No more levers. I know exactly where I'm at every time.
The Bevel Pro All-in-One Clipper + Trimmer will officially launch on April 8th 2022 for $329.00 on www.getbevel.com
For more information on Bevel visit getbevel.com or follow Bevel on Instagram.
Contact: bevel@firstandlastpr.com
View original content to download multimedia:
SOURCE Bevel
|
https://www.whsv.com/prnewswire/2022/04/08/bevel-is-changing-game-again-with-patented-precision-technology-exclusively-available-new-bevel-pro-all-in-one-clipper-trimmer/
| 2022-04-08T18:52:49Z
|
Premiere sports and luxury brand executive will craft partnership strategy for world's leading crypto platform
MIAMI, April 8, 2022 /PRNewswire/ -- Blockchain.com, the world's most popular way to buy, sell, and trade cryptocurrency, today announced that it has joined forces with Marissa Brooks, founder of 4WRD, to craft an innovative sports and entertainment partnership strategy. Brooks will be responsible for creating high impact, groundbreaking relationships with teams, leagues, athletes, entertainers, and other personalities to support the crypto platform's global growth.
A unique boutique collective in Miami, 4WRD lives primarily at the intersection of sports and luxury. The company focuses on brand partnerships and events for leading luxury brands and clientele, most recently producing the Blockchain.com Miami Padel Open. 4WRD also counts Boich Investment Group, Australian Artist Tyson Beck, and a number of luxury brands, as clients.
"As the Blockchain.com brand expands globally, we're excited to work with a premiere sports and luxury marketer like Marissa," said Peter Smith, Blockchain.com CEO and Co-Founder. "Her expertise crafting disruptive brand moments will help us develop stand-out partnerships globally. Marissa will help us bring partnerships to life in a big way as we continue to build the future of finance."
Brooks began her career with the NBA's Miami Heat where she managed corporate partnerships for a decade. She oversaw the team's largest sponsors including luxury watch brand, Hublot, which served as the Swiss brand's entry into North America.
She later joined the LVMH-owned Hublot in Switzerland leading their robust global sponsorship and events platform, where she led the first one-off licensing and luxury watch deal in the NBA. She has worked in over 16 countries around the world, skillfully marrying local cultures and customs with brand objectives. Brooks has negotiated and activated partnerships with Manchester United, Paris Saint-Germain, Formula 1, FIFA and UEFA as well as ambassadors including Usain Bolt, Kobe Bryant, and Pelé, to name a few. Following Hublot, Brooks was CMO/Americas of the Longines Masters, moving the prestigious indoor equestrian competition from Los Angeles to New York.
Marissa resides in Miami where she will join Blockchain.com's fast-growing team.
About Blockchain.com
Blockchain.com is connecting the world to the future of finance. The London and Miami-based company, with an international team spread across the world, is the most trusted and fastest growing crypto company, helping millions across the globe safely access cryptocurrency. Venture backed since 2014, Blockchain.com is valued at $14 billion. Visit Blockchain.com for more info, follow us on Twitter @blockchain, check out The Blockchain.com Podcast, and read our blog for the latest company news.
Contact:
Brooks Wallace
Head of Communications
brooks@blockchain.com
View original content to download multimedia:
SOURCE Blockchain.com
|
https://www.whsv.com/prnewswire/2022/04/08/blockchaincom-hires-marissa-brooks-lead-global-sports-entertainment-partnerships/
| 2022-04-08T18:52:56Z
|
-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden --
-- Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose escalation --
-- Initiating SYMPHONY trial cohort to evaluate BLU-945 in combination with osimertinib --
-- Clinical trial supply agreement signed with AstraZeneca to provide osimertinib for combination development in ongoing BLU-945 and BLU-701 trials --
-- Blueprint Medicines to host investor conference call and webcast on Friday, April 8 at 2:00 pm ET --
CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced proof-of-concept data from the Phase 1/2 SYMPHONY clinical trial of BLU-945, an investigational precision therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC). The trial results showed early evidence of safety and clinical activity consistent with preclinical data, supporting plans to expand development of BLU-945 in combination with multiple agents including osimertinib, with the goal of preventing or treating tumor resistance to prolong patient benefit. The data were reported today at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans.
Early data from the ongoing Phase 1 dose escalation part of the SYMPHONY trial showed dose-dependent decreases in circulating tumor DNA (EGFR variant allele fractions) and radiographic tumor reductions, including a partial response (PR) in a patient treated with 400 mg once daily (QD), the highest dose tested as of the data cutoff date. Pharmacokinetic results showed BLU-945 exposures at higher doses were associated with broad EGFR mutation coverage, including the activating L858R mutation with or without the osimertinib-resistant C797S mutation. BLU-945 was generally well-tolerated, with no significant adverse events (AEs) associated with wild-type EGFR inhibition. The maximum tolerated dose and recommended Phase 2 dose have not yet been identified, and dose escalation is continuing.
"Today, targeted therapies are the mainstay treatment for EGFR-mutant lung cancer, but tumor resistance emerges in the majority of patients, driving mutational heterogeneity and disease progression. Innovative treatment strategies, including targeted therapy combinations, are urgently needed to prevent or treat this mutational heterogeneity and prolong patient benefit," said Elaine Shum, M.D., assistant professor in the Department of Medicine and a medical oncologist at NYU Langone Health's Perlmutter Cancer Center, and an investigator on the SYMPHONY trial. "The initial BLU-945 data reported today, which highlight its potential to address resistance to current standard of care therapies including osimertinib and enable well-tolerated, broad-acting combinations, are an important step forward toward improving outcomes for patients with EGFR-mutant lung cancer."
"We believe BLU-945 is distinguished from other EGFR-directed therapies, based on its ability to inhibit the most difficult-to-target EGFR mutations while maintaining a wide therapeutic index over wild-type EGFR, a known driver of toxicity. As a result, BLU-945 has significant potential as a combination partner with other targeted therapies and broad-acting agents," said Fouad Namouni, M.D., President, Research & Development at Blueprint Medicines. "We are excited to see the preclinical profile of BLU-945 translated in the clinic, with early dose escalation data showing evidence of clinical activity, broad EGFR mutation coverage and tolerability. Based on these promising data, we plan to rapidly expand development of BLU-945 in combination with osimertinib and other agents to address important medical needs across all lines of therapy."
Blueprint Medicines is initiating a SYMPHONY trial cohort assessing BLU-945 in combination with osimertinib in patients with second-line or later EGFR-mutant NSCLC, following disease progression on osimertinib. After the selection of a recommended Phase 2 combination dose regimen, the company plans to initiate an expansion cohort with registration potential in biomarker-selected second-line patients, as well as an expansion cohort in front-line patients, by the end of 2022. Additional combinations with BLU-701, chemotherapy and antibody-drug conjugate therapy are planned across multiple mutation profiles and lines of therapy.
In addition, Blueprint Medicines announced today a clinical trial supply agreement with AstraZeneca (LSE/STO/Nasdaq: AZN). Under the terms of the agreement, Blueprint Medicines will evaluate BLU-945 and BLU-701 in combination with osimertinib in the ongoing SYMPHONY and HARMONY trials, respectively.
BLU-945: Data from the Phase 1/2 SYMPHONY Trial
As of a data cutoff date of March 9, 2022, 33 patients with EGFR-mutant NSCLC have been treated with BLU-945 across five dose escalation cohorts (range: 25-400 mg QD). The majority of patients (79 percent) previously received at least three lines of systemic therapy, including osimertinib (97 percent). Patient eligibility criteria require the presence of an EGFR mutation based on local assessment of tumor biopsy or circulating tumor DNA (ctDNA).
BLU-945 was generally well-tolerated at all doses tested. The most common AEs (regardless of relationship to BLU-945; ≥10 percent) were nausea, headache, fatigue, cough, dyspnea, vomiting, hyponatremia, dry mouth and anemia. Reported AEs associated with wild-type EGFR inhibition were infrequent and low grade, including rash (one patient; Grade 1) and diarrhea (three patients; all Grade 1). One dose-limiting toxicity (Grade 3 transaminitis) occurred in the 400 mg QD cohort, which improved with dose interruption. There were no treatment discontinuations due to AEs.
Pharmacokinetic data showed dose-proportional plasma concentrations, with exposures at increasing doses consistent with broad EGFR mutation coverage, based on preclinical activity thresholds. Mean plasma exposures at doses of 100 mg QD or higher exceeded the IC90 for mutants harboring the T790M and C797S resistance mutations, regardless of activating mutation. In addition, mean plasma exposure at 400 mg QD exceeded the IC90 for mutants harboring the activating L858R mutation with or without the C797S mutation.
The SYMPHONY trial is one of the first oncology studies to analyze plasma ctDNA via real-time next-generation sequencing to assess tumor biology and early drug activity. Results for patients with detectable T790M and C797S allele fractions at baseline and available post-baseline assessments showed dose-dependent reductions in both variant allele fractions. In patients treated with 400 mg QD, all detectable T790M and C797S allele fractions declined, including three that fell below the limit of detection (clearance).
Patients with measurable target lesions at baseline and at least one post-baseline scan were evaluable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. In a heavily pre-treated population, higher BLU-945 doses led to increased antitumor activity. Tumor shrinkage was observed in patients treated with 200-400 mg QD, including an unconfirmed PR1 in a patient treated with 400 mg QD. This patient had NSCLC harboring exon 19 deletion, T790M and C797S mutations, and previously received platinum-based chemotherapy, erlotinib and osimertinib with a best response of stable disease.
Copies of Blueprint Medicines data presentations from the AACR annual meeting, including the SYMPHONY trial presentation, are available in the "Science--Publications and Presentations" section of the company's website at www.blueprintmedicines.com.
Investor Conference Call Information
Blueprint Medicines will host a live webcast today, April 8, 2022 beginning at 2:00 p.m. ET, to discuss the data reported at AACR. To access the live call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to conference ID 084402. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines' Clinical Development Programs in EGFR-Mutant NSCLC
Blueprint Medicines is developing three investigational agents, BLU-701, BLU-945 and BLU-451, with the goal of addressing nearly all activating mutations (>90 percent) in EGFR-mutant NSCLC. The introduction of EGFR-targeted therapies, including osimertinib, has transformed the care of patients with EGFR-mutant NSCLC; however, there is a significant need for new treatment options designed to prevent or treat a broad range of resistance mechanisms before they emerge, with the goal of prolonging patient benefit. There are no approved targeted therapies for patients with disease progression following osimertinib, and limited treatment options for patients with EGFR exon 20 insertion-positive NSCLC.
BLU-701 and BLU-945 were designed to provide broad coverage of common activating and on-target resistance mutations, spare wild-type EGFR and other kinases to help limit off-target toxicities, and prevent or treat central nervous system (CNS) metastases. These preclinical profiles may enable BLU-701 and BLU-945 to become the backbones of a range of combination strategies across lines of therapy. The Phase 1/2 SYMPHONY trial (NCT04862780) of BLU-945 and the Phase 1/2 HARMONY trial (NCT05153408) of BLU-701 are currently ongoing for patients with EGFR-mutant NSCLC.
BLU-451 is a selective and potent inhibitor of EGFR exon 20 insertion-positive NSCLC. Based on preclinical data, BLU-451 potently inhibited all common EGFR exon 20 insertion variants with marked selectivity over wild-type EGFR and off-target kinases, and has shown CNS penetration. Blueprint Medicines has initiated a Phase 1/2 trial of BLU-451 (NCT05241873) in EGFR exon 20 insertion-positive NSCLC.
To learn about ongoing or planned clinical trials, contact Blueprint Medicines at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768). Additional information is available at blueprintclinicaltrials.com or clinicaltrials.gov.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' plans, strategies, timelines and expectations for clinical trials, trial cohorts and indications; the anticipated benefits of the preclinical profiles of BLU-945, BLU-701 and BLU-451; Blueprint Medicines' plans, strategies and timelines for the development of BLU-945 and BLU-701 as monotherapies and in combination with other agents; the potential benefits of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plans in establishing a commercial infrastructure, and successfully launching, marketing and selling current or future approved products, including AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib); Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT and GAVRETO or obtain marketing and reimbursement approvals for AYVAKIT and GAVRETO in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing applications; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for its current and future drug candidates; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines' ability to realize the anticipated benefits of its executive leadership transition plan; and the success of Blueprint Medicines' current and future acquisitions, collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
Trademarks
Blueprint Medicines, AYVAKIT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.
1 An unconfirmed PR is a PR in which tumor reduction ≥30% has occurred, but has not yet been confirmed via a subsequent scan.
View original content to download multimedia:
SOURCE Blueprint Medicines Corporation
|
https://www.whsv.com/prnewswire/2022/04/08/blueprint-medicines-announces-blu-945-proof-of-concept-data-supporting-initiation-comprehensive-combination-development-strategy-egfr-mutant-non-small-cell-lung-cancer/
| 2022-04-08T18:53:02Z
|
- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer models
- Onvansertib-olaparib combination was well tolerated in vivo
SAN DIEGO, April 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the results of preclinical studies evaluating the anti-cancer activity of onvansertib in combination with the PARP inhibitor (PARPi) olaparib in PARPi-resistant patient-derived xenograft (PDX) ovarian cancer models. The results are featured in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.
"In these studies, we sought to evaluate how combining onvansertib with PARP inhibition, an approved maintenance treatment for ovarian cancer, might mitigate the known phenomenon of acquired tumor resistance to PARP inhibitors," said Tod Smeal, Ph.D., chief scientific officer at Cardiff Oncology. "We are very pleased with the results, which showed onvansertib and olaparib synergistically combining to generate strong activity against PARPi-resistant patient-derived ovarian cancer models. Given the current lack of effective treatment options for patients showing PARPi resistance, we believe these data are supportive of evaluating this combination within a PARPi-resistant clinical setting."
Preclinical studies featured in the AACR poster evaluated onvansertib-olaparib combination treatment in three olaparib-resistant patient-derived xenograft (PDX) ovarian cancer models. Two of the three PDX models used (MNHOC22, MNHOC266) were cisplatin-sensitive with a mutated BRCA1 gene, while the third (MNHOC316DDP) was cisplatin-resistant with wild type BRCA1. BRCA1-mutant tumor cells are deficient for homologous recombination (HR)-mediated DNA repair and are initially sensitive to PARPi. This suggests that PARPi resistance was acquired in the MNHOC22 and MNHOC266 tumors due to the restoration of HR-mediated DNA repair, while being naturally conferred in MNHOC316DDP tumors due to continuous HR-proficiency.
Data showed that combining onvansertib with olaparib led to a statistically significant survival benefit compared to treatment with either agent alone in each of the three evaluated PDX models. Results showed the combination was well tolerated.
An electronic copy of the poster and corresponding abstract, entitled, Combining PARP inhibition with the Polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance, is available to registered attendees of the AACR annual meeting on the meeting website. The in-person presentation will take place during the "Drug Resistance and Reversal of Resistance" poster session on April 12, 2022, from 1:30 PM – 5:00 PM CT. Following the meeting, the poster will be available on the "Scientific Presentations" section of the Cardiff Oncology website at https://cardiffoncology.com/scientific-presentations/.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, an oral highly selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:
SOURCE Cardiff Oncology, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/cardiff-oncology-announces-data-showing-combination-parp-inhibition-with-onvansertib-overcomes-parp-inhibitor-resistance-brca1-mutant-wildtype-patient-derived-xenograft-ovarian-cancer-models/
| 2022-04-08T18:53:09Z
|
- Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA
- Disease control increased with increasing dose density of onvansertib from 29% to 45% of patients achieving PSA stabilization and from 53% to 75% of patients with radiographic stable disease; Arm A (n=17) – onvansertib 24mg/m2 days 1-5 in 21-day cycle to Arm C (n=20) – 12mg/m2 days 1-14 in 21-day cycle
- Median progression-free survival (mPFS) has increased with increasing onvansertib dose density from 4.1 months in Arm A to 13.2 months to-date in Arm C patients
- Genomic analysis of ctDNA showed a correlation between alterations in two key genes of the PI3K signaling pathway—MTOR and PTEN, which appears to underly increased pathway activity, and sensitivity to onvansertib/abiraterone combination in mCRPC patients with early abiraterone resistance
SAN DIEGO, April 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced updated clinical data and new biomarker analyses from its ongoing Phase 2 trial of onvansertib in combination with abiraterone/prednisone in metastatic castrate-resistant prostate cancer (mCRPC) patients. The data are featured in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.
"Results from the mCRPC trial demonstrate clinically meaningful disease control rates in patients showing early resistance to abiraterone," said David Einstein, M.D., principal investigator at Beth Israel Deaconess Medical Center. "As the dose density of onvansertib was increased in three consecutive Arms (A, B and C), we observed an increase in disease control rates with both PSA stabilization and radiographic stable disease twelve weeks into treatment and some of these patients have experienced durable stabilization. Pre-clinical data suggest that the synergistic effect is independent of androgen receptor signaling."
The primary efficacy endpoint of the mCRPC trial is disease control rate at 12 weeks (12-week DCR), which is defined by a decline or stabilization of PSA levels (rise of <25% over baseline or less than 2 ng/mL). Each of the trial's three arms has evaluated a different dosing schedule of onvansertib alongside abiraterone and prednisone administered throughout the respective treatment cycle. Arm A evaluated 24 mg/m2 onvansertib on Days 1-5 of 21-day cycles, Arm B evaluated 18 mg/m2 onvansertib on Days 1-5 of 14-day cycles, and Arm C is evaluating 12 mg/m2 onvansertib on Days 1-14 of 21-day cycles.
"Biomarker correlative studies have revealed significant and positively associated mutations in MTOR, FAT1, PTEN and FOXA1, with tumors harboring these mutations achieving stable disease or a partial response within the initial abiraterone-resistant setting," said Tod Smeal, Ph.D., chief scientific officer of Cardiff Oncology. "In addition, gene expression signatures from patient tumor tissue biopsies correlated with treatment response included those corresponding to the ERG+ and Notch pathways, which are involved in cell-invasion, epithelial-mesenchymal transition and metastasis. We continue to examine these promising biomarker studies with the goal of identifying the genomic alterations most closely associated with response to the combination regimen of onvansertib and abiraterone."
Key data and conclusions from the AACR poster (cut-off date of February 2, 2022) and ongoing trial include:
Efficacy:
- 75% (15/20) of evaluable patients in Arm C, which represents the most dose dense treatment schedule, showed disease control by radiographic SD/PR at 12-weeks, compared to 53% (9/17) and 58% (11/19) in the less dose dense Arms A and B, respectively
Biomarker:
- Treatment response (SD/PR) was positively associated with mutations in PTEN and MTOR, key genes in the PI3K signaling pathway
- Gene signatures correlating with treatment response included those corresponding to the ERG+ and Notch pathways, which are involved in cell-invasion, epithelial-mesenchymal transition and metastasis
- Genes related to mitochondrial and immune functions were downregulated in patients achieving SD or a PR compared to those showing progressive disease
Safety:
- The treatment regimen of onvansertib in combination with abiraterone/prednisone has been well tolerated
An electronic copy of the poster and corresponding abstract, entitled, Biomarkers of response to abiraterone and the polo-like kinase 1 (PLK1) inhibitor onvansertib in metastatic castration resistant prostate cancer (mCRPC) patients, is available to registered attendees of the AACR annual meeting on the meeting website. The in-person presentation will take place during the "Biomarkers Predictive of Therapeutic Benefit 1" poster session on April 11, 2022, from 9:00 AM – 12:30 PM CT. Following the meeting, the poster will be available on the "Scientific Presentations" section of the Cardiff Oncology website at https://cardiffoncology.com/scientific-presentations/.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, an oral highly selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:
SOURCE Cardiff Oncology, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/cardiff-oncology-announces-updated-clinical-new-biomarker-data-phase-2-metastatic-castration-resistant-prostate-cancer-trial-aacr-annual-meeting/
| 2022-04-08T18:53:16Z
|
- Findings further indicate the potential of engineered macrophages as a new treatment pathway for hard-to-treat cancers and other serious illnesses
- Research findings point to feasibility of a shortened manufacturing process for CAR-monocytes
PHILADELPHIA, April 8, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, LA, Friday, April 8 – Wednesday, April 13. The accepted data reinforce the potential of Carisma's differentiated and proprietary cell therapy platform focused on engineered macrophages as a novel treatment pathway for hard-to-treat cancers and other serious illnesses and provides information on the feasibility of a shortened manufacturing process for chimeric antigen receptor (CAR) monocytes.
Carisma will share key findings from recent studies including, "Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy," presented by Stefano Pierini, PhD, Principal Scientist at Carisma. Findings demonstrate robust synergy between the CAR-Macrophage platform and T cell checkpoint inhibitor therapy. Using pre-clinical solid tumor animal models that are resistant to PD1 blockade, Carisma demonstrated that adding CAR-Macrophages to the treatment regimen significantly enhanced tumor control, overall survival, and tumor microenvironment (TME) activation. Notably, while CAR-Macrophage monotherapy led to TME remodeling, the combination with anti-PD1 led to an increased infiltration of T cells, dendritic cells, and other inflammatory immune cells. Carisma will seek to further evaluate CT-0508, the anti-human epidermal growth factor receptor 2 (HER2) CAR-Macrophage, in a combination study with pembrolizumab in patients with HER2 overexpressing tumors.
"Pre-clinical development of CAR Monocytes (CAR-Mono) for solid tumor immunotherapy," presented by Carisma Principal Scientist, Daniel Blumenthal, PhD, demonstrated that CAR-Monocytes can be produced in a single day, induce robust and targeted anti-tumor activity in vitro and in vivo, differentiate into M1 polarized CAR-Macrophage within tumors, and persist for over six months in animal models. In this study, Carisma established an ultra-rapid, same-day CAR-Monocyte manufacturing process, which holds the potential to significantly reduce the future cost of goods and manufacturing turnaround time associated with the autologous cell therapy.
Also accepted for AACR presentation is the clinical trial design and foundational details regarding Carisma's lead candidate, CT-0508, a HER2-targeted CAR-Macrophage, "A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST)," presented by Kim A. Reiss, MD, Assistant Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania (Penn) and the principal investigator for Carisma's clinical trial of CT-0508. This first-of-its kind Phase 1 clinical trial is actively enrolling patients at five sites, including Penn; the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill; City of Hope in Duarte, California; University of Texas MD Anderson Cancer Center in Houston, Texas; and Sarah Cannon Research Institute at Tennessee Oncology – Nashville.
"The preclinical data presented at the AACR Annual Meeting reinforces the exciting potential of Carisma's engineered macrophage and monocyte platforms," shared Debora Barton, MD, Chief Medical Officer at Carisma Therapeutics. "Our commitment remains steadfast to providing new solutions to patients and their providers, as we continue our first-of-its-kind clinical trial of CT-0508 and look to expand utilization of this technology."
The following poster presentations will be published on the AACR Annual Meeting website and available for registered attendees during the dates/times indicated below:
- Sunday, April 10 at 1:30 pm ET:
- Monday, April 11 at 1:30 pm ET:
- Tuesday, April 12 at 9:00 am ET:
Editor's Note: Carisma has licensed certain Penn-owned intellectual property from the University of Pennsylvania, and Penn's Perelman School of Medicine receives sponsored research and clinical trial funding from the company. Penn may also be entitled to receive additional financial benefits from technologies licensed and optioned to Carisma in the future. In addition, Penn is a co-founder of the company and holds equity interests in Carisma.
About Carisma Therapeutics
Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA.
For more information, please visit www.carismatx.com
Carisma Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:
SOURCE Carisma Therapeutics Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/carisma-therapeutics-present-engineered-cell-therapy-data-american-association-cancer-research-annual-meeting/
| 2022-04-08T18:53:22Z
|
WASHINGTON, April 8, 2022 /PRNewswire/ -- Certified Financial Planner Board of Standards, Inc. (CFP Board) announced that it has imposed an interim suspension of the CFP® certification against Michael Giannetti, which was effective as of April 5, 2022.
CFP Board issued an automatic interim suspension order suspending Mr. Giannetti's right to use the CFP® certification marks after receiving evidence that the Financial Industry Regulatory Authority, Inc. (FINRA) permanently barred Mr. Giannetti from associating with any FINRA member in any capacity on March 22, 2022. FINRA determined that Mr. Giannetti refused to produce to FINRA information or documents in connection with its investigation of Mr. Giannetti's potential participation in undisclosed outside business activities, in violation of FINRA Rules 8210 and 2010. Under the automatic interim suspension order, Mr. Giannetti's right to use the CFP® certification marks is suspended pending CFP Board's completed investigation and possible further disciplinary proceedings.
An interim suspension is a suspension of a CFP® professional's Certification and Trademark License during the pendency of proceedings. A Respondent subject to an Interim Suspension Order must not use the CFP® certification marks or state or suggest that Respondent is a CFP® professional while the Interim Suspension Order is in effect. An Interim Suspension Order is a temporary sanction and does not preclude CFP Board from imposing a final sanction. An Interim Suspension Order will remain in place until the Disciplinary and Ethics Commission (DEC) or, if an appeal is filed, CFP Board's Appeals Commission, issues a final order. CFP Board may vacate an Interim Suspension Order if the Professional Discipline is vacated or reversed or if Respondent provides sufficient evidence indicating that Respondent was not the subject of Professional Discipline. A Hearing Panel of the DEC may issue an Order to vacate an Interim Suspension Order upon a successful Petition to Vacate an Interim Suspension Order by Respondent.
The basis for this decision also may be found on CFP Board's website at CFP.net/verify. At that website, CFP Board provides the public with:
- The ability to check on any individual's CFP Board disciplinary history and CFP® certification status.
- Links to other sources of information about CFP® professionals that may be more recent or that may contain information that has not led to CFP Board discipline and does not appear on CFP Board's website. This information may include customer disputes, disciplinary actions taken by a regulator or employer, certain criminal matters, and certain financial matters (such as bankruptcy proceedings and unpaid judgments or liens).
- Links to FINRA's BrokerCheck and the U.S. Securities and Exchange Commission's (SEC) Investment Adviser Public Disclosure databases for individuals who are subject to FINRA or SEC oversight.
CFP Board's Enforcement Process
As part of their certification, CFP® professionals make a commitment to CFP Board to abide by CFP Board's Code of Ethics and Standards of Conduct (Code and Standards), or its predecessor, the Standards of Professional Conduct (Standards), which included the Code of Ethics and Professional Responsibility, Rules of Conduct, and Financial Planning Practice Standards. CFP Board's Procedural Rules set forth the process for investigating matters and imposing sanctions where violations have been found.
CFP Board enforces its ethical standards by investigating alleged violations and, where there is probable cause to believe there are grounds for sanction, presents a Complaint containing the alleged violations to CFP Board's DEC. The DEC meets at least six times a year to review any matter in which CFP Board has alleged that a CFP® professional has violated the Code and Standards, or its predecessor Standards. The DEC functions in accordance with the Procedural Rules and reviews all matters on a case-by-case basis, considering the details specific to an individual case. If the DEC determines there are grounds for sanction, then it may impose a sanction. DEC orders may be appealed by a CFP® professional or CFP Board pursuant to the Procedural Rules.
In certain circumstances, such as when a CFP® professional is in default due to failure to acknowledge receipt of a Notice of Investigation or file an Answer, CFP Board staff must deliver an Administrative Order of Suspension, Temporary Bar, Revocation or Permanent Bar. Administrative Orders also are subject to appeal.
More information on CFP Board's enforcement process can be found at CFP.net/ethics/enforcement.
ABOUT CFP BOARD
Certified Financial Planner Board of Standards, Inc. is the professional body for personal financial planners in the U.S. CFP Board sets standards for financial planning and administers the prestigious CFP® certification – one of the most respected certifications in financial services – so that the public has access to and benefits from competent and ethical financial planning. CFP Board, along with its Center for Financial Planning, is committed to increasing the public's awareness of CFP® certification and access to a diverse, ethical and competent financial planning workforce. Widely recognized by firms and consumer groups as the standard for financial planning, CFP® certification is held by more than 92,000 people in the United States.
View original content to download multimedia:
SOURCE Certified Financial Planner Board of Standards, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/cfp-board-imposes-an-interim-suspension-michael-giannetti-grapevine-texas/
| 2022-04-08T18:53:30Z
|
NORWOOD, Mass., April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting being held from April 8-13, 2022, in New Orleans, LA. CRB-601 is a potent and selective αvb8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment. TGFb is thought to be the only ligand of the αvb8 integrin. Inhibiting its ability to bind to αvb8 could therefore play an important role in the regulation of this pleiotropic cytokine. The in vitro preclinical data presented demonstrate the high affinity of CRB-601 for αvb8 and the resulting effect on TGFb. The data also show significant inhibition of tumor growth in a syngeneic model of colon cancer (MC38) by CRB-601, both as a single agent and in combination with anti PD-1 treatment. These effects are supported by the coincident increase in CD8-positive T cells in the tumor microenvironment.
"The increase of tumor infiltration by T-cells stimulated by CRB-601 is quite exciting. The effects of CRB-601 are consistent with the proposed mechanism of blocking TGFb activation, which can potentially enable an anti-tumor immune response and be an effective adjunct to immune checkpoint therapies. We are excited to bring this mechanism of action to the clinic and define the potential benefit it could bring to patients," commented Rachael Brake, Ph.D., Chief Scientific Officer of Corbus.
Corbus is currently developing CRB-601 as a potential treatment for solid tumor cancers, and the program is advancing toward an IND submission in the first half of 2023.
The AACR poster is available on the Company's website at: www.corbuspharma.com/AACRposter
Additionally, Corbus has published an updated Corporate Presentation providing an overview of the Company's full portfolio on its website at: ir.corbuspharma.com/presentations
Corbus is an immunology company committed to connecting innovation to our purpose of improving lives by developing new medicines that target the nexus between the immune system and cancer. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Brian Walsh
VP, Corporate Development
brian.walsh@corbuspharma.com
View original content to download multimedia:
SOURCE Corbus Pharmaceuticals
|
https://www.whsv.com/prnewswire/2022/04/08/corbus-presents-first-preclinical-data-crb-601-american-association-cancer-research-aacr-annual-meeting/
| 2022-04-08T18:53:40Z
|
- First in vivo data demonstrates anti-tumor activity of Glypican-3 (GPC3) Flex-NK™ cell engager (CYT-303) in combination with iNK cells in an animal model of Hepatocellular carcinoma (HCC)
- First in vitro data evaluating CD38 Flex-NK™ cell engager (CYT-338) demonstrates a favorable profile compared to daratumumab
AVENTURA, Fla. and NATICK, Mass., April 8, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the American Association of Cancer Research's annual meeting in New Orleans on April 12th, 2022 is now available on both the AACR and Cytovia websites.
"We are very pleased with the decisive progress of Cytovia's R&D team towards the manufacturing and preclinical validation of its two synergistic platforms," commented Dr. Daniel Teper, CEO and Chairman of Cytovia Therapeutics. "The data presented at AACR supports the advancement of our lead GPC3-targeting hepatocellular carcinoma (HCC) program towards clinical trials and our differentiated CD38-targeting multiple myeloma program to IND-enabling studies. Cytovia is the first company to combine its own iPSC-derived natural killer (iNK) cells and multispecific, NK cell-engaging antibodies and is building a pipeline that encompasses both hematological malignancies and solid tumors."
"Cytovia's GPC3-directed NK-engager in combination with iPSC-derived NK cells demonstrated impressive anti-tumor activity in mice that merits clinical development," added Dr. Michael Friedman, a member of Cytovia's Board of Directors. "For the large number of hepatocellular cancer patients who currently have such limited, poor clinical options, a novel tumor antigen-directed NK engager is needed. It would be a welcome addition to a physician's armament, with high potential for numerous combinations. The early CYT-338 data, showing superiority over daratumumab in several in vitro assays, is similarly impressive and warrants further preclinical development in my opinion."
Highlights from Posters Presented at the AACR Annual Meeting
CYT-303
- The FLEX-NKTM tetravalent, multifunctional antibody CYT-303 directed against NKp46 and GPC3 demonstrated in vitro and in vivo activity against HCC tumor targets.
- iNK cells expressed a favorable combination of multiple activation and few inhibitory receptors that corresponded to more potent cytolytic activity against HCC targets.
- The combination of the FLEX-NKTM and iNK platforms demonstrated greater in vitro and in vivo anti-tumor activity in HCC models than iNK cells alone, with a favorable in vitro cytokine release and immune cell subset safety profile.
- These preclinical proof of concept studies with CYT-303 alone or in combination with iNK cells in HCC warrant clinical development.
CYT-338
- The FLEX-NKTM multifunctional engager antibody CYT-338 directed against NKp46 and CD38 demonstrated in vitro activity against multiple myeloma tumor targets.
- An analysis of binding sites on CD38 indicates CYT-338 binds an epitope that is distinct from daratumumab.
- The binding, cytokine release, cytotoxicity, and fratricide profiles of CYT-338 were superior to daratumumab.
- These data support further development of CYT-338 as a therapeutic for targeting CD38 expressing multiple myeloma cells.
For details on in-person poster presentations, please see the following:
Title: Preclinical characterization of FLEX-NKTM tetravalent NKp46 engager directed against GPC3 (CYT-303) alone or in combination with iPSC derived Natural Killer cells (iNKs) against hepatocellular carcinoma (HCC)
Presenter: Antonio Arulanandam
Session Title: Adoptive Cell Therapy
Session Date and Time: Tuesday, Apr 12, 2022, 9:00 AM - 12:30 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 30
Poster Board Number: 8
Permanent Abstract Number: 2752
Abstract Link
Title: Novel multifunctional tetravalent CD38 NKp46 FLEX NKTM engagers actively target and kill multiple myeloma cells
Presenter: Liang Lin
Session Title: Combination Immunotherapies / Therapeutic Antibodies
Session Date and Time: Tuesday, Apr 12, 2022, 1:30 PM - 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 32
Poster Board Number: 17
Permanent Abstract Number: 3436
Abstract Link
About Cytovia Therapeutics
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. The company is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology.
These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma.
Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA., and a GMP cell manufacturing facility in Puerto Rico. The company's own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation and the University of California San Francisco (UCSF).
Cytovia has recently formed CytoLynx Therapeutics, a strategic partnership focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.
Find out more at www.cytoviatx.com and follow us on Facebook, Twitter, LinkedIn, YouTube, and Instagram.
About GPC3
Glypican-3 (GPC3) is a cell-surface heparan sulfate proteoglycan. It is expressed in the liver and kidney of fetuses but is hardly expressed in adults, except in the placenta. However, it is highly expressed in HCC and other pediatric and adult solid tumors. GPC3 promotes Wnt-dependent cell proliferation and it has been strongly suggested that it is related to the malignant transformation of HCC, making it a promising target for cancer immunotherapy.
About CD38
Cluster of differentiation 38 (CD38) is a type II receptor membrane glycoprotein that plays a role in cell adhesion, migration, and signal transduction. Additionally, CD38 is an ectoenzyme involved in generation of nucleotide metabolites, such as ADP-Ribose that regulate cell metabolism. CD38 is highly expressed in multiple myeloma (MM) on malignant plasma cells and is also moderately expressed on normal T, B, NK and myeloid cells. Antibodies targeting CD38, such as daratumumab and isatuximab, are FDA approved for the treatment of MM as monotherapy and in combination.
Investor Contact:
Anna Baran-Djokovic
VP, Investor Relations and Capital Markets
anna@cytoviatx.com
+1 (305) 615 9162
Media Contact:
Ignacio Guerrero-Ros, Ph.D.
Russo Partners
ignacio.guerrero-ros@russopartnersllc.com
View original content to download multimedia:
SOURCE Cytovia Therapeutics
|
https://www.whsv.com/prnewswire/2022/04/08/cytovia-therapeutics-reports-preclinical-activity-its-ipsc-derived-nk-ink-cells-flex-nk-cell-engagers-2022-aacr-annual-meeting/
| 2022-04-08T18:53:48Z
|
HACKENSACK, N.J., April 8, 2022 /PRNewswire/ -- Diamond Braces, one of the Northeast's leading group orthodontic practices, has a new informational article available to advise upcoming orthodontic residency grads about their options as they begin their professional careers.
"5 Reasons Why New Orthodontic Residency Graduates Should Join Diamond Braces" offers a look at multiple ways Diamond Braces gives young orthodontists an opportunity to work as a professional without worrying about the uncertainty and complications surrounding operating their own standalone practice.
Rather than throwing their young doctors into the proverbial deep end, residency graduates at Diamond Braces learn under the tutelage of an experienced orthodontist before handling cases on their own. Along with using common educational exercises like shadowing, Diamond Braces also offers young doctors an easily accessible and secure database that allows them to access patient records from anywhere, letting them ask questions of our doctors regarding a patient's treatment plan, clinical applications, or to simply help with the decision-making process.
Among the topics covered in "5 Reasons Why…" include:
- Diamond Braces' specialization in orthodontics versus general dentistry
- Mentorship programs
- Continuing education allowances
- Pathways to partnership - both equity and non-equity
- Advanced technology designed to streamline daily operations
- Doctor-friendly contracts with multiple benefits and without non-compete requirements
"Diamond Braces is proud to offer young doctors a place to grow as professionals and as people," said Dr. Oleg Drut, Chief Dental Officer at Diamond Braces. "This new informational article will concisely explain to residency graduates that our company can offer them a safe place to begin their careers and learn to become true orthodontic professionals under the guidance of one of our veteran doctors."
To read "5 Reasons Why New Orthodontic Residency Graduates Should Join Diamond Braces," visit the Diamond Braces website here. There, you'll be able to read the article, contact a Diamond Braces representative for more information, or apply to join the Diamond Braces team. Diamond Braces looks forward to meeting the next generation of great orthodontists!
About Diamond Braces
Diamond Braces, a Diamond Plus Invisalign Provider, is a leader in a quality orthodontic care on the East Coast. For over 20 years, Diamond Braces has been guided by its principles of affordability, accessibility, and amazing service. For more information, visit www.diamondbraces.com
CONTACT: Jeff Kotuby, jeffk@diamondbraces.com
View original content to download multimedia:
SOURCE Diamond Braces
|
https://www.whsv.com/prnewswire/2022/04/08/diamond-braces-new-informational-article-advises-ortho-residency-grads-their-post-graduation-career-options/
| 2022-04-08T18:53:55Z
|
- Throughout April, company will focus on organizations, programs that enhance natural resources of state.
- This week's nonprofit – TreesUpstate – provides free trees to residents, along with information on how they can help reduce energy consumption.
GREENVILLE, S.C., April 8, 2022 /PRNewswire/ -- Throughout the month of April, Duke Energy will highlight organizations in South Carolina that promote sustainability and environmental efforts across the state.
This campaign will provide nearly $400,000 to numerous nonprofits and governmental agencies and highlight global efforts like Earth Day and Arbor Day at the local level.
This week, the company highlights TreesUpstate and the Energy Saving Trees Program. TreesUpstate is a nonprofit with the mission to plant, promote and protect trees in the Upstate.
Since 2016, Duke Energy Foundation funding has supplied more than 15,000 free trees through the TreesUpstate Energy Saving Trees Program to residents along with information on how planting the right tree in the right place can reduce energy consumption by up to 20% each year.
Most recently, $78,000 in grant funding has supported expanding the program by focusing outreach to underrepresented Hispanic communities and translating materials into Spanish.
"Trees help save on energy, reduce utility bills, and help clean the water and air throughout the Upstate," said Joelle Teachey, executive director of TreesUpstate. "With the Duke Energy Foundation's continued support, we can share even more trees and this message with more residents."
Last week, Duke Energy kicked off the monthlong initiative by providing PalmettoPride $100,000 to support the programs in local communities managed by the 37 Keep South Carolina Beautiful affiliate organizations, who focus on litter pick up and beautification throughout their areas.
"We think it's important to work alongside our community partners to ensure all of the beautiful places in South Carolina can be enjoyed for years to come," said Mike Callahan, Duke Energy South Carolina state president.
"The organizations these funds support will aid in the protection of the environment and provide communities with much-needed resources to promote good stewardship of the natural beauty around us."
Additional funding will be distributed over the next month to support organizations that manage and maintain public trails, plant and giveaway trees, foster flood prevention and mitigation, and cleanup rivers and roadsides in communities across the Palmetto State.
Duke Energy employees and retirees will also be volunteering their time and efforts with these and other organizations throughout the month to assist these programs in their neighborhoods.
The Duke Energy Foundation provides more than $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The foundation is funded by Duke Energy shareholders.
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. Its electric utilities serve 8.2 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 51,000 megawatts of energy capacity. Its natural gas unit serves 1.6 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The company employs 28,000 people.
Duke Energy is executing an aggressive clean energy strategy to create a smarter energy future for its customers and communities. The company has goals of at least a 50 percent carbon reduction from electric generation and net-zero methane emissions from its natural gas business by 2030, and net-zero emissions by 2050 from its electric and natural gas businesses, including Scopes 1, 2 and certain Scope 3 emissions. The company also is investing in major electric grid upgrades and expanded battery storage, and exploring zero-emitting power generation technologies such as hydrogen and advanced nuclear.
Duke Energy was named to Fortune's 2022 "World's Most Admired Companies" list and Forbes' "America's Best Employers" list. More information is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos and videos. Duke Energy's illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.
Media contact: Ryan Mosier
800.559.3853
View original content to download multimedia:
SOURCE Duke Energy
|
https://www.whsv.com/prnewswire/2022/04/08/duke-energy-continues-400000-monthlong-focus-sustainability-environmental-efforts-south-carolina-by-helping-grow-energy-saving-trees-program/
| 2022-04-08T18:54:01Z
|
The Staffing Giant Saw Nearly 1 Million Postings Last Week Alone.
While Hospitality Industry Jobs Continue to Top The List, Demand Grew for Construction Workers, Landscapers, Cleaning Workers and Support Staff for Events and Entertainment
TACOMA, Wash., April 8, 2022 /PRNewswire/ -- In line with the March unemployment figures, job growth is continuing to outpace the number of available workers. According to a new jobs report by staffing giant PeopleReady, 8 million new jobs were posted in the last 30 days. Staggeringly, this included 1 million in just the past seven days. To guide workers to the right job opportunities, here is PeopleReady's list of some of the fastest-growing jobs in the U.S. right now.
"As spring arrives across the country, many industries are experiencing an increase in activity, including hospitality, construction, and events and entertainment. That means additional opportunities for job seekers to earn more income, develop new skills and explore their career options," said Taryn Owen, president and COO, PeopleReady and PeopleScout. "In today's strong job market, we are committed to finding ways to make it easier than ever for job seekers to connect with vital work and for companies to connect with the workforce they need."
According to the PeopleReady analysis of millions of jobs, some of the most in-demand jobs, along with their growth rate in the past 30 days, include:
- Restaurant and short order cooks: 100%
- Food preparation workers: 94%
- Waiters and waitresses: 73%
- Dishwashers: 71%
- Landscapers and groundskeepers: 71%
- Janitors and cleaning workers: 52%
- General construction workers: 37%
To connect job seekers with available jobs across many different industries, PeopleReady is holding nationwide hiring events this week. The staffing company has a variety of ways for job seekers to access job opportunities via app (JobStack[play.google.com]) and online (jobs.peopleready.com).
Those who work already with PeopleReady in the U.S. during the month of April will be automatically entered into the staffing firm's Work, Win, Drive sweepstakes. It will feature over $100,000 in cash and prizes—including a grand prize drawing for $25,000 or a car of the winner's choice. For more information on the sweepstakes, visit peopleready.com/WorkWinDrive.
PeopleReady, a TrueBlue company (NYSE: TBI), specializes in quick and reliable on-demand labor and highly skilled workers. PeopleReady supports a wide range of blue-collar industries, including construction, manufacturing and logistics, waste and recycling, and hospitality. Leveraging its game-changing JobStack platform and 600-plus branch offices across all 50 states, Puerto Rico and Canada, PeopleReady served approximately 94,000 businesses and put approximately 220,000 people to work in 2021. Learn more at www.peopleready.com.
Press Contact:
Caroline Sabetti
Chief Marketing Officer, PeopleReady and PeopleScout & Senior Vice President of TrueBlue Communications
csabetti@trueblue.com
312.560.9173
View original content:
SOURCE PeopleReady
|
https://www.whsv.com/prnewswire/2022/04/08/employment-shows-no-signs-slowing-down-eight-million-new-jobs-were-posted-just-last-month-report-by-staffing-giant-peopleready/
| 2022-04-08T18:54:08Z
|
ST. LOUIS, April 8, 2022 /PRNewswire/ -- Energizer Holdings Inc. (NYSE: ENR) will report its Second Quarter Fiscal 2022 results before the market opens on May 9. Energizer also will discuss its results during an investor conference call that will be webcast beginning at 10 a.m. ET. The call will be hosted by Mark LaVigne, Chief Executive Officer, and John Drabik, Chief Financial Officer.
All interested parties may access a live webcast of this conference call at www.energizerholdings.com, under the Investors and Events & Presentations tabs or by using the following link:
For those unable to participate during the live webcast, a replay will be available on www.energizerholdings.com, under the "Investors," "Events & Presentations" and "Past Events" tabs.
Energizer Holdings ("Energizer," NYSE: ENR), headquartered in St. Louis, is one of the world's largest manufacturers and distributors of primary batteries, portable lights, and auto care appearance, performance, refrigerant, and fragrance products. Our portfolio of globally recognized brands include Energizer, Armor All, Eveready, Rayovac, STP, Varta, A/C Pro, Refresh Your Car!, California Scents, Driven, Bahama & Co., LEXOL, Eagle One, Nu Finish, Scratch Doctor, and Tuff Stuff. As a global branded consumer products company, Energizer's mission is to be the leader in our categories by better serving consumers and customers. Visit www.energizerholdings.com for more details.
View original content to download multimedia:
SOURCE Energizer Holdings, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/energizer-holdings-inc-webcast-discussion-second-quarter-fiscal-2022-results-may-9/
| 2022-04-08T18:54:15Z
|
Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients
ANITAC degraders inhibit AR-dependent transcription and reduce viability of AR-dependent prostate cancer cells
Data to be presented at the 2022 American Association for Cancer Research Annual Meeting
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, BC, April 8, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data for its first generation of androgen receptor (AR) ANITen bAsed Chimera (ANITAC™) N-terminal domain (NTD) degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
"We look forward to presenting our first preclinical data demonstrating the potential of ESSA's ANITAC degraders as a new approach to AR pathway inhibition. The NTD is a promising target for the suppression of AR biology which is responsible for driving most prostate cancers, but due to the intrinsically disordered nature of the NTD region of AR, it has been generally considered undruggable. Through their unique ability to bind to the NTD of AR, ANITACs have the ability to inhibit NTD-mediated AR transcription while also degrading AR protein including resistant forms of AR which are commonly associated with castration-resistant prostate cancer," said Dr. David. R. Parkinson, Chief Executive Officer, ESSA Pharma Inc. "Our bifunctional degraders leverage ESSA's deep scientific expertise and success in targeting the AR NTD with a new treatment modality aimed at suppressing AR biology by eliminating the AR protein itself. We look forward to providing further updates this year from this exciting new preclinical program."
The preclinical results demonstrate that ANITAC degraders utilize the ubiquitin proteasome system and can degrade many forms of AR including full length, mutant and splice variants which are often expressed in CRPC patients. Specifically, the ANITAC degraders show robust potency in inhibiting AR transcriptional activity driven by AR-FL, AR-V7, or AR-V567es. In addition, the orally bioavailable ANITAC degraders exhibit high potency in inhibiting AR-dependent transcription and reducing viability of AR-dependent prostate cancer cells.
Poster presentation details are as follows:
Title: Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models
Authors: Nan Hyung Hong, et al.
Abstract Number: 429
Session Title: Protein Degraders and Proteasome Inhibitors
Session Date and Time: Sunday, April 10, 2022 | 1:30 p.m. - 5:00 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26
The poster is available to 2022 AACR Annual Meeting attendees and in the Science section of the Company's website at www.essapharma.com.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone can lead to metastatic CRPC (mCRPC). The treatment of mCRPC patients has evolved rapidly over the past ten years. Despite these advances, many patients with mCRPC fail or develop resistance to existing treatments, leading to continued disease progression and limited survival rates.
This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding the potential of ESSA's ANITAC degraders as a new approach to AR pathway inhibition, NTD being a promising target for the suppression of AR biology, the potential benefits of ANITAC degraders, the anticipated timeline for providing further updates on preclinical programs, the ability of ANITAC degraders to utilize the ubiquitin proteasome system and degrade many forms of AR, inhibit AR-dependent transcription and reduce viability of AR-dependent prostate cancer cells and other statements surrounding the Company's clinical evaluation of ANITAC degraders.
Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.
Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Quarterly Report on Form 10-Q dated February 3, 2022 under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile www.sedar.com.Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
View original content:
SOURCE ESSA Pharma Inc
|
https://www.whsv.com/prnewswire/2022/04/08/essa-pharma-announces-presentation-preclinical-data-its-first-generation-androgen-receptor-n-terminal-domain-degraders/
| 2022-04-08T18:54:22Z
|
Executive Producer Jessica Sarowitz meets with The Pontiff About the Film Focusing on the Legacy of Sister María Rosa Leggol
VATICAN CITY, April 8, 2022 /PRNewswire/ -- With This Light, directed by Nicole Bernardi-Reis and Laura Bermúdez, was screened at the Vatican for dignitaries and invited guests and also presented to Pope Francis at Vatican City. Jessica Sarowitz met with His Holiness to discuss the important legacy of the Miraflores Films documentary's subject, Sister María Rosa Leggol
The discussion with The Pontiff focused on the inspiring life's work of Sister María Rosa Leggol during her 70 years as a Franciscan nun, helping more than 87,000 Honduran children escape poverty and abuse. They also discussed the importance of making sure her story and impact is known beyond Honduras.
Invited guests to the private screening at the Augustinian Patristic Institute included international and local press, members of religious orders and Ambassadors to the Holy See from Honduras, Panama, Mexico, Cuba, El Salvador and Brazil, the Secretary General of the Italian Supreme Court of Cassation, amongst other dignitaries.
On behalf of the filmmaking team, Executive Producer Jessica Sarowitz said, "The early opportunity to screen With This Light to an audience with His Holiness was a privilege. One life can inspire and educate others, as Sister María Rosa has done for so many individuals in the Honduran community, and we are so grateful to be sharing her story with a wider audience."
The screening was in partnership with L'Osservatore Romano (Spanish edition), the Vatican's official newspaper, and the Honduran Embassy to the Holy See.
About Miraflores Films
Miraflores Films is a media company dedicated to amplifying the voices of inspiring women through quality documentary film, building space for those excluded from mainstream narratives to have their stories seen and heard. By sharing these untold stories of extraordinary lives and perseverance, Miraflores Films creates authentic connections with diverse audiences — empowering them with the tools to become actively engaged citizens. Miraflores' deliberate and dynamic distribution of projects inspires others to lead with compassion and be change-makers within their own communities.
MEDIA CONTACT:
Wolf Kasteler Public Relations
Omar Gonzales | omarg@wk-pr.com
View original content to download multimedia:
SOURCE Miraflores Films
|
https://www.whsv.com/prnewswire/2022/04/08/executive-producer-documentary-with-this-light-meets-with-his-holiness-pope-francis/
| 2022-04-08T18:54:32Z
|
A leader in build-to-order products expands its growing portfolio
CYPRESS, Calif., April 8, 2022 /PRNewswire/ -- Exemplis, a California-based furniture manufacturer, proudly announces the acquisition of Edloe Finch, a Texas-based e-commerce retailer of home furniture and parent company to Albany Park. The acquisition will expand the Exemplis portfolio of industry-defining brands.
"I'm thrilled about the new possibilities for our companies," says Paul DeVries, CEO and founder of Exemplis. "Darryl and Jessica have created one of the fastest-growing brands in the residential furniture space. Their forward-looking leadership, creativity and competitive drive are perfect complements to the nonstop innovation that's propelled Exemplis for over 25 years. I'm very excited to be joining forces with them."
It will be business as usual for Edloe Finch. They will continue to operate independently, and all products will continue to be ordered from, fulfilled by and serviced through their respective factories and customer service teams.
"We are very excited to be a part of the Exemplis family," says Darryl Sharpton, CEO and co-founder of Edloe Finch. "In Paul [DeVries] and Exemplis, we've found an ideal partner who shares our passion for creating great furniture while keeping the focus on the customer experience. Jessica and I will continue to run Edloe Finch and Albany Park as co-CEOs. With the support from Exemplis, we're ready to spread coziness across America like never before!"
About Exemplis
Exemplis, the parent company of SitOnIt Seating®, Timbuk2®, X-Chair®, Mavix® Gaming, and The Healthy Back Store® brands, has been a leader in build-to-order products since its founding in 1996 in California. SitOnIt Seating is one of the largest manufacturers of office solutions in the world with an unlimited array of customizable designs and the fastest shipping times in the industry. Timbuk2 crafts high-quality handmade bags, packs and more for a global community on the go. X-Chair advances office chairs with proprietary ergonomic technology. Mavix breaks the mold to provide the future of gaming comfort. The Healthy Back Store is a leader in high-end comfort solutions. For more information, visit www.exemplis.com.
About Edloe Finch
Edloe Finch, the parent company of Albany Park®, was founded in 2017 by Darryl Sharpton and Jessica Sharpton. The company launched Albany Park in 2019. Albany Park was designed to make buying the perfect sofa easy by eliminating decision fatigue — they offer three collections that satisfy both the style and comfort needs of their growing customer base. Edloe Finch is a digitally native e-commerce company that continually strives to improve the furniture buying experience while being a leader in the digital revolution of the furniture industry. For more information, visit www.edloefinch.com and www.albanypark.com.
Media Contact | Exemplis
Karen Robinson
Exemplis • 714.763.1880
krobinson@exemplis.com
Media Contact | Edloe Finch
Jumi Aluko
Edloe Finch • 443.718.0494
press@edloefinch.com
View original content to download multimedia:
SOURCE Exemplis LLC
|
https://www.whsv.com/prnewswire/2022/04/08/exemplis-acquires-edloe-finch-parent-company-albany-park/
| 2022-04-08T18:54:40Z
|
LONG ISLAND CITY, N.Y., April 8, 2022 /PRNewswire/ -- In today's world of technology, many youth experience the negative consequences of increased connectivity and socialization in the form of cyberbullying. Cyberbullying differs from traditional bullying in several ways, and as a result, Fidelis Care wants to educate adults and youth across New York about the risks of cyberbullying and how it impacts overall health.
Cyberbullying is harassment that takes place over digital devices, social media platforms, and gaming experiences. According to the Pew Research Center, 59% of U.S. teens have been bullied or harassed online. Unlike traditional bullying, cyberbullying can take place 24 hours a day and includes actions such as making threats, spreading rumors, sharing personal information to humiliate, excluding someone on purpose, and more.
"The pervasiveness of technology has created new avenues for bullying, making it more difficult for our youth to escape its harmful effects," said Fidelis Care Chief Medical Officer Vincent Marchello, MD. "Cyberbullying can be uncharted territory for parents and caregivers from past generations, so Fidelis Care wants to raise awareness to help adults and youth recognize negative behavior and provide support."
Cyberbullying can lead to social and emotional distress, behavioral problems, and mental health issues. Additionally, youth who are bullied are at increased risk for substance misuse, academic problems, and violence to others. These effects on the mental wellbeing of youth can translate into physical health challenges later in life, extending the impact of cyberbullying long after it stops. The U.S. Surgeon General recently issued an advisory stating the youth mental health crisis has been further exposed by the COVID-19 pandemic.
To further spread awareness, Fidelis Care is encouraging youth in New York to take action to promote prevention with their peers and community by participating in the Centene Institute Youth Impact Award for Cyberbullying Prevention. As part of the Centene family, Fidelis Care invites youth ages 14-19 to watch a short video and read a fact sheet on cyberbullying before submitting their own original visual art entry that conveys cyberbullying awareness and prevention. The contest is open to eligible youth nationwide. All submissions are eligible to account for up to 10 hours of community service. The contest is now open and runs until May 20, 2022.
Below are some tips from the CDC, American Academy of Pediatrics and the Department of Health and Human Services to raise awareness and prevent cyberbullying that can inspire contest entries as well as be used to handle situations in everyday life:
- Talk about bullying to reduce stigma and identify potential instances of cyberbullying
- Plan for what to do if witnessing or experiencing bullying
- Teach youth to treat others respect and practice inclusivity
- Create positive community environments that build confidence and social skills
- If bullied, immediately stop communication and block the person via digital channels
- Speak up if you feel uncomfortable with the comments or actions of someone
- Understand the possible warning signs of emotional distress
For more information about the Youth Impact Award and how to enter, visit https://www.centeneinstituteaward.com/cyberbullying-prevention/2022. For more information on Fidelis Care and its activities, visit www.fideliscare.org.
About Fidelis Care:
Fidelis Care is a mission-driven health plan offering quality, affordable coverage for children and adults of all ages and at all stages of life. With more than 2.4 million members statewide, Fidelis Care believes that all New Yorkers should have access to affordable, quality health insurance. Follow us on Twitter at @fideliscare, Instagram at @fideliscare, and on Facebook at facebook.com/fideliscare. For more information, call Fidelis Care at 1-888-FIDELIS (1-888-343-3547) or visit fideliscare.org.
Contact: MediaInquiries@fideliscare.org
View original content to download multimedia:
SOURCE Fidelis Care
|
https://www.whsv.com/prnewswire/2022/04/08/fidelis-care-shines-light-cyberbullying-encourages-new-york-youth-make-difference/
| 2022-04-08T18:54:46Z
|
Advanced Nutrients' Sensi Professional Series uses a unique methodology to Hit the Shift between the grow phase and the bloom phase, improving potency, yields, and reputation.
LOS ANGELES, April 8, 2022 /PRNewswire/ -- Advanced Nutrients' latest innovation enables commercial growers to maximize economies of scale while improving the ROI of every run. It's called the Sensi Professional Series, the only water-soluble powder base nutrient system that Hits the Shift, meeting the phase-dependent nutritional needs of cannabis plants and boosting cannabinoid production, yield, flavor, and aroma.
Backed by 22 years of cannabis research, the Sensi Professional Series leverages the dramatic difference in macro, secondary, and micronutrient ratios cannabis needs during each phase to unleash its true genetic potential. By delivering these precise ratios at the exact right time, commercial growers can apply the same award-winning quality of Advanced Nutrients' liquid fertilizers and add more value to their large scale grows.
"Cannabis plants require very different nutrient ratios between the grow phase and the bloom phase in order to reach their peak performance," says Advanced Nutrients founder and CEO Michael 'BigMike' Straumietis. "The Sensi Professional Series Hits this crucial Shift, offering growers a convenient, comprehensive, and cost-effective path to maximum crop value."
In addition to phase-dependent nutrient ratios, the Sensi Professional Series also contains three premium chelated forms of iron — providing a greater range of pH and significantly higher absorption rates . It's also rich in cations like urea, which lock pH levels into the sweet spot for improved uptake. Consistent with the company's two existing water-soluble fertilizers, Big Bud® Powder and Bud Blood™, the Sensi Professional Series has been engineered with the highest quality ingredients — and is backed by the most stringent quality control measures — to ensure growers enjoy a clean, safe, productive run.
The Sensi Professional Series is available now in hydroponic stores across the United States. Contact your nearest authorized retailer for more information.
About Advanced Nutrients
Founded by Michael "BigMike" Straumietis, Advanced Nutrients is widely regarded as one of the world's most influential nutrient brands. In 1999, the company revolutionized the industry by developing the first and only complete growing system for cannabis that optimizes all phases of the vegetative and bloom cycles to bring the plant to its true genetic potential. With 39 years of experience overseeing the cultivation of millions of plants, BigMike has brought 53 innovations to cannabis science. For additional information, please visit: www.advancednutrients.com
View original content to download multimedia:
SOURCE Advanced Nutrients
|
https://www.whsv.com/prnewswire/2022/04/08/first-phase-dependent-water-soluble-powders-set-disrupt-commercial-cannabis-market/
| 2022-04-08T18:54:56Z
|
PITTSBURGH, April 8, 2022 /PRNewswire/ -- FlexScreen is pleased to announce the opening of its newest manufacturing plant in Nashua, New Hampshire. The Nashua location is the seventh FlexScreen facility, with five more across the US and one in Canada.
Along with this plant comes an expanded partnership with Harvey Building Products, which has several production facilities located in New England and surrounding areas
Regarding the new partnership, FlexScreen Inventor & CEO Joe Altieri said, "Harvey Building Products is one of the most respected window manufacturers in the country, and it's an honor to align FlexScreen with their premium products. New England is one of the only areas in the country without a screen vendor, so we're excited that our new Nashua, NH plant will finally be filling that void."
Justin St. Hilaire, President of Harvey Building Products, said, "Harvey Building Products is proud to have FlexScreen as a partner and supplier for our business. We are excited about the proximity of their new facility to our own manufacturing plants and look forward to increasing our business with them."
The new FlexScreen facility is set to start shipping orders on June 1, 2022.
View original content to download multimedia:
SOURCE FlexScreen
|
https://www.whsv.com/prnewswire/2022/04/08/flexscreen-opening-new-plant-procures-sizeable-commitment-with-harvey-building-products/
| 2022-04-08T18:55:03Z
|
Imagine Learning Illustrative Mathematics K-5 Completes Full Math Portfolio with EdReports' Distinction
SCOTTSDALE, Ariz., April 8, 2022 /PRNewswire/ -- Imagine Learning, the largest provider of digital curriculum solutions in the U.S., serving 10 million students in more than half the school districts nationwide, today announced that Imagine Learning Illustrative Mathematics K-5 (formerly LearnZillion) has received near-perfect ratings by EdReports, an independent nonprofit designed to improve education through evidence-based reviews of K-12 instructional materials. These new ratings complete Imagine Learning's entire "all green" K-12 core mathematics series.
Imagine Learning Illustrative Mathematics® K-12 is a problem-based IM-Certified curriculum that is designed to provide conceptual understanding, procedural fluency, strategic competence, adaptive reasoning, and a productive disposition. Students learn by doing, working their way through problems in both mathematical and real-world contexts, and constructing arguments using precise language. With this new rating, Illustrative Mathematics for all grades has met EdReports' expectations for all three gateways: Focus & Coherence, Rigor & Mathematical Practices, and Usability.
EdReports provides independent reviews of instructional materials designed to improve Grades K-12 education. The EdReports rubric supports a sequential review process through the three gateways. Green ratings indicate that a curriculum meets expectations for each gateway of the EdReports review system. Illustrative Mathematics K-5 scored green on all three gateways and received perfect scores for two of the three gateways.
"We strive to provide all students the best access to grade-level mathematics with Imagine Learning Illustrative Mathematics," said Terry Gilligan, Vice President & General Manager, Core Curriculum. "Receiving all greens from EdReports is a great honor and energizes our team to continue to provide the most innovative and effective solutions to teachers and students."
"We are proud to see Imagine Learning's Illustrative Mathematics Certified version of our grades K-5 curriculum pass EdReports' criteria for Focus & Coherence, Rigor & Balance, and Usability with flying colors," said Dr. William McCallum, CEO and co-founder of Illustrative Mathematics.
Imagine Learning Illustrative Mathematics, formerly LearnZillion, delivers a digital-first classroom experience, which enables teachers to create a student-centered, cohesive learning environment, based on research and driven by data that fully leverages the impact of high-quality curricula. As an IM-Certified partner, Imagine Learning collaborates with the Illustrative Mathematics team every step of the way by enhancing the curricula through an immersive experience with digital and print resources, including ready-to-go, customizable, and assignable lesson cards; virtual manipulatives and interactive math tools that foster mathematical practices; digital tasks, practice, and assessment that provide real-time feedback and data to inform instructional decisions; and live synchronous instruction virtually with LiveLearn.
About Illustrative Mathematics
Illustrative Mathematics is a nonprofit organization dedicated to creating a world where all learners know, use, and enjoy mathematics. Learn more at IllustrativeMathematics.org.
About Imagine Learning
Imagine Learning is a PreK–12 digital learning solutions company that ignites learning breakthroughs by designing forward-thinking solutions at the intersection of people, curricula, and technology to drive student growth. Imagine Learning serves more than 10 million students and partners with more than half the school districts nationwide. Imagine Learning's flagship products include Imagine Edgenuity®, online courseware and virtual school services solutions; supplemental and intervention solutions for literacy, language, mathematics, robotics, and coding; and high-quality, digital-first core curriculum, including Illustrative Mathematics®, EL Education®, and Odell Education®—all on the Imagine Learning Classroom—and Twig Science®. Read more about Imagine Learning's digital solutions at imaginelearning.com.
View original content to download multimedia:
SOURCE Imagine Learning LLC
|
https://www.whsv.com/prnewswire/2022/04/08/imagine-learning-rounds-out-full-k-12-math-suite-products-with-all-green-scores-edreports/
| 2022-04-08T18:55:10Z
|
OMAHA, Neb., April 8, 2022 /PRNewswire/ -- Omaha has a new indoor golf & entertainment attraction! X-Golf Omaha features 7 high-tech golf simulator bays and a full service bar. Golfers will be able to play over 45 real world courses like Pebble Beach, St. Andrews, Harbour Town, Kapalua and Bay Hill.
Players of all ages and skill levels are welcome to play on the golf simulators. X-Golf Omaha will give beginners the opportunity to tee it up and have fun without worrying about pace of play or finding their golf ball after errant shots!
Golfers can bring their own golf clubs or rent Callaway clubs. X-Golf simulators feature various game modes such as scramble, alternate shot, match play, driving range, longest drive, and closest to the pin.
The 5559 sq. ft indoor golfing facility is the perfect venue for parties, company events, or just a night out with friends and family. Andrew, one of X-Golf Omaha's first customers, gave a glowing review "Such a great time! Staff was great! Double eagle service!"
Advanced Golf Simulator Technology
The accuracy of X-Golf's simulators may have customers believing it's the real thing. "Our golf simulators use a combination of high speed cameras and laser optics to predict your shots at 98% accuracy. The chipping and putting really separate us from other simulator options'', said General Manager Ally Roos.
The simulators perform 6000 calculations with every swing to give golfers analytical readings like ball and club speed, launch angle, club path, and side/back spin. Later this year, X-Golf Omaha will be introducing a full-time PGA Professional. Lessons, group clinics, and custom club fittings will be elevated through the use of the advanced golf simulator technology.
About X-Golf
X-Golf Omaha is located at 808 N 102nd St, right next door to Topgolf. Simulator bay time can be booked online or by phone (531-867-4705) and will range from $35 to $55/hr. X-Golf is a national franchise with over 50 locations across the U.S. Omaha will be Nebraska's first location. The franchise was ranked No. 1 in Category in Entrepreneur magazine's Franchise 500®
Press Contact:
Ally Roos
Mobile (402) 216-1891
Email: Allyroos@xgolfnebraska.com
View original content to download multimedia:
SOURCE X-Golf Omaha
|
https://www.whsv.com/prnewswire/2022/04/08/indoor-golf-amp-sports-bar-now-open-omaha/
| 2022-04-08T18:55:17Z
|
PITTSBURGH, April 8, 2022 /PRNewswire/ -- "I wanted to create an accessory to secure nasal cannula and prevent it from slipping," said an inventor, from Anacoco, La., "so I invented the NOSE CANULA ASSIST. My design would enhance comfort for cannula users."
The patent-pending invention provides a more comfortable way to hold nasal cannula in place. In doing so, it eliminates the need to tighten cannula or use tape. As a result, it reduces skin irritation and it increases convenience for caregivers and patients. The invention features an effective design that is easy to use so it is ideal for individuals who use supplemental oxygen and medical facilities.
The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-JMC-2373, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:
SOURCE InventHelp
|
https://www.whsv.com/prnewswire/2022/04/08/inventhelp-inventor-develops-comfortable-way-secure-nasal-cannula-jmc-2373/
| 2022-04-08T18:55:25Z
|
PITTSBURGH, April 8, 2022 /PRNewswire/ -- "I wanted to create a simple and easy way to grip, hold and view 24 playing cards," said an inventor, from Michigan City, Ind., "so I invented FLIP'S CARD HOLDER. My design helps to reduce the frustration and energy required with manually supporting playing cards in the hands."
The invention provides an easier way to support several playing cards in the hands. In doing so, it enables the user to grip up to 24 cards at one time. As a result, it enhances comfort and convenience. The invention features a novel design that is easy to use so it is ideal for individuals with arthritis and limited manual dexterity. Additionally, it is producible in design variations and a prototype is available.
The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-JMC-2386, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:
SOURCE InventHelp
|
https://www.whsv.com/prnewswire/2022/04/08/inventhelp-inventor-develops-easier-way-hold-24-playing-cards-jmc-2386/
| 2022-04-08T18:55:32Z
|
PITTSBURGH, April 8, 2022 /PRNewswire/ -- "I'm a retired police chief and I thought there should be a quick and easy way to secure doors in a school during an active shooter situation," said an inventor, from Moorcraft, Wy., "so I invented the LOCKED-IN. My design eliminates the time and need to locate barricade materials."
The patent-pending invention provides a new security product to protect against active shooters. In doing so, it prevents a shooter from accessing the room or area. As a result, it increases safety and security and it can be adapted for use on most doors. The invention features an adaptable design that is easy to employ so it is ideal for schools, offices and other buildings.
The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-JMC-2381, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:
SOURCE InventHelp
|
https://www.whsv.com/prnewswire/2022/04/08/inventhelp-inventor-develops-product-protect-against-active-shooters-jmc-2381/
| 2022-04-08T18:55:40Z
|
PITTSBURGH, April 8, 2022 /PRNewswire/ -- "I thought there needs to be an alternative to wearing a mask," said the inventor from Raymond, Miss. "I thought of this idea to help protect lives by restricting the inflow of airborne agents through the nostrils."
He created the patent-pending BREATHABLE NOSE INSERTS (FILTERED) to fulfill the need for breathing filtered air to avoid sickness and disease. This device provides an alternative to wearing a mask and peace of mind for safety-conscious citizens venturing out in public places. Additionally, this device is compact, affordable, lightweight, comfortable to wear and disposable.
The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-JTK-123, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:
SOURCE InventHelp
|
https://www.whsv.com/prnewswire/2022/04/08/inventhelp-presents-nostril-filtration-device-jtk-123/
| 2022-04-08T18:55:47Z
|
PITTSBURGH, April 8, 2022 /PRNewswire/ -- "My husband had always used a lawn mower but after having problems with his knees he had difficulty getting on and off safely," said the inventor from Fort White Fla. "I thought of this idea to help provide assistance when entering or exiting the mower deck."
She created a prototype for PULL BAR that fulfills the need for a bar or handle device that could be affixed to any zero-turn riding lawn mower for safe entrance and exit. This invention provides an easy accessible component to hold onto, providing stability and safety. Additionally, this could help reduce slips, falls and potential associated injuries.
The original design was submitted to the Miami sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-JXA-117, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:
SOURCE InventHelp
|
https://www.whsv.com/prnewswire/2022/04/08/inventhelp-presents-riding-mower-assistant-jxa-117/
| 2022-04-08T18:55:53Z
|
Results from Phase 1 Dose Escalation Study of Tegavivint in Patients with Desmoid Tumors to Be Featured as in a Poster Presentation on April 12, 2022
HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that three posters involving research into tegavivint will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including initial results from a Phase 1 study of tegavivint in patients with desmoid sarcomas. AACR 2022 is being held April 8-13, 2022, in New Orleans.
Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin Beta-like Protein One (TBL1), a novel downstream co-factor in the Wnt/beta-catenin signaling pathway. Increased expression beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types. Tegavivint's targeting of TBL1 prevents TBL1/beta-catenin complex formation, specifically inhibiting beta-catenin's oncogenic transcriptional activity without disrupting key cell membrane functions that have been linked to toxicity common to other drugs in this pathway.
The first poster, titled, "A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors," will be presented on Tuesday, April 12, 2022, at 9:00 a.m., CDT, during the Phase I Clinical Trials 2 session (poster board number 10; abstract number CT185). The poster details results from the dose-escalation portion of a Phase 1 trial of tegavivint in adult patients with progressive, unresectable desmoid sarcoma. The primary objective of the study was to evaluate the safety and tolerability of tegavivint administered once weekly and to determine a recommended phase 2 dose (RP2D). As described in the poster, tegavivint was well tolerated with grade 3 treatment related adverse events (TRAEs) reported in four patients for hypophosphatemia, stomatitis, headache, and elevated ALT; no grade 4 or 5 TRAEs were observed. No dose-limiting toxicities (DLT) were observed, and the maximum tolerated dose (MTD) was not declared. Objective responses (WHO and RECIST) were observed at multiple dose levels and the clinical benefit rate was 82% (n = 14). The RP2D was declared based on lack of DLTs, pharmacologically relevant plasma concentrations, and preliminary efficacy. In conclusion, tegavivint's preliminary efficacy and favorable safety profile supported continued development through a dose expansion arm of the study, data from which will be presented at a future conference.
"We are very excited to report research describing tegavivint's unique properties and therapeutic potential in multiple poster presentations at AACR 2022; particularly the results of our first-in-man Phase 1 clinical study," said Rahul Aras, PhD, CEO of Iterion. "Taken together, these results demonstrate inhibition of TBL1 as a clinically viable strategy to curtail nuclear beta-catenin oncogenic activity in multiple cancer indications."
Dr. Aras continued, "Importantly, results from the dose-escalation part of the Phase 1 study of tegavivint in patients with progressive desmoid sarcomas demonstrated the drug to be well-tolerated and indicated clinical activity in this difficult-to-treat disease. While regarded as a high value oncology target, nuclear beta-catenin has historically been considered undruggable through conventional drug development. Upstream approaches targeting the Wnt/beta-catenin pathway have not clinically advanced, typically because of toxicity in early phase clinical development. However, we believe tegavivint's ability to selectively disrupt the interaction of beta-catenin and TBL1 results in the specific degradation of nuclear beta-catenin without impacting key cell membrane functions that have been linked to previously reported toxicity. The Phase 1 data presented at AACR 2022 demonstrate this capability, which we are now further investigating in three separate, ongoing clinical trials of tegavivint in AML, non-small cell lung cancer, and pediatric solid tumors."
The second poster, titled, "Targeting TBL1 inhibits nuclear β-catenin activity and enhances immune checkpoint inhibition efficacy in osteosarcoma," will be presented virtually by Kengo Nakahata, MD, PhD, Postdoctoral Associate, Texas Children's Hospital on Friday, April 8, 2022, at 12:00 p.m., CDT. The poster reports results from a pre-clinical study examining the influence of tegavivint on the osteosarcoma (OS) tumor immune microenvironment and potential combination with anti-PD1 antibody therapy. Data from the study indicated that tegavivint as a monotherapy significantly suppressed the growth of murine OS tumors (p<0.05), while anti-PD1 monotherapy did not show any significant anti-tumor activity. Combining anti-PD1 with tegavivint was able to further improve overall anti-tumor activity. Tegavivint treatment was also associated with an intratumoral increase in CD8-positive T-cells and NK cells compared with control tumors.
The third poster, titled, "Novel combination therapies against AML with 3q26 lesions and EVI1 overexpression," will be presented virtually by Christine Birdwell, Research Scientist, MD Anderson Cancer Center on Tuesday April 12, 2022, at 9:00 a.m., CDT. The poster describes a study examining the potential for tegavivint as a therapy against AML models harboring 3q26 lesions and EVI1 overexpression. EVI1 overexpression is known to confer poor response to therapy and, subsequently, inferior relapse-free and overall survival in AML. As reported in the poster, in vitro treatment with tegavivint dose-dependently induced apoptosis in AML cell lines and patient-derived AML cells with 3q26.2 lesions with and without monosomy. Furthermore, in vivo studies demonstrated that tegavivint combined with BCL2 inhibitor, venetoclax, significantly reduced AML burden and improved overall survival in mouse models, without toxicity, compared to treatment with each drug alone.
Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, tegavivint, is a potent and selective small molecule that binds to TBL1 in the nucleus, inhibiting nuclear beta-catenin signaling and oncogenic activity. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that tegavivint has the potential for clinical utility in multiple cancer types. Currently, tegavivint is the subject of three separate clinical trials: a Phase 1 clinical trial sponsored by MD Anderson Cancer Center in patients with relapsed or refractory acute myeloid leukemia (AML); a Phase 1/2 clinical trial sponsored by Children's Oncology Group Pediatric Early Phase Clinical Trials Network in pediatric patients with sarcomas, lymphomas and other solid tumors, and a Phase 1 clinical trial sponsored by Ohio State University Comprehensive Cancer Center in EGRF-positive non-small cell lung cancer (NSCLC). Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on Iterion, please visit https://iteriontherapeutics.com.
Contact
Tiberend Strategic Advisors, Inc.
Jason Rando (Media)
917-930-6346
jrando@tiberend.com
View original content to download multimedia:
SOURCE Iterion Therapeutics
|
https://www.whsv.com/prnewswire/2022/04/08/iterion-therapeutics-announces-presentation-three-posters-involving-research-into-tegavivint-aacr-2022-annual-meeting/
| 2022-04-08T18:56:00Z
|
Novel, investigational drug JZP815 inhibited tumor growth in several RAS- and BRAF-mutated solid tumor models, and demonstrated enhanced activity when combined with other MAPK pathway inhibitors
Jazz plans to submit an investigational new drug application (IND) for JZP815 this year
DUBLIN, April 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and collaboration partner Redx Pharma (AIM: REDX) today presented data showing the pan-RAF kinase inhibitor, JZP815, was active in multiple RAF- and RAS-mutant tumor pre-clinical models, with a pharmacokinetic profile that may provide drug exposure required for target engagement in humans.
"As a precision pan-RAF inhibitor with a differentiated mechanism of action, JZP815 is a promising drug candidate for several types of difficult-to-treat solid tumors, including colorectal cancer, non-small cell lung cancer, melanoma and ovarian cancer," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "By not inducing paradoxical pathway activation, which can stimulate the growth of certain cancers, JZP815 may offer a significant advancement in the pan-RAF inhibitor class with the potential to address unmet patient need. We look forward to submitting the investigational new drug application for JZP815 this year."
JZP815 targets specific components of the mitogen-activated protein kinase (MAPK) pathway, namely all three RAF proteins – ARAF, BRAF and CRAF – that when activated by oncogenic mutations, can be a frequent driver of human cancer.
Pre-clinical data of JZP815 administered orally as both a monotherapy and in combination with mitogen-activated protein kinase (MAPK) pathway inhibitors were presented at the American Association for Cancer Research 2022 Annual Meeting (AACR). Key findings of several pre-clinical models include1:
- JZP815 inhibited all 3 RAF kinase family members (ARAF, BRAF, CRAF) at low-to-sub nanomolar potencies in biochemical assays.
- JZP815 did not induce significant paradoxical pathway activation, observed with approved first generation BRAF-selective inhibitors, while demonstrating equivalent cellular potencies for MAPK pathway inhibition driven by either mutant RAF monomers or dimers or mutant RAS-induced RAF dimers in tumor cells.
- JZP815 significantly inhibited tumor growth, including inducing tumor regression, as a single agent in multiple mouse xenograft solid tumor models harboring RAS and/or BRAF mutations.
- JZP815's pharmacokinetic profile sustained on-target pathway pharmacodynamic responses in a predictable dose and time dependent manner.
- JZP815 demonstrated enhanced activity when combined with inhibitors of other MAPK pathway components including MEK1/2, SOS1, SHP2 and EGFR inhibitors in both class 2 and class 3 mutant BRAF patient-derived tumor cells ex vivo, and KRAS mutant NSCLC and colorectal cancer xenografts in vivo.
The full Jazz presentation abstract, titled, "JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models" is available at https://www.abstractsonline.com/pp8/#!/10517/presentation/15283.
Jazz acquired JZP815 from Redx Pharma, and the two companies are collaborating on this pre-clinical research. Jazz plans to submit an IND for JZP815 this year.
About JZP815
JZP815 is an investigational, pre-clinical stage pan-RAF kinase inhibitor that was discovered and developed using state-of-the-art screening methodologies and medicinal chemistry. JZP815 targets specific components of the mitogen-activated protein kinase (MAPK) pathway that, when activated by oncogenic mutations, can be a frequent driver of human cancer. JZP815 potently inhibits both monomer- and dimer-driven RAF signaling (e.g., RAS-induced), prevents paradoxical pathway activation induced by BRAF selective inhibition, and is active against class 1, class 2, and class 3 BRAF mutants, as well as BRAF fusions and CRAF mutants. JZP815 is not currently approved for use anywhere in the world. JZP815 is part of Jazz's growing early-stage R&D pipeline focused on precision oncology in solid tumors.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' belief in the potential of JZP815 to provide a potentially new therapeutic option for multiple solid tumor types; progressing JZP815 to the clinic and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, effectively registering JZP815 with FDA and initiating clinical trials; launching and commercializing new products; obtaining and maintaining adequate coverage and reimbursement for the company's products; delays or problems in the supply or manufacture of the company's products; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2021 and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
References
1 Hauptschein, R. et al. JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models. American Association for Cancer Research 2022 Annual Meeting. Available at www.abstractsonline.com/pp8/#!/10517/presentation/15283. Accessed April 2022.
View original content to download multimedia:
SOURCE Jazz Pharmaceuticals plc
|
https://www.whsv.com/prnewswire/2022/04/08/jazz-pharmaceuticals-presents-pre-clinical-data-pan-raf-inhibitor-jzp815-including-pharmacokinetic-properties-efficacy-multiple-solid-tumor-types/
| 2022-04-08T18:56:07Z
|
SILVER SPRING, Md., April 8, 2022 /PRNewswire/ -- Ensuring the availability of innovative interventions for people is a shared priority for both the Centers for Medicaid & Medicare Services (CMS) and the U.S. Food and Drug Administration (FDA). We recognize the important and related – but different – roles of our respective agencies and know that CMS and FDA decisions have an outsized impact on the U.S. health care system, as well as implications for the rest of the world.
Underpinning both of our agencies' work is the unwavering commitment to use reliable data to ensure that effective treatments are made available to patients. The FDA's decision to approve a new medical product is based on a careful evaluation of the available data and a determination that the medical product is safe and effective for its intended use. In some instances, the FDA has the authority to require additional studies after approval to provide additional information regarding the anticipated clinical benefit for the medical product.
CMS can conduct its own independent review to determine whether an item or service should be covered nationally by Medicare, including examining whether it is reasonable and necessary for use in the Medicare population.
The work of both of our agencies is critical to ensure that medical products are available to people across the country.
We recognize the impact these decisions have on people with serious and life-threatening conditions and their loved ones. We share a common goal of wanting to advance the development and availability of innovative medical products. Our agencies remain committed to using our distinct set of authorities to ensure the continued availability of medical products that meet our respective standards to care for the people we serve.
# # #
Media Contact: FDA Office of Media Affairs, 301-796-4540
Consumer Inquiries: 888-INFO-FDA
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
View original content to download multimedia:
SOURCE U.S. Food and Drug Administration
|
https://www.whsv.com/prnewswire/2022/04/08/joint-statement-cms-administrator-chiquita-brooks-lasure-fda-commissioner-robert-m-califf-md-ensuring-access-safe-effective-treatments/
| 2022-04-08T18:56:16Z
|
TORONTO, April 8, 2022 /PRNewswire/ - Global IT research and advisory firm Info-Tech Research Group has highlighted the key changes in Microsoft's new agreement type, the new commerce experience (NCE). Through expert analysis, the firm explains how this will impact licensing renewals and shift the landscape of how Microsoft will do business moving forward. Understanding these changes will be essential for organizations to negotiate upcoming renewals effectively.
"Customers renewing agreements with Microsoft will want to take the appropriate time and do the necessary due diligence to ensure there are no surprises waiting for them in their deals," says Research Director Aadil Nanji. "Microsoft will continue to institute changes like these. To be able to negotiate from a position of strength, customers must know what cards Microsoft is holding."
Info-Tech states that organizations with fewer than 2,400 licenses and those that require month-to-month flexibility will likely be migrated to this model. Along with pricing increases on its cloud subscription products, Microsoft has made changes to its Unified Support commercial terms.
New Commerce Experience
In late 2021, Microsoft unveiled the new commerce experience (NCE) as a successor to the Cloud Solution Provider (CSP) program. The general availability of the NCE started in January 2022, with promotions available to customers when migrating over from a CSP agreement.
The CSP channel was primarily used by customers for the flexibility it provided. For licenses purchased on a month-to-month basis, the CSP allowed customers to change quantities easily. Additionally, the CSP was the channel that customers were pushed toward since the shift in minimum quantities on the Enterprise Agreement (EA) changed from 250 to 500 licenses.
"With the NCE agreement, Microsoft's aim was to standardize purchasing transactions with Azure, which they later extended outward to Office 365, Microsoft 365, Dynamics 365, Windows 365, and Power Platform transactions," adds Nanji.
There are three core differences between the CSP and NCE:
- Microsoft charges a 20% premium if a month-to-month agreement is desired in NCE.
- NCE reduces flexibility for midterm true-down.
- NCE agreements provide the ability to go from a one-year-only agreement to a three-year option.
Additional differences are listed in the table below:
"Microsoft may allow customers who are currently on a CSP agreement one final renewal term before migrating them over to the NCE agreement," explains Nanji. "This final renewal will be beneficial, as it will preserve month-to-month flexibility for organizations who require it. Customers who have already signed the overarching Microsoft Customer Agreement (MCA) will not have to sign it again to purchase through the NCE. However, similar to a CSP, an MCA agreement will be required to purchase from an NCE."
Pricing Increases
In September 2021, Microsoft announced pricing increases that would affect the productivity suite subscription products. These increases went into effect on March 1, 2022 and apply globally. The table below lists the old and new pricing.
"Microsoft has attributed the price changes to the addition of various applications and features, focusing in particular on security features such as email encryption, data loss prevention, and compliance requirements for eDiscovery and core litigation hold," states Nanji. "Additionally, Teams improvements and the addition of audioconferencing capabilities to all E3 SKUs contribute to the price increases."
The current recourse for customers to combat these price increases is to seek additional discounts. However, Microsoft has tied a product portfolio mix to any additional discounting. The desired product mix would include Azure, Dynamics, Power Platform, and E5 Security bundles.
Unified Support
"Microsoft has implemented an array of changes related to Unified Support that will have a significant impact on deals negotiated," explains Nanji. "Some of those changes relate to the services or levels of support offered and how these costs are calculated."
When signing a new deal or renewing, Info-Tech recommends that organizations examine the following key points:
- Beware of hyperlinks with information that could change at Microsoft's will.
- Ensure detailed information of the previous term's usage is provided.
- A new offering has been introduced called Unified Enterprise, which is separate from the Advanced and Performance support tiers. Unified Enterprise has redefined severity and response time levels.
- Multi-year deals are now available.
- Ask Microsoft to provide detailed breakdowns of any pricing provided.
- Discounts can be negotiated but are dependent on deal structure characteristics.
"The most impactful change Microsoft has made relates to repricing a Unified Support Agreement," shares Nanji. "In agreements that Info-Tech has reviewed, we've seen that Microsoft has begun including a clause within the Unified Support statement of work stating that, should the organization's Enterprise Agreement spend change by 5% or more than the preceding annual period, Microsoft can reprice the correlated Unified Support Agreement. This could cause many organizations heartburn throughout their agreements and unexpected spend. We at Info-Tech recommend that customers ask Microsoft to strike out that language."
Info-Tech adds that organizations considering purchasing additional Microsoft services, such as an E5, can experience significant and unexpected cost increases. Organizations that are growing or have merger activity are also at greater risk. The best course of action for customers is to negotiate with Microsoft to strike this clause since it has only recently been included in Unified Support Agreements.
"With the magnitude of the aforementioned cost impacts, a growing proportion of organizations are looking toward third-party Microsoft support," says Nanji. "Depending on the criticality of systems being supported, this may be a viable solution to reduce support fees by close to 50%."
Customers renewing agreements with Microsoft will want to take the appropriate time and do the necessary due diligence to ensure there are no surprises waiting for them in their deals.
"Microsoft will continue to institute changes like these, and to be able to negotiate from a position of strength customers must know what cards Microsoft is holding. A trusted partner like Info-Tech can aid in this process by reviewing and assessing inherent risks within Microsoft agreements and providing recommendations based on industry knowledge and deals seen daily.
To learn more on how to take control of Microsoft licensing, download and read Info-Tech's complete Modernize Your Microsoft Licensing for the Cloud Era blueprint.
To learn more about Info-Tech Research Group and to download all the latest research, visit www.infotech.com and connect via LinkedIn, Twitter, and Facebook.
Media professionals are encouraged to register for Info-Tech's Media Insiders program for more research and insights. This program provides unrestricted, on-demand access to IT, HR, and software industry content and subject matter experts from a group of more than 200 research analysts. To apply for access, contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is the one of the world's leading information technology research and advisory firms, proudly serving over 30,000 IT professionals. The company produces unbiased and highly relevant research to help CIOs and IT leaders make strategic, timely, and well-informed decisions. For 25 years, Info-Tech has partnered closely with IT teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations.
View original content to download multimedia:
SOURCE Info-Tech Research Group
|
https://www.whsv.com/prnewswire/2022/04/08/key-changes-that-will-impact-future-microsoft-licensing-renewals/
| 2022-04-08T18:56:22Z
|
Enhanced recommendation engine for content and bots puts Conversational AI
to work for agents, saving time and improving conversation outcomes
NEW YORK, April 8, 2022 /PRNewswire/ -- LivePerson, Inc. (Nasdaq: LPSN), a global leader in Conversational AI, today announced significant upgrades to its Conversation Assist capabilities, which provide agents with AI-driven, real-time recommendations for inserting content and bots directly into customer conversations with a single click.
Conversation Assist instantly arms agents with the right answers and AI support to help customers get assistance or purchase products. It analyzes every message from a customer to determine if a recommendation can help resolve their intent, then presents relevant content and automations directly inline within the conversation in the agent's workspace. Agents can then immediately send recommended answers or delegate tasks to recommended bots.
With Conversation Assist, agents remain in full control of providing the best customer experiences. They can easily personalize any recommended text before sending, as well as remove bots from conversations as needed.
New enhancements to Conversation Assist's recommendation engine include:
- The ability to draw from several recommendation sources at once, including a brand's knowledge base, automations built through LivePerson's Conversation Builder, and bots from third-party platforms like DialogFlow and Watson.
- An intuitive interface presenting multiple recommendations inline in the conversation, allowing agents to select the best one for the job.
- An easy-to-use dashboard of rich analytics, empowering brands to continuously monitor and improve recommendation performance and agent engagement.
Conversation Assist drives meaningful outcomes for consumers, agents, and brands, including:
- Improved consumer sentiment
- Reduced agent handle time and time to respond
- Increased number of concurrent agent conversations
- Reduced time to onboard new agents
- Increased revenue
A major British telco brand uses Conversation Assist to increase efficiency and compliance accuracy for sales conversations. By taking advantage of over 15,000 bot recommendations per month, the brand has seen estimated productivity savings of 5 minutes per conversation, as well as agent handling time reduction of 13.5%, all while increasing sales.
"LivePerson's Conversational AI helps brands better understand customer intents, connect across channels, and deliver meaningful outcomes. Powered by our natural-feeling AI, Conversation Assist's enhanced recommendation engine helps balance the efficiency of bots and human touch of a brand's agents to provide consumers with even more efficient and helpful conversations," said Rob LoCascio, founder and CEO of LivePerson.
Conversation Assist is a fully integrated solution within LivePerson's Conversational Cloud, which powers customer care and commerce across industries including retail, healthcare, financial services, travel and hospitality, and more.
For more information, please visit www.liveperson.com.
About LivePerson, Inc.
LivePerson (NASDAQ:LPSN) is a leading Conversational AI company creating digital experiences that are Curiously Human. Every person is unique, and our technology makes it possible for companies to treat their audiences that way at scale. Our customers, including leading brands like HSBC, Orange, and GM Financial, can now meet consumers where they are across social media, messaging, email, voice, and more. Nearly a billion conversational interactions are powered by our Conversational Cloud each month. Out of that comes a uniquely rich data set for AI for brands to build connections that are anything but artificial. Fast Company named us the #1 Most Innovative AI Company in the world. To talk with us or our Conversational AI, please visit liveperson.com.
Forward-Looking Statements
Statements in this press release regarding LivePerson that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including but not limited to financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It should be clearly understood that the current information and beliefs upon which we base our expectations may change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Some of the factors that could cause actual results to differ materially from the forward-looking statements contained herein include, without limitation: major public health issues, and specifically the pandemic caused by the spread of COVID-19; delays in our implementation cycles; customer retention and their purchase of additional services, attracting new customers and new consumer users of our consumer services; concerns relating to the Internet that could result in new legislation or negative public perception; risks related to new regulatory or other legal requirements that could materially impact our business; risks relating to governmental export controls risks related to industry-specific regulation and unfavorable industry-specific laws, regulations or interpretive positions; future regulation of the Internet or mobile devices; failures or security breaches in our services, those of our third party providers, or customers; risks related to the regulation or possible misappropriation of personal information belonging to our customers' digital users; technology systems beyond our control and technology-related defects that could disrupt the LivePerson services, risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties; risks associated with the use of AI in our product offerings; errors, failures or "bugs" in our products may be difficult to correct; our ability to license necessary third party products or software for use in our products and services, and our ability to successfully integrate third party software;legal liability and/or negative publicity for the services provided to consumers via our technology platforms. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to the reports and documents filed from time to time by us with the Securities and Exchange Commission for a discussion of these and other important factors that could cause actual results to differ from those discussed in forward-looking statements.
CONTACT: Mike Tague, mtague@liveperson.com
View original content to download multimedia:
SOURCE LivePerson, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/liveperson-upgrades-conversation-assist-supercharge-agents-with-real-time-ai-recommendations/
| 2022-04-08T18:56:29Z
|
Note to editors: Relevant photos are available here for your use.
WHITTIER, Calif., April 8, 2022 /PRNewswire/ -- Today, the Los Angeles County Sanitation Districts, which manages wastewater and solid waste for over half the residents in Los Angeles County, announced that its operations result in a net reduction of greenhouse gases into the environment. A third party reviewed and verified the Districts' 2021 emissions inventory.
"Our mission is to convert waste into resources. For decades, we and our partners have undertaken activities that reduce greenhouse gas emissions. For example, by converting sewage into recycled water, we reduce the need to import water, the energy used to import water and the greenhouse gas emissions used to create energy," said Robert C. Ferrante, Chief Engineer and General Manager for the Sanitation Districts. "We're proud to have exceeded carbon neutrality in 2021 and are looking for more ways to reduce regional greenhouse gas emissions."
The Sanitation Districts recently published a document called "Reducing Our Carbon Footprint: The Sanitation Districts' Greenhouse Gas Reduction Initiatives," which is available at lacsd.org/GHG . This summary describes the agency's seven biggest initiatives that reduce greenhouse gas emissions. Most of these initiatives produce green power, which reduces use of fossil fuels, a main contributor to global greenhouse gas emissions. For example, the biogas created at the agency's landfills and wastewater treatment plants is converted into enough electricity to meet the needs of 23,000 homes. Other initiatives include converting food waste into vehicle fuel, commodities recycling, water recycling, using alternatives to fossil fuel in vehicles, biosolids management and green waste management. Collectively, these initiatives avoided 362,000 metric tons of carbon dioxide equivalents, which is equivalent to taking 78,000 cars off the road.
The Sanitation Districts are a regional public agency that serves the wastewater and solid waste management needs of 78 cities and unincorporated areas in Los Angeles County. The agency protects public health and the environment and, in so doing, converts waste into resources like recycled water, green energy and recycled materials.
Districts Contact: Bryan Langpap
(562) 908-4288, ext. 2302
blangpap@lacsd.org
View original content to download multimedia:
SOURCE Sanitation Districts of Los Angeles County
|
https://www.whsv.com/prnewswire/2022/04/08/los-angeles-county-sanitation-districts-achieve-carbon-neutrality/
| 2022-04-08T18:56:36Z
|
LOS ANGELES, April 8, 2022 /PRNewswire/ -- Today, Penske Media (PMC) announced that Marquetta Moore joins the company presiding over Talent Curation and Bookings across PMC's prestigious portfolio of brands. Moore's role will focus primarily on curating and programming talent for Penske Media's proprietary LA3C festival, a first-time music and culture festival celebrating Los Angeles, launching December 10 and 11, 2022 in Los Angeles State Historic Park. Moore will also work closely with Penske Media's brands to secure talent and drive the programming for signature events and live experiences.
Prior to joining PMC, Moore served as the Vice President of Music and Celebrity Talent for Revolt TV for 9 years. At Revolt Media, Moore reinvigorated original programming, digital initiatives, conferences, awards shows, and activations by consistently identifying, booking, and bringing top-tier talent to the stage. She has been responsible for countless landmark events leveraging her vast network and sterling reputation among record labels, publicists, agents, and managers.
"We are thrilled to have Marquetta join our team. Her passion and creativity are evident, and we look forward to watching her bring her incredible skill set, vision, and infectious energy to the LA3C festival and beyond", said Brooke Jaffe, VP of Public Affairs and Strategy.
"Having the opportunity to curate the talent for LA3C in its launch year is a dream. As a long time Angelino, I am passionate about highlighting the incredibly rich and diverse talent of the city and feel so inspired by the mission of the festival," said Moore. "I am also so thrilled to join PMC, working with such world-class and iconic brands. "
Born and raised just outside of Los Angeles in San Bernardino, CA, Moore attended the Annenberg School for Communications & Journalism at University of Southern California. Studying the culture of the entertainment industry in class and after hours, she went on to intern at ABC Entertainment as part of the Emma Bowen Foundation—which supports minority interests in media. During 2001, she took her first full-time job as a Talent Associate at ABC. Over the course of the next decade, she worked as a Talent Associate at MTV and Talent Executive at BET Networks before becoming Broadcast Relations Director for MEETON in 2011. She spent two years at Complex Media as a Celebrity Producer Consultant, proving integral to the launch of Complex TV. 2013 saw her join Revolt in the role of Director, Music & Talent Relations.
About Penske Media Corporation
PMC is a leading independent global media and information services company whose award-winning content attracts a passionate audience. Since 2004, Penske Media has been a pioneer in digital media and a platform innovator, reaching viewers on all screens across its ever-growing constellation of iconic brands, which includes Variety, Rolling Stone, The Hollywood Reporter, Billboard, WWD, SHE Media, Robb Report, Deadline, Sportico, BGR, ARTnews, Fairchild Media, Vibe, IndieWire, Dirt, Gold Derby and Spy.com, among many others. PMC's journalists and content creators deliver daily the most comprehensive news and information in their industries and areas of coverage, unequaled in ambition, depth, and courage. Headquartered in New York and Los Angeles with additional offices in 14 countries worldwide, PMC believes companies should not only be profitable but also forces for good.
View original content to download multimedia:
SOURCE Penske Media Corporation
|
https://www.whsv.com/prnewswire/2022/04/08/marquetta-moore-joins-penske-media-head-talent-curation-bookings/
| 2022-04-08T18:56:42Z
|
Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models
Results support advancement of preclinical development toward initiating clinical studies in metastatic colorectal cancer patients
HOUSTON, April 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that preclinical data of Annamycin tested in syngeneic models of metastatic colorectal cancer established in lungs or liver was accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.
Details of the poster presentation are as follows:
Title: New approach to target metastatic colorectal cancer organotropism with L-Annamycin
Track: Experimental and Molecular Therapeutics
Poster Number: 4048
Session: PO.ET06.05 - New Chemotherapy Agents
Presentation Type: E-Poster presentation
Session Date and Time: Wednesday, April 13, 2022, from 9:00 am – 12:30 p.m. CDT
Section: 27
The objective of this study was to assess the efficacy of Annamycin in experimental colorectal cancer liver and lung metastasis models. The efficacy of Annamycin was tested in syngeneic models of metastatic colorectal cancer established in lungs or liver. For lung metastasis model, CT26-Luc cells were injected intravenously (IV) into Balb/c mice, followed by weekly IV treatment of Annamycin (4 and 6 mg/kg). The liver metastatic model was established using intrasplenic injection protocol. Mice received six weekly IV injections of 4 mg/kg of Annamycin or vehicle. Bioluminescent imaging (BLI), Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) were used to track tumor progression.
Annamycin exhibited robust antitumor activity in both models. In the lung metastasis model, a dose-dependent delay in the tumor progression was visualized by both BLI and CT scan in the Annamycin treated group. The delay correlated with 272% extension of survival in the group receiving 6 mg/kg Annamycin [median survival (MS) 79d for treated vs 29d vehicle, p<0.0001] and 234% for the animals dosed with Annamycin at 4 mg/kg [MS 68d, p=0.0012]. In the liver metastasis model, all vehicle-treated mice showed massive tumors in the liver and peritoneal cavity as monitored by BLI and MRI. In the vehicle group, 13/14 died or were euthanized by 35d (median survival was 34.5d). Yet, no tumors were detected by BLI or MRI in Annamycin treated mice as of 44d and 0/14 mice died (100% survival). This indicates a highly significant (P< 0.0001) extension of survival (ongoing experiment).
"We continue to be encouraged by the growing body of robust preclinical and human clinical data demonstrated by Annamycin. The positive results seen in these preclinical models provide added confidence in the potential follow-on development opportunities we believe Annamycin holds. While metastatic colorectal cancer is not an immediate area of focus for us, this data set continues to provide valuable insight as we advance its clinical development for the treatment of highly resistant tumors," commented Walter Klemp, Chairman and CEO of Moleculin.
In summary, the strategy to develop anticancer agents that imitate metastatic colorectal cancer organotropism appears to be highly promising and is supported by these results. This study demonstrating efficacy of Annamycin in colorectal cancer models provides convincing evidence for further preclinical development aimed at initiation of clinical studies in metastatic colorectal cancer patients.
Annamycin is the Company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin, as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines. Importantly, Annamycin has also demonstrated a lack of cardiotoxicity in multiple human clinical trials, including ongoing trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, and the Company believes that the use of Annamycin may not face the same usage limitations imposed on doxorubicin, one of the most common currently prescribed anthracyclines. Annamycin is currently in development for the treatment of AML and STS lung metastases and the Company believes it may have the potential to treat a number of additional indications.
Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of STS lung metastases, in addition to Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia.
For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether the results described in the poster will be shown in follow on preclinical and clinical development and whether the Company will be able to develop Annamycin to treat additional indications . Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:
SOURCE Moleculin Biotech, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/moleculin-announces-presentation-positive-preclinical-annamycin-data-aacr-2022-annual-meeting/
| 2022-04-08T18:56:49Z
|
DENVER, April 8, 2022 /PRNewswire/ -- Morris Animal Foundation is proud to be recognized by The NonProfit Times as one of the top 50 Best Nonprofits To Work For 2022. The Foundation, which works with researchers from around the world to advance animal health, ranked 17th among medium-sized nonprofits. The award, designed to identify and recognize the best employers in the nonprofit industry, is the second in as many years for the Foundation.
"We are honored to be recognized by The NonProfit Times as a Best Nonprofits To Work For 2022, particularly given the ongoing challenges of the COVID-19 pandemic in workplaces globally," said Tiffany Grunert, Morris Animal Foundation President and CEO. "Year two of primarily remote work came with its own set of unique challenges for us, but I am so proud of how our leadership team, staff members and Board of Trustees were able to adapt and thrive.
"Our mission as a foundation has always been to advance the health and well-being of animals around the world and it's our incredible staff members who make it all possible."
As the pandemic stretched into year two, Morris Animal Foundation continued to practice its safety-first approach and maintain its work-from-home policy. Having a year of remote experience helped the Foundation refine its approach which included new virtual activities to help employees stay connected, expanded benefits, more investment in virtual infrastructure, expanded cybersecurity efforts and other enhancements.
Today, the Foundation continues to focus on investing in its mission and its people by supporting the well-being of all staff members and nurturing a thriving, inclusive culture grounded in the Foundation's core values of excellence, respect, compassion, collaboration, innovation and determination.
The Best Nonprofits To Work For survey and awards process is conducted by Best Companies Group. Winners are announced and published in The NonProfit Times, the leading national business publication for nonprofit managers.
Nonprofits from across the country compete for the prestigious honor by entering a two-part survey process. Part one consists of an evaluation of the organization's workplace policies, practices, philosophies, systems and demographics. The second part of the survey process measures employee satisfaction. When combined, the scores determine which organizations make the list of top 50 nonprofits in the country.
About Morris Animal Foundation
Morris Animal Foundation's mission is to bridge science and resources to advance the health of animals. Headquartered in Denver, and founded in 1948, it is one of the largest nonprofit animal health research organizations in the world, funding more than $142 million in critical studies across a broad range of species. Learn more at morrisanimalfoundation.org.
View original content to download multimedia:
SOURCE Morris Animal Foundation
|
https://www.whsv.com/prnewswire/2022/04/08/morris-animal-foundation-named-one-top-50-best-nonprofits-work-2022-by-nonprofit-times/
| 2022-04-08T18:56:56Z
|
FAIRFIELD COUNTY, Conn. , April 8, 2022 /PRNewswire/ -- Nardelli's Grinder Shoppe continues to open more Connecticut locations to sell their famous Award-Winning grinders. G. Matthew Youngs, the franchise owner of the newly opened location in Norwalk, CT, – as of March 2022 – discovered Nardelli's in 2012 when he and his friends were at a lacrosse tournament in central Connecticut. After experiencing Nardelli's, Matthew and his friends made it a competition to find the best Italian combo by exploring various delis. They were never able to find one that beat Nardelli's. Because of this, Matthew and his friends would drive 20-30 minutes to the Danbury or Milford locations for the sensational Italian combo. Matthew was intrigued by an opportunity to bring Nardelli's to lower Fairfield County – and succeeded.
"Since opening, customers that are familiar with Nardelli's are already saying 'We're so glad you're finally open and you're here,' and customers that didn't already know Nardelli's are quickly becoming repeat customers," said Matthew Youngs, franchise owner of the Norwalk, CT, Nardelli's location. Matthew intends to open at least four more stores targeting Fairfield, Greenwich, Stamford, and Westchester County.
For more information on the new Norwalk location, contact franchise owner, G. Matthew Youngs, 345 Main Ave, Norwalk, CT 06851 at (203) 354-8300. Closed on Sunday's. For menu and catering options, please visit https://nardellis.com.
About Nardelli's Grinder Shoppe: Nardelli's Grinder Shoppe, established in 1922, pleases guests with Award Winning grinder sandwiches and wraps, salads, and various traditional Italian favorites in a fast-casual restaurant. The business has been in the family for three generations, and this year Nardelli's is celebrating its 100th ANNIVERSARY. The next openings scheduled for Sturbridge, MA and East Lyme, CT. To learn more about Nardelli's Grinder Shoppe, visit their website at https://nardellis.com/.
View original content:
SOURCE Nardelli's Franchising, LLC
|
https://www.whsv.com/prnewswire/2022/04/08/nardellis-grinder-shoppe-opens-its-16th-location-its-first-fairfield-county-ct/
| 2022-04-08T18:57:02Z
|
~ New diacylglycerol kinase assay panel provides researchers for the first time with ten new lipid kinase targets ~
~ New systems biology approach enhances preclinical characterization of the WEE-1 inhibitor adavosertib ~
MALVERN, Pa., April 8, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.
"At AACR 2022, we look forward to showcasing data from our comprehensive suite of innovative drug discovery services that continue to support our clients in their oncology research goals," said Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology. "With these data, we continue to build upon our capabilities as a world leader and partner in drug discovery."
New data will be presented on the Company's diacylglycerol kinase assay panel, which will aid researchers in better informing isoform specific inhibitor discovery and provides researchers for the first time with ten new lipid kinase targets. Additionally, Reaction will share data on a new biology approach, leading to an enhanced preclinical characterization of the WEE-1 inhibitor adavosertib.
Reaction will present data from a number of new and enhanced assays and other drug discovery services in oncology. The full range of data presented at AACR include:
- Development of diacylglycerol kinase assays to facilitate isoform specific inhibitor discovery (Sunday, April 10, 2022, 1:30 PM - 5:00 PM; Poster Section 8, Poster Board Number: 24, Permanent Abstract Number: 170)
- Characterization of KRas pathway inhibitors in 2D and 3D screening formats (Sunday, April 10, 2022, 1:30 PM - 5:00 PM; Poster Section 23, Poster Board Number: 7, Permanent Abstract Number: 357)
- Application of NanoBRET target engagement cellular assay for measurement of inhibitor binding to wild type and mutant RAS in live cells (Sunday, April 10, 2022, 1:30 PM - 5:00 PM; Poster Section 24, Poster Board Number: 15, Permanent Abstract Number: 379)
- Benefit of using a spectral flow analyzer for the analysis of immune cell populations in tumors (Sunday, April 10, 2022, 1:30 PM - 5:00 PM; Poster Section 39, Poster Board Number: 14, Permanent Abstract Number: 629)
- A systems biology approach combining ProLiFiler and Cancer Data Miner for an enhanced preclinical characterization of the WEE-1 inhibitor adavosertib (Monday, April 11, 2022, 9:00 AM - 12:30 PM; Poster Section 24, Poster Board Number: 22, Permanent Abstract Number: 1132)
- Comparison and consequences of different implantation techniques on the orthotopic growth of syngeneic Hepa1-6 liver cancer cells (Monday, April 11, 2022, 1:30 PM - 5:00 PM; Poster Section 11, Poster Board Number: 13, Permanent Abstract Number: 1621)
- Probing PRMT5 Inhibitors with Distinct Binding Modes Using Surface Plasmon Resonance (Tuesday, April 12, 2022, 9:00 AM - 12:30 PM; Poster Section 40, Poster Board Number: 6, Permanent Abstract Number: 2921)
- Exploring the combinatorial potential of bispecific T-cell engagers in high throughput format (Tuesday, April 12, 2022, 9:00 AM - 12:30 PM; Poster Section 38, Poster Board Number: 8, Permanent Abstract Number: 2893)
- Comprehensive characterization of CDK inhibitors using a complete panel of all 20 human cyclin-dependent kinases (Tuesday, April 12, 2022, 9:00 AM - 12:30 PM; Poster Section 5, Poster Board Number: 8, Permanent Abstract Number: 2304)
- Real-time quantitative PCR based analysis of transcriptional effects of CDK8/Cyclin C inhibitors (Tuesday, April 12, 2022, 9:00 AM - 12:30 PM; Poster Section 5, Poster Board Number: 22, Permanent Abstract Number: 2318)
- A versatile assay suite for the discovery of new KRAS pathway inhibitors (Tuesday, April 12, 2022, 1:30 PM - 5:00 PM; Poster Section 4, Poster Board Number: 16, Permanent Abstract Number: 2987)
- Cytotoxic effects of LRRK2 inhibitors in combined treatment with chemotherapeutic agents on a large panel of cancer cell lines (Wednesday, April 13, 2022, 9:00 AM - 12:30 PM; Poster Section 27, Poster Board Number: 26, Permanent Abstract Number: 4072)
"This year, we celebrate the Company's 20-year history of delivering superior science and driving customer-centric innovation, while we build upon our expanding suite of comprehensive services and support," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology. "These data at AACR represent the breadth and depth of Reaction Biology's pre-clinical research services in oncology and underscore why we are a preferred global partner in the area of drug discovery."
Copies of the poster presentations will be available at Reaction Biology's booth (#1247) during exhibit hall hours April 10 – April 13 and on the Company's website.
Founded in 2001, Reaction is a contract research organization (CRO) that provides a full suite of drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction's capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies, and an extensive array of cell-based assays. Reaction maintains one of the largest panels of kinase assays in the world with over 750 unique assays. The Company performs over 5,000 client projects annually with its over 2,000 validated assays. The Company has lab facilities in Malvern, PA, and Freiburg, Germany, with approximately 130 employees.
Contact:
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
View original content:
SOURCE Reaction Biology
|
https://www.whsv.com/prnewswire/2022/04/08/new-data-aacr-showcase-reaction-biologys-innovative-approach-oncology-drug-discovery-services/
| 2022-04-08T18:57:09Z
|
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
IRVING, Texas, April 8, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC). These results will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting being held April 8 - 13, 2022 in New Orleans, Louisiana.
The research with poster titled, "Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5-FU, oxaliplatin or irinotecan" (Abstract #1231), was led by Wafik El-Deiry, M.D., Ph.D., FACP, Director of Brown University's Legorreta Cancer Center, Associate Dean at the Warren Alpert Medical School, a member of Caris' Precision Oncology Alliance (POA). Caris' POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. This work is being presented in New Orleans by Lindsey Carlsen, a Pathobiology graduate student in the EL-DEIRY Lab at Brown.
The goal of this study was to identify predictive biomarkers for chemotherapies used in CRC. The study used CRC cell lines to identify differentially expressed genes following 5-fluorouracil, irinotecan, or oxaliplatin treatment and stratified the signatures based on p53 status. From these in vitro studies, the researchers then examined whether these genes and gene signatures could predict CRC patient outcomes following chemotherapy (FOLFOX, 5-fluorouracil, irinotecan or oxaliplatin). 2,983 wild-type and 6,229 loss-of-function p53 CRC patient samples were analyzed by DNA/RNA next-generation sequencing at Caris Life Sciences. Real-world survival outcomes were inferred from insurance claims data and Kaplan-Meier estimates. Both prognostic and non-prognostic gene expression had a significant effect on survival outcomes following specific drug treatments.
"This study helps us understand the importance that gene signatures have in demonstrating an enhanced predictive ability compared to individual transcripts," said El-Deiry. "Bridging basic and clinical research, this research allows us to better understand which therapies are more likely to benefit CRC patients." The study found that tumor expression of genes related to drug exposure can predict outcomes after chemotherapy treatment:
- High EGR1 and FOS mRNA independently predict response to FOLFOX in patients with wild-type p53 tumors.
- Low CCNB1 mRNA correlates with good prognosis of CRC patients with tumors harboring TP53 loss of function mutations.
- Low expression of BTG2 predicts better prognosis in patients with MSI-High TP53 mutated tumors.
- Gene signatures may demonstrate enhanced predictive ability as compared to individual transcript effects.
"Caris is focused on biomarkers that can predict patient response to the newest therapies, but also tried and true chemotherapies like FOLFOX," said W. Michael Korn, M.D., Chief Medical Officer at Caris. "We are excited to see the translational research capability empowered by the tremendous multi-omic data and analytical tools that Caris has developed and continues to make progress on."
Caris' comprehensive molecular profiling assesses whole exome (DNA), whole transcriptome (RNA) and protein expression, providing an unmatched resource and the ideal path forward to conduct the translational research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of cancer. All presentations will be made available online through Caris' website beginning April 8, 2022.
Additional Presentations Reveal Impact of Comprehensive Molecular Profiling and Potential Clinical Actionability
- Comprehensive characterization of FGF/FGFR alterations in invasive breast cancers (Abstract #5793)
FGFR signaling is central for cancer cell proliferation, migration, angiogenesis and survival; FGFR alterations have become clinically actionable in increasing number of cancer types. This study evaluated the incidence and characterization of numerous FGF/FGFR alterations in over 12,000 invasive breast cancers and highlighted the tremendous heterogeneity of FGF/FGFR alterations in various histologic and molecular subtypes as well as different metastatic sites of breast cancer. Further, the associations of FGFR alterations and resistance to therapies were shown in a large clinical database with matched molecular results. - Genomic and immune characteristics of EGFR subtypes in non-small cell lung cancer (NSCLC) (Abstract #4119)
While EGFR mutant NSCLC tumors generally are resistant to PD-1/PD-L1 inhibitors, a small subset of patients can have durable responses. EGFR-mutant tumors demonstrate significant molecular heterogeneity, however, there is a lack of clarity on the genomic and immune profiles of EGFR mutation subtypes, and further elucidation of this may help in identifying patients likely to respond to immune based therapies. Leveraging the multi-omic molecular data generated by Next-Generation Sequencing of DNA and RNA on a large cohort of NSCLC tumors, this study confirms the decreased immunogenicity associated with most subtypes of EGFR mutations manifested by biomarkers including PD-L1, TMB and CD8+ T cell infiltration; and reveals rare EGFR mutations associated with favorable immune profile that may suggest responsiveness to immune therapy.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement, which is currently available within its Precision Oncology Alliance, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Caris Life Sciences Media Contact:
Ann Obeney
Vice President, Corporate Communications
aobeney@carisls.com
469-550-1589
View original content to download multimedia:
SOURCE Caris Life Sciences
|
https://www.whsv.com/prnewswire/2022/04/08/new-research-caris-precision-oncology-alliance-finds-prognostic-predictive-drug-induced-gene-signatures-colorectal-cancer-patients/
| 2022-04-08T18:57:16Z
|
MILWAUKEE, April 8, 2022 /PRNewswire/ -- Northwestern Mutual announced today that over 100 of its financial advisors – more than ever before – have been listed among the best in their state according to a ranking by Forbes.
"Northwestern Mutual's dedicated and highly skilled financial advisors continue to set new standards and break records in wealth management," said Aditi Javeri Gokhale, the company's chief strategy officer, president of retail investments and head of institutional investments. "I'm deeply grateful for our advisors' tireless efforts to help a growing number of Americans plan for the future, and thrilled to see the well-deserved recognition they continue to earn for delivering greater value and peace of mind to the clients they proudly serve."
Forbes Best-In-State Wealth Advisors are nominated by their firms, and each advisor is thoroughly vetted, interviewed, and assigned a ranking by SHOOK Research. SHOOK takes a wide variety of factors into consideration when evaluating nominees, including industry experience, compliance records, revenue produced and assets under management. Forbes receives more than 30,000 applicants annually, and only a small percentage are named among the best wealth advisors in their state.
The Northwestern Mutual advisors recognized in Forbes' 2022 Best-In-State Wealth Advisors list are:
About Northwestern Mutual
Northwestern Mutual has been helping people and businesses achieve financial security for more than 165 years. Through a holistic planning approach, Northwestern Mutual combines the expertise of its financial professionals with a personalized digital experience and industry-leading products to help its clients plan for what's most important. With more than $570 billion in combined company and client assets, $34 billion in revenues, and $2.1 trillion worth of life insurance protection in force, Northwestern Mutual delivers financial security to nearly five million people with life, disability income and long-term care insurance, annuities, and brokerage and advisory services. Northwestern Mutual ranked 90 on the 2021 FORTUNE 500 and was recognized by FORTUNE® as one of the "World's Most Admired" life insurance companies in 2022.
Northwestern Mutual is the marketing name for The Northwestern Mutual Life Insurance Company (NM), Milwaukee, WI (life and disability insurance, annuities, and life insurance with long-term care benefits) and its subsidiaries. Subsidiaries include Northwestern Mutual Investment Services, LLC (NMIS) (investment brokerage services), broker-dealer, registered investment adviser, member FINRA and SIPC; the Northwestern Mutual Wealth Management Company® (NMWMC) (investment advisory and services), federal savings bank; and Northwestern Long Term Care Insurance Company (NLTC) (long-term care insurance). Not all Northwestern Mutual representatives are advisors. Only those representatives with "Advisor" in their title or who otherwise disclose their status as an advisor of NMWMC are credentialed as NMWMC representatives to provide investment advisory services.
View original content to download multimedia:
SOURCE Northwestern Mutual
|
https://www.whsv.com/prnewswire/2022/04/08/northwestern-mutual-boasts-record-number-wealth-advisors-new-forbes-best-in-state-ranking/
| 2022-04-08T18:57:23Z
|
NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma
NVL-655 demonstrated differentiation through broad preclinical activity across diverse ALK oncoproteins, resistance mutations, and tumor types while maintaining strong selectivity for ALK over TRKB
Supports broad investigation in advanced ROS1+ and ALK+ NSCLC and other solid tumors through the ongoing Phase 1/2 ARROS-1 study of NVL-520 and planned Phase 1/2 ALKOVE-1 study of NVL-655 beginning Q2 2022
CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL) a clinical-stage biopharmaceutical company creating precisely targeted therapies for patients with cancer, today announced new data to support broad clinical exploration of its parallel lead programs NVL-520 – a ROS1-selective inhibitor – and NVL-655 – an ALK-selective inhibitor. NVL-520 and NVL-655 are central nervous system (CNS)-penetrant kinase inhibitors designed to specifically solve for the dual challenges of kinase resistance and selectivity commonly observed with currently available inhibitors.
The data are available via two posters presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which runs from April 8 through April 13. The posters will also be available on the Nuvalent website at www.nuvalent.com/news/.
"We are pleased to share new data today resulting from our continued collaborations with leading investigators in ROS1 and ALK research, which we believe further demonstrate the potential for our highly selective inhibitors to be differentiated within the dynamic treatment landscapes for non-small cell lung cancer (NSCLC) and beyond," said James Porter, Ph.D., Chief Executive Officer of Nuvalent. "These preclinical data support the inclusion of various fusion partners and resistance mutations in our ARROS-1 and ALKOVE-1 clinical trials for ROS1- and ALK-positive NSCLC, respectively, as well as the inclusion of exploratory cohorts for other advanced solid tumors outside of NSCLC."
Monika Davare, Ph.D. is an Associate Professor of Pediatrics, Division of Hematology and Oncology at Oregon Health & Science University School of Medicine and leading expert in ROS1 oncoprotein biology. Professor Davare's research is directed towards overcoming therapeutic bottlenecks in oncology, including those that arise from the lack of validated translational research models for genomic subsets of cancer.
"Translational models of ROS1-driven cancers have centered on NSCLC, where the clinical impact of fusion partners is not yet well characterized and new treatment-resistant variants continue to emerge. Hypothesizing that broad coverage of fusion partners and resistance mutations is a beneficial feature for next-generation ROS1 inhibitors, we conducted an extensive comparative analysis of NVL-520 versus currently approved as well as investigational ROS1 inhibitors," said Professor Davare. "In contrast to comparator compounds, NVL-520 exhibited consistently high potency (IC50 < 10 nM) across all models tested, and in particular displayed potencies against the recurrently problematic G2032R solvent front mutation that were ≥ 1-order of magnitude higher than all comparative agents tested."
"While models of ROS1-driven cancers outside of NSCLC are sparse, we further present data that NVL-520 induces regression in a human cell-line derived model of glioblastoma driven by a ROS1 fusion," continued Professor Davare. "This suggests potential for clinical utility outside of NSCLC and highlights the importance of developing additional research models to help accelerate the development of new therapies for genomically-driven cancers."
Luc Friboulet, Ph.D. is an investigator at Gustave Roussy focused on investigating molecular mechanisms of tumor adaptation to kinase inhibitors in solid tumors, with particular expertise in understanding resistance to ALK kinase inhibitors.
"ALK oncogenic activations as well as mutations conferring resistance to current ALK inhibitors have been characterized across a range of tumor types, suggesting that broad activity across diverse ALK-driven cancers is a beneficial feature for next-generation ALK inhibitors," said Dr. Friboulet. "In a comparative analysis of NVL-655 versus currently approved as well as investigational ALK inhibitors, NVL-655 exhibited strong activity across a wide range of fusion partners, activating mutations, and disease backgrounds, suggesting potential for broad clinical utility. Importantly, this expansive activity of NVL-655 against ALK does not come at the expense of its ability to avoid inhibition of TRKB, a limitation that has been observed with other investigational ALK inhibitors."
NVL-520 is currently under investigation in the Phase 1 portion of the Phase 1/2 ARROS-1 study (NCT05118789) for advanced ROS1-positive NSCLC and other solid tumors. Nuvalent recently announced the IND clearance for NVL-655 and plans to initiate the Phase 1 portion of the Phase 1/2 ALKOVE-1 study for advanced ALK-positive NSCLC and other solid tumors in the second quarter of 2022. In addition to these parallel lead programs, Nuvalent is advancing a robust discovery pipeline with plans to nominate two new development candidates in 2022 for ALK IXDN compound mutations and HER2 exon 20 insertions.
AACR Presentation Overview:
* Presenting authors
Title: NVL-520: Preclinical Activity of NVL-520 in ROS1-Driven Cancer Models with Diverse Fusion Partners and Kinase-Domain Mutations
Authors: Anupong Tangpeerachaikul*^, Clare Keddy^, Katelyn Nicholson, Monika A. Davare, and Henry E. Pelish*
^ Equal contributions
Poster Number: 14
Permanent Abstract: 3336
Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase and Phosphatase Inhibitors
Session Date and Time: Tuesday April 12, 2022 from 1:30 – 5:00 p.m. Central Time
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26
Summary of Presentation:
- NVL-520 shows high activity against diverse ROS1 fusion partners tested including CD74, CEP85L, EZR, GOPC(L), GOPC(S), and SLC34A2 and induces regression in a ROS1-driven model of glioblastoma harboring GOPC(L)-ROS1.
- NVL-520 shows high activity against diverse ROS1 kinase-domain mutations tested including S1986F, F2004C/V, L2026M, G2032R, D2033N, and G2101A.
- NVL-520 shows a differentiated preclinical activity and selectivity profile compared to other inhibitors tested.
- Preclinical activity against diverse ROS1 fusion partners and kinase domain mutations suggests broad potential clinical utility of NVL-520.
Title: NVL-655: Preclinical Activity of NVL-655 in ALK-Driven Cancer Models beyond Non-Small Cell Lung Cancer
Authors: Anupong Tangpeerachaikul*, Ludovic Bigot, Luc Friboulet, and Henry E. Pelish*
Poster Number: 15
Permanent Abstract: 3337
Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase and Phosphatase Inhibitors
Session Date and Time: Tuesday April 12, 2022 from 1:30 – 5:00 p.m. Central Time
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26
Summary of Presentation:
- NVL-655 shows strong activity in diverse preclinical models of ALK-driven cancers: cholangiocarcinoma, neuroblastoma, lymphoma, and soft-tissue sarcoma.
- Among all inhibitors tested, NVL-655 shows the broadest activity for diverse ALK oncoproteins including fusions, point mutations, and partial N-terminal deletions.
- NVL-655 shows larger ALK-vs-TRK selectivity windows than lorlatinib and TPX-0131.
- Preclinical activity against diverse ALK oncoproteins (fusions, mutations, and partial deletions) in multiple tumor types suggests broad potential clinical utility of NVL-655.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the clinical development programs for NVL-520, NVL-655, ALK IXDN compound resistance mutations and HER2 exon 20 insertions and the timing thereof; the potential clinical effect of NVL-520 and NVL-655; the design and enrollment of the ARROS-1 study and the timing thereof; the design and initiation of the ALKOVE-1 Phase 1/2 study and the timing thereof; the potential of Nuvalent's pipeline programs, including NVL-520 and NVL-655; and Nuvalent's research and development programs for the treatment of cancer. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: risks that Nuvalent may not fully enroll the ARROS-1 study or it will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during clinical trials; the occurrence of adverse safety events; risks of unexpected costs, delays, or other unexpected hurdles; the impact of COVID-19 on countries or regions in which Nuvalent has operations or does business, as well as on the timing and anticipated timing and results of its clinical trials, strategy, and future operations, including the global ARROS-1 study and the planned initiation of the ALKOVE-1 Phase 1/2 study; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and obtaining, maintaining, and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements.
View original content to download multimedia:
SOURCE Nuvalent, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/nuvalent-presents-new-data-demonstrating-expanded-preclinical-activity-with-ros1-selective-inhibitor-nvl-520-alk-selective-inhibitor-nvl-655-aacr-annual-meeting-2022/
| 2022-04-08T18:57:30Z
|
- OTX-2002 suppresses c-Myc gene expression resulting in a loss of cancer cell viability in vitro and reduces tumor growth in in vivo xenograft models
- Data support the potential of the OMEGA Epigenomic Programming™ platform to engineer programmable epigenetic mRNA therapeutics that successfully regulate gene expression
- Robust data support filing of Investigational New Drug application in the first half of 2022 and positions the OTX-2002 program for further development
CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, will present preclinical data highlighting the potential of its lead Omega Epigenomic Controller™, OTX-2002, to regulate overexpression of the c-Myc (MYC) oncogene in models of hepatocellular carcinoma (HCC) in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022.
"Despite its essential role in a broad range of cancers, MYC has remained undruggable to date," said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. "However, we believe that targeting the MYC gene pre-transcriptionally within its Insulated Genomic Domain (IGD), and epigenetically tuning it using our epigenomic controller, could overcome the challenges that have limited previous technologies including small molecules, antisense oligos and siRNA. We believe that these data strongly support OTX-2002's ability to tune and restore MYC expression to a normal range and demonstrate the broader potential of our Epigenomic Programming platform to tackle previously intractable diseases. We are excited to continue advancing OTX-2002 into clinical trials and look forward to filing an Investigational New Drug application in the first half of this year."
Key findings
- A single dose of OTX-2002 induced durable changes in the epigenetic profile of the MYC gene
- OTX-2002 reduced MYC mRNA expression and protein levels over approximately 2 weeks in vitro
- Downregulation of MYC in multiple HCC cell lines resulted in significant loss in viability of MYC-addicted cancer cells while sparing normal cells
- In murine xenograft HCC models, OTX-2002 significantly reduced tumor growth and was well-tolerated
Cumulatively, these data support the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for the clinical development of OTX-2002 in the first half of 2022.
The poster can be viewed on the Omega website at https://omegatherapeutics.com/our-science/#publications-research.
About OTX-2002
OTX-2002 is a first-in-class Omega Epigenomic Controller™ in development for the treatment of hepatocellular carcinoma (HCC). OTX-2002 is designed to modulate levels of c-MYC (MYC) expression by utilizing targeted mRNA-expressed proteins to mediate epigenetic regulation while potentially overcoming MYC autoregulation. The MYC oncogene is associated with aggressive disease in up to ~70% of patients with HCC. Omega is currently evaluating OTX-2002 in Investigational New Drug (IND)-enabling studies.
About Omega Therapeutics
Omega Therapeutics, founded by Flagship Pioneering, is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the deterministic OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA epigenetic medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips™, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, including our lead OEC candidate OTX-2002; and our plans to present preclinical data on OTX-2002 and file an Investigational New Drug application for it in the first half of 2022. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2021, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Contacts
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
Investor contact:
Kevin Murphy/Brendan Burns
Argot Partners
212.600.1902
ArgotOmega@argotpartners.com
View original content to download multimedia:
SOURCE Omega Therapeutics
|
https://www.whsv.com/prnewswire/2022/04/08/omega-therapeutics-presents-preclinical-data-otx-2002-first-in-class-epigenomic-controller-potential-treatment-hepatocellular-carcinoma-aacr-annual-meeting-2022/
| 2022-04-08T18:57:36Z
|
- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication
- A higher dose level of pelareorep led to 50% 24-month median overall survival (mOS) and a patient still alive at 42 months compared to 16.7% mOS at the lower dose
- Investigator-sponsored trial confirms pelareorep's favorable safety profile
SAN DIEGO and CALGARY, AB, April 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive long-term survival data from ReoGlio, an investigator-sponsored phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results, which are the subject of a presentation at the American Association for Cancer Research (AACR) Annual Meeting, show a substantial and durable efficacy signal in newly diagnosed GBM patients and demonstrate the safety and tolerability of the studied treatment combination in this indication.
"These results provide further evidence suggesting that the long-term survival benefits pelareorep delivers to breast cancer patients may be extended to a variety of indications," said Susan Short, M.R.C.P., Ph.D., Professor of Clinical Oncology and Neuro-Oncology at the University of Leeds. "I am highly encouraged by the two-year survival rate and median overall survival observed in ReoGlio and view the relative increases these metrics show in the high dose cohort as a promising sign of this therapy combination's dose-dependent activity in GBM. ReoGlio's long-term results are also consistent with the positive progression-free survival data that were previously reported and confirm pelareorep's favorable safety profile in this new indication. Collectively, these findings highlight pelareorep's potential to drive clinical benefit in GBM patients, who are historically very challenging to treat and in urgent need of novel therapies."
Key data and conclusions from the AACR poster and corresponding abstract include:
- Evaluable patients treated with pelareorep at dose level-2 (3x1010 TCID50) had a median overall survival (mOS) of 16.1 months and a 24-month survival rate of 50% (n=6)
- Evaluable patients treated with pelareorep at dose level-1 (1x1010 TCID50) had a mOS of 12.6 months and a 24-month survival rate of 16.7% (n=6)
- Across both dose levels, mOS was 13.1 months and the 24-month survival rate was 33% (n=12)
- One patient treated at dose level-2 remains alive at 42 months
- The studied treatment combination was deemed safe and well-tolerated at both dose levels by a Safety Review Committee that included two independent physicians
The long-term follow-up data from the ReoGlio study being presented at AACR are an extension of prior data that were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting (link to PR). These data demonstrated an estimated median progression-free survival (mPFS) of 7.8 months across all evaluable patients in the study (n=12), with those treated at dose level-2 showing an estimated mPFS of 9.4 months (n=6) and those treated at dose level-1 showing an estimated mPFS of 6.1 months (n=6).
Matt Coffey, Ph.D., MBA, President and Chief Executive Officer of Oncolytics Biotech Inc. added, "ReoGlio's results strengthen the broad clinical dataset demonstrating pelareorep's potential to address unmet needs across a range of cancers. We believe they warrant additional clinical study, and plan to discuss them with thought leaders and potential partners to identify the best and most efficient potential path forward in GBM. This strategy will allow us to opportunistically expand pelareorep's commercial potential while staying focused on the advancement of our lead breast cancer program to a registrational study. We would like to sincerely thank the University of Leeds, Cancer Research UK, and The Brain Tumor Charity for designing and funding the ReoGlio trial, as well as all of the patients who participated."
An electronic copy of the presentation and the corresponding abstract, entitled, Combination of reovirus (pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): long term follow up results of the ReoGlio phase Ib trial, is available to registered attendees of the AACR annual meeting on the meeting website. A copy of the presentation will also be posted to the Posters & Publications page of Oncolytics' website (LINK) following the conclusion of the meeting.
Details for the online presentation are shown below.
Abstract Number: CT569
Session Title: OPO.CT01.01 - Phase I Clinical Trials
About ReoGlio
The ReoGlio trial was an investigator-sponsored phase 1b, open-label trial evaluating the combination of pelareorep and GM-CSF, alongside standard chemoradiotherapy and adjuvant temozolomide, for the treatment of newly diagnosed GBM. Fifteen patients were treated in the trial, twelve of which were evaluable for efficacy analyses. The primary objective of the study was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy. Secondary objectives were to gain a preliminary assessment of the activity of the pelareorep-GM-CSF combination and to assess treatment compliance. The trial was designed and managed by the University of Leeds and funded through grants provided by Cancer Research UK and The Brain Tumor Charity.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; the timing and results of the presentation to be made at the American Association for Cancer Research Annual Meeting; our plans to discuss the results of the ReoGlio study with thought leaders and potential partners to identify the best and most efficient potential path forward in GBM and the anticipated results of this strategy; our plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
View original content to download multimedia:
SOURCE Oncolytics Biotech® Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/oncolytics-biotech-announces-positive-long-term-survival-data-phase-1b-glioblastoma-multiforme-trial-aacr-annual-meeting/
| 2022-04-08T18:57:43Z
|
- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy
- Results strengthen the clinical dataset demonstrating pelareorep's ability to remodel the tumor microenvironment
SAN DIEGO and CALGARY, AB , April 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.
"The results from this trial provide a powerful example of how pelareorep's immunologic effects trigger a durable clinical benefit in an extremely challenging patient population," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics Biotech Inc. "All patients enrolled into the study had failed prior therapies, yet despite this, treatment with pelareorep-based therapy prevented disease progression for over three years in a subset of the patients. In addition, this study shows that pelareorep's ability to recruit high concentrations of anti-cancer immune cells into the tumor microenvironment (TME) can yield strong clinical outcomes. This impressive finding has implications for cancers beyond multiple myeloma as it builds on existing data that support pelareorep's potential to enhance the effectiveness of a wide array of therapies through its ability to stimulate a pro-inflammatory TME."
Previously reported data highlighted in the poster's corresponding abstract demonstrated the efficacy of the studied combination and showed a subset of trial participants achieving prolonged progression-free survival (PFS) of greater than three years (link to PR). These data also demonstrate a clinical response correlating with changes in T cell clonality and post-treatment increases in innate and adaptive immune cells within the TME. New biomarker analyses featured in the poster show these anti-cancer immune cells clustering more closely around cancer cells containing pelareorep compared to those that did not. Collectively, these results indicate that the sustained clinical benefits observed were driven by pelareorep's recruitment of anti-cancer immune cells into the TME.
Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "This trial generated important proof-of-concept data that reaffirm pelareorep's favorable safety profile, increase our understanding of its mechanism of action, and further support the use of T cell clonality as a biomarker. These important learnings strengthen the systemic effect observed in other datasets supporting each of our clinical programs and can be applied to accelerate their advancement. Moving forward, we plan to use our findings in multiple myeloma to drive conversations with potential partners and collaborators interested in leveraging pelareorep's immunotherapeutic effects to address unmet needs in this and other indications. Internally, we remain primarily focused on our lead breast cancer program and look forward to its expected randomized phase 2 data readout in the fourth quarter of the year."
The electronic AACR poster, entitled, Single Cell Analysis Shows That Reovirus Immune Priming Changes the Tumor Immune Micro Environment in Multiple Myeloma, is available to registered attendees of the AACR annual meeting on the meeting website (Abstract #6354). A copy of the poster will also be posted to the Posters & Publications page of Oncolytics' website (LINK) following the conclusion of the meeting.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; our plan to use our findings in multiple myeloma to drive conversations with potential partners and collaborators; our primary focus on our lead breast cancer program and our expectations regarding its randomized phase 2 data readout in the fourth quarter of the year; our plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
View original content to download multimedia:
SOURCE Oncolytics Biotech® Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/oncolytics-biotech-presents-new-data-demonstrating-durable-clinical-benefit-relapsedrefractory-multiple-myeloma-patients-aacr-annual-meeting/
| 2022-04-08T18:57:49Z
|
CRANBURY, N.J., April 8, 2022 /PRNewswire/ -- Ophthalmology Times® and Optometry Times®, the leading news and information platforms for eye-care professionals, are thrilled to announce new members to their extensive Strategic Alliance Partnership (SAP) networks.
"During the past quarter, we formed new partnerships in the world of eye care with educational institutions, hospitals, state societies, associations and non-profit organizations," said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, parent company of Ophthalmology Times® and Optometry Times®. "I look forward to seeing the collaboration that will come from the addition of this broad list of new partners to our Strategic Alliance Partnership network."
New partners include the following:
- University of Pikeville, the Kentucky College of Optometry
- Orbis International
- NSU Oklahoma College of Optometry
- Moffitt
- Black Eye Care Perspective
- Corporate Optometry
- Corporate Vision Consulting
- Grande Financial Services, Inc.
- Wills Eye Hospital
- OWL, Ophthalmic World Leaders
- UCI Health
- Cleveland Eye Bank Foundation
- Tennessee Academy of Ophthalmology
- Dean McGee Eye Institute
- NYU Langone
The SAP program brings together leading medical associations, health plans, advocacy groups, and medical institutions for national reach and visibility. By utilizing the MJH Life Sciences™ communication platform, these groups can showcase cutting-edge initiatives, content, research, and thought leadership. The SAP program also fosters collaboration and an open exchange of information among trusted peers for the benefit of patients and their families.
For a full list of Ophthalmology Times® SAP partners, click here.
For a full list of Optometry Times® SAP partners, click here.
About Ophthalmology Times®
Ophthalmology Times® is a multimedia platform that offers ophthalmology professionals digital resources they can use to help provide the best patient care, positively affect the identification, diagnosis, treatment, and prevention of eye diseases, and promote progressive eye health. Ophthalmology Times® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
About Optometry Times®
The leading source of breaking news, news analysis, emerging research reports in optometry, Optometry Times® is an optometry-driven publication that disseminates news and information of a clinical, socioeconomic, and political nature in a timely and accurate manner. Optometry Times®'s practical content by optometrists for optometrists can be immediately applied to improve the clinical experience. Optometry Times® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
Media Contact
Michael Altmann
2153130278
maltmann@mjhlifesciences.com
View original content to download multimedia:
SOURCE Optometry Times; Ophthalmology Times
|
https://www.whsv.com/prnewswire/2022/04/08/ophthalmology-times-optometry-times-welcome-new-strategic-alliance-partnership-sap-members-2022/
| 2022-04-08T18:57:57Z
|
LEHI, Utah, April 8, 2022 /PRNewswire/ -- PCF Insurance Services (PCF) is pleased to announce the completion of more than 40 strategic partnerships over the past five months. As a risk management, benefits design, and insurance brokerage services company, PCF Insurance harnesses the power of its Agency Partner network to provide world-class service and unparalleled solutions to its clients. These most recent additions to its expanding national network complement its existing footprint and continue to solidify its leading position in the industry.
"A key competitive advantage for PCF Insurance is the powerful combination of Agency Partner autonomy to lead their businesses as they always have, now with access to a best-in-class team for shared services and resources. This partnership generates significant value for the collective success of all," explains Jeremiah Jewkes, Chief Development & Strategy Officer for PCF Insurance.
- Advocate Insurance Services via Fortiphi
- Alice Bohnker Insurance Services via Fortiphi
- All Access Insurance via Broadfield Insurance
- All Nations Insurance via Colorado Insurance Agency
- Aspen Insurance via Rant Insurance Group
- Automotive Development Services
- Bannister & Associates
- Belter Insurance
- Bolding & McConnell Insurance via McConnell Insurance Agency
- Brian Kernan via Total Insurance Services
- CAL Insurance
- Christian Smith via Kern Insurance Associates
- Corrigan Enterprises
- Dan Corrigan Insurance LLC
- Deluxe Insurance Group
- EZ Insurance Group, LLC DBA GEBCO Insurance
- Gaudreau-Fountain Insurance Agency via Moulton Insurance Agency Inc.
- Halpert Insurance & Financial Services
- I-Connect | William Ritchey Insurance
- Jason White Insurance Agency
- MBN Associates Inc.
- Mike Haffar Insurance Services
- Mountain Star Insurance
- Pamela Stern & Associates LLC
- Paylogics
- Private Client Insurance/Highmark Insurance LLC
- RH Perry & Associates
- Richard J Nelligan Insurance Agency Inc. via New England Insurance Group
- Ridgemark Insurance Services
- Rifkin Insurance Associates
- Robert Mclntyre Insurance Inc.
- Secord Agency
- SCM Insurance
- Siver Insurance via New England Insurance Group
- Southern Group Insurance Agency Inc.
- Stafford & Co. Insurance Services
- Stratford Insurance Group
- Strauss Insurance Services LLC
- TCL Insurance
- Young Insurance & Financial
Peter Foy, Founder & CEO, explains that "As a people-centric organization, the PCF Insurance business model is fueled by the fundamental belief that, through collaboration, Agency Partners can focus on what they do best, knowing there is a support network of skilled professionals bringing forth industry knowledge and experience to provide world-class benefits design, insurance, and risk management services."
Upon joining PCF Insurance, partners gain enhanced market access to national and regional carriers with a full spectrum of insurance and risk management solutions and program capabilities. Combining the bench strength of PCF Insurance with its strong market relationships and the efficiencies and economies of scale generated by a shared services approach, Agency Partners can offer clients enhanced coverage offerings, more competitive pricing, and innovative solutions for a wide variety of industries, specifically agriculture; construction and contractors; hospitals and healthcare systems; trucking; and residential real estate, including condominiums, apartments, and homeowners' associations (HOAs).
Headquartered in Lehi, Utah, PCF Insurance Services is a leading full-service consultant and insurance brokerage firm offering a broad array of commercial, life and health, employee benefits and workers' compensation solutions. A top 20 U.S. broker, PCF's agency-centric operating model and entrepreneurial environment support its tremendous growth profile, offering partners alignment through equity ownership, significant leadership incentives and resources to over 2,000 employees throughout the United States. More information can be found at www.pcfins.com.
View original content:
SOURCE PCF Insurance Services
|
https://www.whsv.com/prnewswire/2022/04/08/pcf-insurance-adds-over-40-strategic-partnerships-within-five-months/
| 2022-04-08T18:58:03Z
|
MARLBOROUGH, Mass., April 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented positive new preclinical data showing PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4), provides abscopal efficacy toward untreated distal tumors and potentiates the efficacy of systemic anti-PD-1 antibody therapy. These new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is being held in New Orleans, Louisiana, from April 8-13, 2022.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Data from in vivo studies demonstrated that PH-894 inhibits tumor growth in both PD-1 inhibition responsive, as well as PD-1 inhibition insensitive models. In both models, after local administration, strong antitumor efficacy was seen in directly treated as well as distal, untreated tumors. Additionally, intratumoral treatment with PH-894 enhanced the antitumor efficacy of systemic anti-PD-1 antibody therapy, not only for the PH-894 locally treated tumors, but for the PH-894 untreated distal tumors. In the PD-1 inhibition insensitive model, local PH-894 therapy was shown to be efficacious as a systemic anti-PD-1 antibody treatment, and enhanced the antitumor efficacy of anti-PD-1 treatment when used together.
"We are excited by these new data on PH-894, our second product candidate, for various reasons," said Dr. Simon Fricker, Phio's VP of Research & Development. "First, these data show that local administration of PH-894 resulted in systemic efficacy, similar to what we have shown with PH-762. In addition, these studies have shown PH-894 to be a potent standalone treatment in a challenging model, while also enhancing the efficacy of systemic anti-PD-1 antibodies. We believe these data provide a strong rationale for the clinical use of PH-894 as a monotherapy, as well as in combination with systemic PD-1 therapy. Considering the novel mechanism of action of PH-894, there is potential for it to play an important role in treating patients who do not respond to anti-PD-1 therapy, or patients who progress after initially responding to such therapy, addressing an important medical unmet need."
Studies were conducted in colon and liver cancer animal models in which the cancer cell lines were implanted subcutaneously into the bilateral flanks of mice. Tumors on only one side were treated with PH-894, and tumors on the opposite side were left untreated. Some of the animals also received systemic anti-PD-1 antibody treatment in addition to local PH-894 administration. These data showed that locally administered PH-894 inhibited tumor growth of both directly-treated and distal tumors in two cancer models. In addition, PH-894 also potentiated the efficacy of a systemic anti-PD-1 antibody toward PH-894 treated and untreated distal tumors. Ex vivo analysis showed that PH-894 silenced BRD4 and its downstream effector PD-L1 in tumor dendritic cells and increased migratory dendritic cells in the tumor, suggesting a mechanism by which local PH-894 treatment confers systemic tumor control.
Phio's presentation detailing the data presented at AACR titled, "Local administration of BRD4-targeting self-delivering RNAi (PH-894) provides abscopal efficacy toward untreated distal tumors and potentiates the efficacy of systemic anti-PD-1 antibody therapy" will be made available on the "Investors – Events and Presentations" section of the Company's website (click here).
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:
SOURCE Phio Pharmaceuticals Corp.
|
https://www.whsv.com/prnewswire/2022/04/08/phio-pharmaceuticals-presents-positive-new-data-ph-894-demonstrating-antitumor-efficacy-model-pd-1-refractory-disease-aacr-annual-meeting-2022/
| 2022-04-08T18:58:10Z
|
The organizations, which make up the Corporate Racial Equity Alliance, are working to transform how the private sector advances equity.
WASHINGTON, April 8, 2022 /PRNewswire/ -- The Corporate Racial Equity Alliance launched an effort Tuesday to garner public feedback on how the private sector can most effectively advance racial and economic equity.
Founded by PolicyLink, FSG, and JUST Capital, the Alliance is undertaking a multiyear effort to develop standards for how businesses can further racial and economic equity, including new common disclosure standards, with performance indicators and metrics to help businesses, investors, workers, consumers, and others more easily track and measure their progress.
The Alliance's latest report outlines the scope and structure of the new framework and invites the public to lend their voice and help shape the standards that will set new norms for equity in the private sector. Core to their development process is engaging a broad array of stakeholders to help shape the standards. In conjunction with the release, the Alliance is launching a 60-day public comment period to get broad stakeholder feedback on the scope and structure of the standards. Members of the public—including equity advocates, community leaders, workers, young people, under- or unemployed people, consumers, investors, businesses, standards setters, public leaders, and business affinity organizations—can learn more about how to get involved and share their insights through June 3, 2022.
Adopting new policies and practices that advance racial and economic equity—defined as just and fair inclusion into a society where all can participate, prosper, and reach their full potential—is a business imperative. A recent JUST Capital survey showed that 84% of Americans agree that companies "often hide behind public declarations of support for stakeholders but don't walk the walk." On top of this, nearly 100 million people in America—one in three—struggle to make ends meet and are locked out of equal opportunities to thrive. This is the everyday reality for over 40 percent of people of color and nearly 25 percent of white people in America. Globally, widening inequality and racial and ethnic discrimination are no less serious – threatening peace, social cohesion, and economic stability.
Businesses of all sizes, in all industries, have an important role to play in the pursuit of equity. To maximize their impact, businesses need a shared language and approach to ensure investments in equity actually translate into equitable outcomes. The Alliance exists to develop resources and support for companies to become champions of racial and economic equity.
"The public is calling for true accountability. Never before has there been so much potential for structural transformation that can finally benefit all people," said Mahlet Getachew, Managing Director of Corporate Racial Equity for PolicyLink. "A sustainable future demands new business models and ways of operating today that do not perpetuate harm to people of color and low-income communities, no less than demands for preserving and protecting our planet."
The Alliance's performance standards framework is a way for companies to walk the walk and builds on the 2021 CEO Blueprint for Racial Equity. The CEO Blueprint offers a path forward for business leaders to realize racial equity beyond diversity and inclusion commitments, enable corporations to better understand their impact on racial equity and develop policies and practices to achieve equitable outcomes. Engaging the public in the development of the corporate standards will ensure that the indicators and performance targets built are comprehensive, actionable, and have the power to lead to the achievement of racial and economic equity.
"In the midst of ever-increasing economic, social, and environmental challenges, a growing chorus of stakeholders across the globe is coalescing around reimagining capitalism to serve all people," said Ashley Marchand Orme, Director of Corporate Equity for JUST Capital. "Our ongoing polling and research analysis shows that companies are making progress, but need common standards to accelerate action, measurement, and accountability to ensure we're building a more just and equitable future."
"Corporations are uniquely positioned to use their resources and business strategies to address the profound social and economic risks presented by inequality. Companies who seek to be leaders for equity are realizing that this requires more than an initiative or set of commitments – it means making equity everyone's job," said Kendra Berenson, Associate Director at FSG. "The goal is to make racial and economic equity part of the DNA of each company and that means orienting towards a new set of norms for equitable business."
View original content:
SOURCE PolicyLink
|
https://www.whsv.com/prnewswire/2022/04/08/policylink-fsg-just-capital-publish-groundbreaking-report-corporate-racial-equity-standards-launch-public-comment-period/
| 2022-04-08T18:58:17Z
|
LOUISVILLE, Ky., April 8, 2022 /PRNewswire/ -- The locally inspired family-owned sports and merchandise retailer, Rally House, proudly opens their third Kentucky location on Friday, April 8th. Rally House Bluegrass is found at The Outlet Shoppes of the Bluegrass, conveniently located just south of I-64.
As the premier destination for sports and local merchandise, Rally House is ready to serve more Kentucky residents with the newest store in Simpsonville. "Excitement to open our doors had been building for weeks," said District Manager Teri Hauenschild. "Kentucky houses some of the most dedicated fans out there, and with such a broad selection of team merch and localized apparel to browse, we're confident everyone will find what they want at Rally House Bluegrass."
Rally House manages to stand out from other retailers by offering a massive assortment of the latest and most popular styles from numerous fan-favorite brand names. While they provide shoppers with a wide range of sports apparel and products from Nike, Adidas and New Era, customers will also find exclusive designs from many other renowned vendors. Plus, they seek to fuel state and city pride even further with merchandise from the in-house RALLY Brand™ that features localized themes and styles only offered at Rally House.
On top of providing customers with a broad selection of local Kentucky apparel, gifts and accessories, this new location has gear for the Reds, Bengals and Colts. Rally House Bluegrass also provides customers with college merch for Kentucky Wildcats, Eastern Kentucky Colonels, Western Kentucky Hilltoppers, Cincinnati Bearcats, Indiana Hoosiers, Ohio State Buckeyes and more.
Customers will be pleased to know Rally House offers a straightforward online shopping experience as well, featuring a full selection of products at www.rallyhouse.com. Every online order is packed and fulfilled by local Rally House locations and able to be shipped to any state.
Stay current on local updates by visiting www.rallyhouse.com/rally-house-outlets-bluegrass or follow Rally House Bluegrass on Facebook (@RallyBluegrass) and Instagram (@rallybluegrass).
About Rally House
Rally House and Sampler Stores Inc. is a family-owned specialty boutique that offers a large selection of apparel, hats, gifts and home décor representing local NCAA, NFL, MLB, NBA, NHL, and MLS teams in addition to locally inspired apparel, gifts and food. Proudly based in Lenexa, Kansas, Rally House operates 100+ locations across 12 states.
CONTACT:
Teri Hauenschild, District Manager
thauenschild@rallyhouse.com
View original content to download multimedia:
SOURCE Rally House
|
https://www.whsv.com/prnewswire/2022/04/08/rally-house-expands-with-new-kentucky-store/
| 2022-04-08T18:58:25Z
|
WACO, Texas, April 8, 2022 /PRNewswire/ -- The locally inspired family-owned sports and merchandise retailer, Rally House, is heading south of Dallas to Waco, to open their 17th Texas store. Rally House Waco is excited to serve an abundance of Baylor Bears merchandise to the people of Waco, providing an assortment of product fans have been waiting for. The Waco location also showcases a wide selection of area teams to choose from.
Rally House brings their vast selection of team and local merchandise to Waco that provides fans the opportunity to shop the latest in gear for all their favorite regional teams. With the wide assortment of product that is constantly being restocked with popular styles and new arrivals, Rally House could not wait to open in Waco and get fans geared up. "We are so excited about the expansion of Rally House in Waco as the first store outside of Dallas Fort-Worth!" said Store Manager Mekala Sears.
Rally House recognized the need for a sports and merchandise retailer in Waco that offers a wide selection of teams, which is what separates them from similar retailers in the area. With apparel from brands like Nike, '47, Columbia and New Era, customers can expect to find the hottest styles when shopping. Rally House supplies merchandise from vendors all over the country to ensure that customers can also shop unique styles in a more convenient fashion. Adding to their unique styles, the Texas-inspired Local section hits home with "Whataburger" and "Dr. Pepper" designs, as well as other fashion styles from RALLY Brand™ only available at Rally House.
Rally House Waco team selection includes but is not limited to: Cowboys, Stars, Rangers, Mavericks, Astros, Baylor Bears, Texas Longhorns, Texas Tech Red Raiders, North Texas Mean Green, Tarleton State Texans, TCU Horned Frogs, OU Sooners, Oklahoma State Cowboys
For more updates, head to https://www.rallyhouse.com/rally-house-waco or follow Rally House Waco on Facebook (@RallyWaco) and Instagram (@rallywaco).
About Rally House
Rally House and Sampler Stores Inc. is a family-owned specialty boutique that offers a large selection of apparel, hats, gifts and home décor representing local NCAA, NFL, MLB, NBA, NHL, and MLS teams in addition to locally inspired apparel, gifts and food. Proudly based in Lenexa, Kansas, Rally House operates 100+ locations across 12 states.
CONTACT:
Stefanie Blowers
District Manager
sblowers@rallyhouse.com
View original content to download multimedia:
SOURCE Rally House
|
https://www.whsv.com/prnewswire/2022/04/08/rally-house-opens-waco-17th-texas-location/
| 2022-04-08T18:58:31Z
|
Leading Performance Suspension and Shocks Brand to Sponsor Trail Runs, Showcase Products at Vendor Show and Expo
SOUTHFIELD, Mich., April 8, 2022 /PRNewswire/ -- Representatives from Rancho® performance suspension and shocks, a leading brand from Tenneco's (NYSE: TEN) DRiV group, will be attending the 56th annual Easter Jeep Safari (EJS) in Moab, Utah, April 9 through April 17, 2022. In addition to sponsoring select trail runs, the Rancho team will be there to showcase its latest suspension technologies at the RR4W EJS Vendor Show and Expo on April 14-15.
Among its featured product offerings at EJS is the Rancho RS7MT® shock absorber. This latest offering from Rancho features an eye-catching design that, like other Rancho products, is designed to fit right out of the box, with application-specific mounting and no need for installing sleeves or other extra hardware. Each RS7MT shock features an integrated dirt wiper sealing system that helps keep moisture, dirt and other debris from contaminating the shock, and a hardened piston rod that resists scuffs and corrosion. Its large two-inch monotube body filled with all-weather fluid allows for cooler operation, increased vehicle control, and ability to withstand internal temperatures of -40 to 248° Fahrenheit.
Also featured is the new RS7MT steering stabilizer. Specifically designed for vehicles with oversized tires and wheels, the RS7MT steering stabilizer is also highly effective in the dissipation of heat and in keeping out dirt and debris thanks to the same integrated dirt wiper sealing system used on the RS7MT shock. The RS7MT steering stabilizer is ideal for off-road driving and towing applications and features a hardened piston rod that resists scuffs and corrosion, and an internal rebound bumper to smooth out the ride on any terrain.
"Drivers that are looking to upgrade the performance of their Jeeps should look no further than the full array of products that Rancho has to offer," said Michael Sype, brand manager, Rancho. "We are excited to be able to participate in the EJS and can't wait to show off how well our products perform with precision handling and control for an exhilarating on- or off-road experience."
The Rancho brand specializes in performance suspension systems, shock absorbers, ride control products and popular rockGEAR® off-road performance accessories. Known for the off-road market's first nine-position adjustable shock absorber, the RS9000®XL (which allows off-road enthusiasts to adjust the level of compression/rebound damping to suit their riding style), Rancho continues to add fully-engineered, industry-leading technologies like Dynamic Rebound Springs (DRS), D2 bushings and more.
The Easter Jeep Safari consists of trail rides, mostly day long trips, departing from Moab throughout the 9-day-long event that draws off-road enthusiasts from all over the country. The official event is hosted by the Red Rock 4-Wheelers Inc., one of the local four-wheel drive clubs of Moab.
To learn more, visit GoRancho.com.
About Tenneco
Tenneco is one of the world's leading designers, manufacturers and marketers of automotive products for original equipment and aftermarket customers, with full year 2021 revenues of $18 billion and approximately 71,000 team members working at more than 260 sites worldwide. Through our four business groups, Motorparts, Performance Solutions, Clean Air and Powertrain, Tenneco is driving advancements in global mobility by delivering technology solutions for diversified global markets, including light vehicle, commercial truck, off-highway, industrial, motorsport and the aftermarket.
Visit www.tenneco.com to learn more.
CONTACT:
Karen Shulhan (DRiV) – 313.617.2086
Bill Dawson (DRiV) – 847.482.5807
bdawson@driv.com
View original content to download multimedia:
SOURCE DRiV
|
https://www.whsv.com/prnewswire/2022/04/08/rancho-be-featured-56th-annual-easter-jeep-safari/
| 2022-04-08T18:58:38Z
|
NEW FAZE CLAN X RESPAWN CHAIRS AVAILABLE LATER THIS YEAR
LOS ANGELES, April 8, 2022 /PRNewswire/ -- FaZe Clan, the lifestyle and media platform rooted in gaming and youth culture, today announced RESPAWN as the organization's official gaming chair partner. The new collaboration will outfit FaZe Clan's diverse roster of premiere content creators and esports pros with RESPAWN's premium gaming chairs. Additionally, a new set of FaZe Clan x RESPAWN branded chairs, which will come in various colorways and three different price points, will be available for purchase later this year.
The collaboration between the two gaming industry leaders highlights FaZe Clan's roster of content creators such as FaZe Faxuty and FaZe Scope with RESPAWN's best-in-class gaming chairs. More importantly, this partnership supports the joint mission of FaZe Clan and RESPAWN in creating impactful content and providing every type of gamer access to a comfortable gaming setup.
"RESPAWN is excited to partner with FaZe Clan, bringing together two powerhouses in the gaming community," says Rachael Boone, President of OFM, Inc. (parent company of RESPAWN). "This partnership highlights the best of gaming performance by uniting ergonomic furniture expertise with top-level gamers and creators - resulting in meaningful content and a performance-driven product to meet the needs of the gaming community."
"We are proud to partner with RESPAWN as the official gaming chair partner of FaZe Clan," says Adam Bauer, SVP of Partnerships at FaZe Clan. "This partnership came together organically through both FaZe Clan and RESPAWN'S quest of making sure our content creators, esports pros and gamers around the world have access to a comfortable gaming setup for long term player health."
More details on the FaZe Clan x RESPAWN branded chairs to be announced soon.
ABOUT RESPAWN
RESPAWN is for All Gamers. A leader within the industry, RESPAWN fuses more than 75 years of ergonomic expertise with gaming culture to create best-in-class chairs for gamers to level up their experience. We believe that comfort and performance should be inclusively designed into every gaming chair we create, which is why we're immersed in the gaming community and build every RESPAWN product from real consumer feedback. From industry-leading partnerships with content creators and eSports teams to engaging with the gaming community through events and social media, we're committed to welcoming all gamers to the RESPAWN community. RESPAWN is trusted by the pros, supported by the community, and designed for ALL gamers. Learn more about RESPAWN's community, performance, and design at https://respawnproducts.com/.
ABOUT FAZE CLAN
FaZe Clan is a digital-native lifestyle and media platform rooted in gaming and youth culture, reimagining traditional entertainment for the next generation. Founded in 2010 by a group of kids on the internet, FaZe Clan was created for and by Gen Z and Millennials, and today operates across multiple verticals with transformative content, tier-one brand partnerships, a collective of notable talent, and fashion and consumer products. Reaching over 350 million followers across social platforms globally, FaZe Clan delivers a wide variety of entertainment spanning video blogs, lifestyle and branded content, gaming highlights and live streams of highly competitive gaming tournaments. FaZe Clan's roster of more than 85 influential personalities consists of engaging content creators, esports professionals, world-class gamers and a mix of talent who go beyond the world of gaming, including NFL star Kyler "FaZe K1" Murray, Lebron "FaZe Bronny" James Jr., Lil Yachty aka "FaZe Boat" and Snoop Dogg aka "FaZe Snoop." Its gaming division includes ten competitive esports teams who have won over 30 world championships. For more information, visit www.fazeclan.com, investor.fazeclan.com and follow FaZe Clan on Twitter, Instagram, YouTube, TikTok, and Twitch.
View original content to download multimedia:
SOURCE FaZe Clan
|
https://www.whsv.com/prnewswire/2022/04/08/respawn-named-official-gaming-chair-partner-faze-clan/
| 2022-04-08T18:58:45Z
|
Roanoke College faculty voted to add the College's first graduate program in 100 years.
SALEM, V.A., April 8, 2022 /PRNewswire/ -- Roanoke College is poised to offer its first graduate program in more than a century, pending approval by the regional higher education accreditor, Southern Association of Colleges and Schools Commission on Colleges (SAACS-COC).
Faculty voted on March 23 to approve a Master of Business Administration (MBA) degree, and if approved, the College will begin administering the degree in summer 2023. If approved, this would be the first time the College will offer graduate courses since the 1920s, when Roanoke offered masters-level chemistry courses.
"This is a victory for Roanoke and our students," President Michael C. Maxey said. "The faculty worked hard on the proposal and created an excellent final product. We are grateful to everyone involved in developing this program. It is a great step forward for Roanoke College and our students."
The program will be a four-plus-one program, where students will complete their undergraduate degree in four years and their MBA after a fifth year. It will require summer and regular-term courses and will consist of 11 courses taken by yearly cohorts of 20 students. These cohorts will contain four teams working together on projects that will culminate in a comprehensive team project. The MBA degree provides in-depth knowledge and application in the core areas of business: accounting, leadership, ethics, economics, management, marketing, finance, and data analysis.
The MBA program connects to and supports the liberal arts tradition at Roanoke College by enhancing the knowledge students receive as undergraduates and preparing them for career and professional advancement.
Dr. Richard Grant, interim vice president for academic affairs, spearheaded the movement, as did a variety of faculty and staff members including Prof. Sharon Gibbs, interim associate dean for academic affairs and student engagement; Dr. Michelle Hagadorn, associate professor of business administration and economics; Dr. Gail Steehler, associate dean of academic affairs and administration; Dr. Shannon Anderson, associate professor of sociology and public health; and Dr. Charlene Kalinoski, professor of modern languages.
Roanoke College has an established academic reputation in business administration. The Princeton Review has named Roanoke a Great School for Business/Finance Majors every year since 2014. Business administration is the College's most popular major and offers students a wide array of real-world learning experiences in addition to a solid background of the major functional areas of business.
View original content:
SOURCE Roanoke College
|
https://www.whsv.com/prnewswire/2022/04/08/roanoke-college-prepares-offer-mba-program/
| 2022-04-08T18:58:51Z
|
- Part of global promotion campaign of K-spicy to commemorate the 10th anniversary of the launching Buldak
SEOUL, South Korea, April 8, 2022 /PRNewswire/ -- Samyang Foods announced on April 8 that it will participate as the main sponsor of BTS PERMISSION TO DANCE ON STAGE – LAS VEGAS, commemorating the 10th anniversary of the launching Buldak, Korean noodles with secret spicy sauce.
BTS is holding BTS PERMISSION TO DANCE ON STAGE - LAS VEGAS on April 8 to 9 (local time) and on April 15 to 16 at the Allegiant Stadium in Las Vegas.
During the concert, Samyang Foods plans to promote Buldak to fans around the world who love K-culture, and carry out various promotions.
First, a Buldak promotional booth will be operated during the BTS Permission to Dance on Stage – Las Vegas period. The 10-year-history since the debut of Buldak will be introduced and the event in which fans can directly participate will be held. The English advertisement Firely and Greatly released in Korea and China, will be shown to local fans at the concert. In addition, the Samyang Foods Buldak logo is included as an official sponsor on limited edition BTS swags and photo cards of the group members.
In particular, the Buldak promotional booth will reveal a work that reinterprets the value of Buldak from the perspective of the millennials and Generation Z through SAMBYPEN (Se Dong Kim), a K-illustrator known for collaborating with brands like Louis Vuitton and Nike.
Buldak, launched in 2012, is the best contributor to Samyang Foods' exports. Through Korea's representative spicy taste, Buldak has become a trend beyond simply noodles, and a strong fan base has been formed globally. Buldak has also earned a reputation as a video content, going beyond just a single product. In fact, as an icon of a challenge that anyone should try at least once, if you search for 'Fire Noodle Challenge' on YouTube, more than a million videos are found. At the 58th Trade Day Commemoration ceremony in Korea, Samyang Foods was awarded the 300 million Dollar Export Tower for the first time in the Korean food industry, in December last year.
An official from Samyang Foods said, "Participating BTS Permission to Dance on Stage – Las Vegas as the main sponsor is a great opportunity to introduce Buldak representing K-spicy to ARMY (the fan club associated with the band BTS) as well as to consumers around the world." He added, "We will continue to make every effort through Samyang America, which was established last year, so that Buldak can successfully settle into the US mainstream."
View original content to download multimedia:
SOURCE Samyang Foods
|
https://www.whsv.com/prnewswire/2022/04/08/samyang-foods-sponsors-bts-permission-dance-stage-las-vegas/
| 2022-04-08T18:58:58Z
|
BGR Analyzes DA Sales Tax in St. Tammany Parish
ST. TAMMANY PARISH, La. (press release) — The Bureau of Governmental Research (BGR) released a new report that analyzes a 0.14% parishwide, 10-year sales tax proposed by the District Attorney for St. Tammany Parish to fund criminal prosecutions.
On the Ballot: District Attorney Sales Tax, St. Tammany Parish, April 30, 2022, seeks to help voters make an informed decision on the tax proposition. BGR’s report analyzes the proposition based on a series of questions that address the efficient and effective use of public resources. The report also explains BGR’s position in support of the tax.
This report is part of BGR’s On the Ballot series, which provides voters with objective, nonpartisan analysis of significant ballot propositions in the New Orleans metropolitan area. In producing these reports, BGR recommends positions consistent with its mission of promoting informed public policy making and the effective use of public resources to improve local government.
|
https://www.bizneworleans.com/bgr-analyzes-da-sales-tax-in-st-tammany-parish/
| 2022-04-08T18:59:03Z
|
Lead oncology program candidate SG-3-06686 shows potential to become first in class CXCR3 immune activator
BRISBANE, Calif., April 8, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company's CXCR3 chemokine receptor modulator, SG-3-06686 (referred to as SG-3-00802DC in the AACR presentation), enhances effector T cell migration to improve the immune system's activity against tumors, and showed anti-tumor activity in preclinical models as a monotherapy and in combination with anti-Programmed Death Protein-1 (PD-1) treatment. The data is being presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 8–13 virtually and in New Orleans, Louisiana.
"We are excited about our pre-clinical data that show the ability of this potential mechanism to go beyond checkpoint blockade as an emerging new immunologic strategy for treating cancers. Checkpoint inhibitor therapy has been transformative for the clinical outcome of cancer patients and additional new checkpoint targets, such as TIGIT/LAG3, continue to be added to this important treatment approach. However, if the proper immune cells are underrepresented or lacking in the tumor microenvironment, these interventions tend to be less effective, and a significant portion of patients have limited or transient benefit. To augment and improve anti-tumor efficacy, we need to develop new therapeutics to better facilitate the ability of effector cells to access the tumor microenvironment. CXCR3 pathway modulation is a well validated and exciting approach to potentially enhance effector cell recruitment and improve existing immunotherapy interventions," said Joe Dal Porto, Ph.D., Chief Scientific Officer of Second Genome. "We look forward to submitting an investigational new drug (IND) application for SG-3-06686, a potential first in class CXCR3 immune modulator, in early 2023."
This data presentation can be accessed during the online-only poster session at the AACR. The information is provided below:
Session Category: Clinical Research Excluding Trials
Session Title: Immuno-oncology
Abstract Number: 6349
Title: Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the
immune system to enhance anti-tumor immunity
SG-3-06686 is a potent CXCR3 chemokine receptor engager that acts as a positive allosteric modulator to increase receptor activity to the three known ligands (CXCL9/10/11). It has demonstrated to increase the activity of CXCL11 on CXCR3 activation by greater than 10-fold from a nM to a pM range with similar effects on CXCL9 and CXCL10. This activity in turn drives strong antitumor activity in several preclinical cancer models.
The poster (#6349) entitled, "Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the immune system to enhance anti-tumor immunity," will be available for on-demand viewing on the AACR website and will also be made available on the Company's website at https://www.secondgenome.com/events/.
About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Pfizer (formerly Arena Pharmaceuticals) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit www.secondgenome.com.
Investor Contact:
Argot Partners
212-600-1902
secondgenome@argotpartners.com
Media Contact:
Argot Partners
212-600-1902
secondgenome@argotpartners.com
View original content to download multimedia:
SOURCE Second Genome
|
https://www.whsv.com/prnewswire/2022/04/08/second-genome-presents-new-preclinical-data-aacr-2022-demonstrating-that-sg-3-06686-cxcr3-chemokine-receptor-modulator-induces-migration-immune-effector-cells-inhibits-tumor-growth-monotherapy-boosts-anti-programmed-death-protein-1-pd-1-activity/
| 2022-04-08T18:59:05Z
|
Cancer Research Conference Convenes in New Orleans
NEW ORLEANS (press release) — The American Association for Cancer Research (AACR) will host its Annual Meeting at the New Orleans Ernest N. Morial Convention Center April 8-13, marking the largest gathering of cancer researchers in the world and the largest meeting New Orleans has hosted since the start of the pandemic.
Approximately 14,000 scientists, clinicians, survivors, patients, and advocates from 73 countries and nearly 500 exhibitors will convene to discuss and share the latest advances in cancer science and medicine, bringing an estimated $16 million in economic impact to the city.
Roughly 300 attendees will participate in the AACR Runners for Research 5K Run/Walk on April 9 at 7:30 am, at Canal Place. AACR Ambassador, Louisiana native, and Las Vegas Raiders running back Brandon Bolden will kick off the event and motivate the runners with the story of his cancer journey.
Press conferences highlighting exciting progress in cancer immunotherapy, cancer disparities, the intersection of COVID-19 and cancer, and more will be held every morning from Sunday, April 10-Tuesday, April 12.
If interested, there will be media credentials available and a media room in the Convention Center. The AACR is requiring all attendees, including press, to be fully vaccinated against COVID-19.
|
https://www.bizneworleans.com/cancer-research-conference-convenes-in-new-orleans/
| 2022-04-08T18:59:09Z
|
ALPHARETTA, Ga., April 8, 2022 /PRNewswire/ -- Spectrum Plastics Group ("SPG," "Spectrum" or the "Company"), a leading medical components and contract manufacturer, today announced that John Wolf has been appointed permanent President and Chief Executive Officer, effective immediately. John Wolf was appointed interim President and CEO in December 2021.
Rahul Goyal, Chairman of Spectrum Plastics Group and a Partner at AEA Investors, said, "John has led Spectrum impressively, contributing to the continued growth and success of the Company. The world class leadership team and all of our Spectrum teammates continue to execute well, and we are confident that John will provide the management and expertise needed to guide Spectrum through its next phase of growth and success."
Mr. Wolf brings over 20 years of professional experience delivering strong and sustainable growth, customer service improvement and operational efficiencies across multiple business disciplines. He previously served as President of Spectrum's Plastic Films Division, a role he held for nearly three years. Prior to joining Spectrum, he spent nearly 20 years with Sealed Air Corporation, holding executive leadership roles including Global Vice President and General Manager for the Automated Fulfillment Solutions Business Unit, Global Vice President of Marketing for the $1.6 billion Product Care Packaging Division, Vice President of Global General Packaging and Vice President of Strategy and Execution. He earned a Bachelor of Science in Chemical Engineering from North Carolina State University.
"I am very humbled at the opportunity to lead Spectrum Plastics and serve our customers," said Mr. Wolf. "I look forward to continuing to work with the Board, the world class global management team and my 1,900+ Spectrum teammates to continue driving the Company's upwards trajectory as we collaborate on identifying new opportunities to enhance our market leadership and delivering for our customers, partners, and stakeholders."
Spectrum's history spans over 60 years of applications expertise including precision extrusion, specialty injection molding, blown film extrusion and conversion, medical balloon fabrication, laser processing, additive manufacturing, and complex assembly of catheters and other devices. Today, Spectrum is a leading full-service partner for the development and manufacturing of critical polymer-based components and finished devices for medical and other demanding applications. With 20 locations and over one million square feet of manufacturing space in six countries worldwide, we have the resources to solve customers' most challenging problems with proven quality, responsiveness, innovation and technical expertise.
AEA Investors LP was founded in 1968 by the Rockefeller, Mellon and Harriman family interests and S.G. Warburg & Co. as a private investment vehicle for a select group of industrial family offices with substantial assets. AEA has an extraordinary global network built over many years which includes leading industrial families, business executives and leaders; many of whom invest with AEA as active individual investors and/or join its portfolio company boards or act in other advisory roles. Today, AEA's approximately 100 investment professionals operate globally with offices in New York, Stamford, San Francisco, London, Munich and Shanghai. The firm manages funds that have over $15 billion of invested and committed capital including the leveraged buyouts of middle market companies and small business companies, growth capital and mezzanine and senior debt investments.
Spectrum Plastics Marketing
404-445-1172
marketing@spectrumplastics.com
Alexandra Douglass
650-619-5328
adouglass@aeainvestors.com
View original content:
SOURCE Spectrum Plastics Group
|
https://www.whsv.com/prnewswire/2022/04/08/spectrum-plastics-group-announces-appointment-john-wolf-permanent-president-amp-ceo/
| 2022-04-08T18:59:11Z
|
Family Business – The Gateway to Change Generations
Sponsored Content
Business, when done right, can change the life of its founders. However, when entrepreneurship is done well it can change generations. The opportunities that result from the creation and success of a business can last a lifetime. The impact of a successful small business can touch many families, changing their lives for the better. At RYCARS Construction, the Burks family is attempting to change the lives of generations. The company was founded 20 years ago in the home of Ryan and Stephanie Burks. They dreamed of success but initially the true goal was to be able to pay for their three children to go to college and purchase vehicles for them. The original goal was swiftly accomplished due to the company’s rapid success.
Over the past 20 years, RYCARS has grown from a home-based business to a multi-million-dollar regional contractor with offices in three states; Louisiana, Georgia, and Texas. RYCARS is a regional, full service commercial roofing contractor specializing in low slope and steep slope roof systems. The family business currently has three generations working together, primarily at the headquarters in Kenner, Louisiana. The name of the company is an acronym from the members of the family Ryan (RY) Caleb (C), Arielle (A), Ryan II (R) and Stephanie (S). All the children have worked in the business. However, currently Arielle and Ryan II are full-time Project Managers within the organization. Ryan’s mother, Claudette Madere functions as a Contract Administrator for Louisiana Operations. Stephanie is the Vice President and leads Accounting and HR. Ryan is the CEO of the organization with daily emphasis being focused on business development and operations management. The family members work together extremely well primarily because they are all committed to the company’s success.
Usually, family businesses are challenging to manage and even more difficult for family succession. At RYCARS the family continues to thrive off a slogan in which it was built, “Success is not an Accident”. Team RYCARS believes in preparation, planning, and execution for successful projects. The Burks family believes in each person playing their part and doing whatever it takes to create win-win solutions for the family business and its customers.
Ryan E. Burks is a man with a life mission to bestow a legacy of discipline, hard work and perseverance in the areas of Faith, Family and Business. Mr. Burks lives by the following creed: “Success is not an Accident. Success in life is directly proportional to the level of sacrifice made to achieve the desired success level.” After graduating from Tulane University with a degree in Civil Engineering, he launched his professional career as a design engineer in Atlanta, Georgia where he worked on projects for the 1996 Olympic Games. Mr. Burks later advanced to be a Project Manager, Construction Manager and Operations Manager for various construction firms in Georgia, Florida, Alabama and Louisiana before founding RYCARS Construction, LLC in 2002. The name RYCARS stands for the family members of President and CEO, Ryan E. Burks (RYan Caleb Arielle Ryan Stephanie).
RYCARS Construction, LLC is a regional specialty contractor with a core competency in commercial roofing applications. Its mission is to provide construction services specifically related to building envelopes. Since March of 2002, Mr. Burks has led RYCARS Construction, LLC in completing over $200 million in commercial roofing and construction projects for over 80 different customers, in multiple industries such as healthcare, higher education, vocational, correctional, commercial, industrial and Federal Government. RYCARS has performed successfully on projects in ten (10) states: Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, Tennessee, Texas and Virginia. The company has completed high profile projects such as the Mercedes Benz Superdome in New Orleans, NASA’s Johnson Space Center in Houston, Texas and the Army Air Force Exchange Facility in Newport News, VA. RYCARS is headquartered in Kenner, Louisiana with regional satellite offices in Atlanta, GA and Austin, TX.
|
https://www.bizneworleans.com/family-business-the-gateway-to-change-generations/
| 2022-04-08T18:59:15Z
|
Auto Show Adoption Events Resulted in More Than 700 Adoptions Since 2019
CAMDEN, N.J., April 8, 2022 /PRNewswire/ -- Subaru of America, Inc. announced that the automaker's popular Subaru Loves Pets exhibit, featuring adoptable pets from local pet organizations, will return to the 2022 New York International Auto Show.
Taking place in the Subaru Booth at the Jacob K. Javits Convention Center between April 15 and April 24, 2022, the exhibit invites visitors to play and interact with adoptable pets with the goal of uniting these pets with loving homes and donating to local animal welfare organizations.
Since the Subaru Loves Pets auto show adoption events began in 2018, more than 700 pets have been adopted. To date in the 2021-2022 auto show season, more than 200 pets have been adopted and Subaru has donated more than $164,000 to help aid pet organizations in local communities.
"The Subaru Loves Pets adoptions have brought an extra dose of joy to the auto show, and we're excited to bring this much-loved event back to New York City next week," said Alan Bethke, Senior Vice President of Marketing, Subaru of America, Inc. "We welcome all auto show attendees to stop by and consider adding a loving pet to their family."
The Subaru Loves Pets exhibit will feature adoptable pets from animal shelters in the greater New York City area, including Southampton Animal Shelter Foundation, NYC Second Chance Rescue, Zani's Furry Friends, AMA Animal Rescue and Bobbi and the Strays.
The exhibit will be open to auto show attendees at the following dates and times ET:
- Friday, April 15 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Saturday, April 16 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Sunday, April 17 – 10 a.m. – 2 p.m. and 3 – 7p.m.
- Monday, April 18 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Tuesday, April 19 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Wednesday, April 20 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Thursday, April 21 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Friday, April 22 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Saturday, April 23 – 11 a.m. – 3 p.m. and 4 – 8 p.m.
- Sunday, April 24 – 10 a.m. – 2 p.m. and 3 – 7 p.m.
As part of the Subaru Love Promise, the Subaru Loves Pets initiative is dedicated to helping pets, with a focus on uniting adoptable pets with loving homes. To date, Subaru has supported the rescue and adoption of nearly 350,000 animals nationwide. For more information about Subaru Loves Pets, please visit www.subaru.com/pets and follow #SubaruLovesPets on social media.
To learn more about the Subaru Love Promise, please visit www.subaru.com/lovepromise.
Subaru of America, Inc. (SOA) is a wholly owned subsidiary of Subaru Corporation of Japan. Headquartered at a zero-landfill office in Camden, N.J., the company markets and distributes Subaru vehicles, parts and accessories through a network of more than 630 retailers across the United States. All Subaru products are manufactured in zero-landfill plants and Subaru of Indiana Automotive, Inc. is the only U.S. automobile manufacturing plant to be designated a backyard wildlife habitat by the National Wildlife Federation. SOA is guided by the Subaru Love Promise, which is the company's vision to show love and respect to everyone, and to support its communities and customers nationwide. Over the past 20 years, SOA and the SOA Foundation have donated more than $270 million to causes the Subaru family cares about, and its employees have logged nearly 78,000 volunteer hours. As a company, Subaru believes it is important to do its part in making a positive impact in the world because it is the right thing to do.
For additional information visit media.subaru.com. Follow us on Facebook, Twitter, and Instagram.
Diane Anton
Corporate Communications Manager
(856) 488-5093
danton@subaru.com
Jessica Caufield
Corporate Communications Specialist
(856) 488-3173
jcaufi@subaru.com
View original content to download multimedia:
SOURCE Subaru of America, Inc.
|
https://www.whsv.com/prnewswire/2022/04/08/subaru-helps-adoptable-pets-find-loving-homes-2022-new-york-international-auto-show/
| 2022-04-08T18:59:18Z
|
LCMC, City of New Orleans Launch Health Literacy Partnership
NEW ORLEANS (press release) — LCMC Health announced a partnership with the City of New Orleans Health Department to address health literacy, enhance cultural competency, and continue to improve COVID-19 vaccination rates with a new program called, “Be in the KNOW.” This citywide initiative will educate locals on the importance of healthcare advocacy and aims to empower communities for better health.
April is National Minority Health Month, four weeks dedicated to raising awareness of health disparities that continue to affect underserved communities. Historically, many minority communities have expressed an overall lack of trust in hospitals and health systems. In order to continue building trust, and eventually stronger, healthier communities, LCMC Health and the New Orleans Health Department is encouraging individuals and caregivers to take action through health education and community collaboration to increase health literacy in the greater New Orleans area and neighboring communities.
“LCMC Health is proud to kick-off our partnership with the City of New Orleans Health Department during National Minority Health Month to address the needs of our community,” said Dr. Toni Flowers, LCMC Health chief diversity and social responsibility officer. “Health equity and health literacy are serious concerns that require caring and smart collaboration. Through this partnership, we will provide our community with the proper tools and resources needed to advocate for better health.”
According to the U.S. Department of Health & Human Services, nearly 9 out of 10 adults have difficulty comprehending everyday health information that is routinely available in healthcare facilities, retail outlets, media, and communities. The Be in the KNOW partnership aims to empower patients with educational resources, and offer training to enhance the skill sets of healthcare providers.
|
https://www.bizneworleans.com/lcmc-city-of-new-orleans-launch-health-literacy-partnership/
| 2022-04-08T18:59:21Z
|
Low interest rates, consumer preference for more expensive vehicle types expected to support sales gains through 2025
CLEVELAND, April 8, 2022 /PRNewswire/ -- Retail sales of new motor vehicles (MVs) in the US are forecast to increase 3.2% annually in unit terms through 2025, according to Motor Vehicles: United States, a report recently released by Freedonia Focus Reports. Suppliers will benefit from a continuation of low interest rates as well as easing supply chain constraints on MV production. Other factors such as increasing disposable personal incomes, an expanding population, and growth in freight, construction, and mining activity will also support growth in retail sales. Further gains over the forecast period will be limited by:
- ongoing retirement of baby boomers
- later acquisition of drivers' licenses among young people
- the US urban population growing faster than the general population, expanding the size of a cohort with easy access to public transport and ridesharing services
- increasing reliability of vehicles
Ongoing competition from used vehicle sales will continue to restrain sales of new MVs. However, the current limited availability of used vehicles will mitigate this constraint in the near term.
Retail sales of motor vehicles in unit terms are expected to rise 1.7% in 2021. A release of pent-up demand will lead to growth in vehicle sales following delayed purchases in 2020 due to COVID-19 pandemic uncertainty. Low interest rates will further support this trend. However, a vehicle production shortage will raise prices and restrain availability, preventing faster gains.
In value terms, US retail sales of new MVs are forecast to see growth of 5.5% annually through 2025. In addition to rising unit sales, sales in value terms will be boosted by an increase in average vehicle prices and ongoing consumer preference for more expensive SUVs, CUVs, and light trucks, as well as ongoing adoption of more expensive electric vehicles. Sales are expected to grow over 17% in 2021, driven by price increases, dealer markups, and competition between consumers as they draw from pandemic-related savings to buy from a limited supply. Many consumers began making new MV purchases in 2021 that they delayed making the previous year due to the COVID-19 pandemic. However, prices will be driven up as growing demand is met with reduced supply caused by a shortage of semiconductor chips.
These and other key insights are featured in Motor Vehicles: United States. This report forecasts to 2021 and 2025 US motor vehicle retail sales in units and nominal US dollars, as well as production in units. Total new retail sales and production volumes are segmented by type in terms of:
- light-duty trucks
- automobiles
- medium-duty trucks
- heavy-duty trucks
- medium- and heavy-duty buses
Total new vehicle retail sales in value terms are segmented by type as follows:
- light-duty trucks
- automobiles
- medium- and heavy-duty trucks and buses
To illustrate historical trends, total retail sales, total production, and the various segments are provided in annual series from 2010 to 2020.
Other forms of motorized transport equipment, such as all-terrain vehicles; bicycles; military armored vehicles and tanks; motorcycles; off-road agriculture, construction, and mining equipment; race cars; snowmobiles; and parts are excluded from the scope of this report. New MV leases originated are included in volume retail sales figures. Re-exports of motor vehicles are excluded from demand figures.
This report includes the results of a proprietary national online consumer survey of US adults (age 18+). This Freedonia Focus Reports National Survey has a sample size of 1690, screened for response quality, and representative of the US population on the demographic measures of age, gender, geographic region, race/ethnicity, household income, and the presence/absence of children in the household.
More information about the report is available at:
https://www.freedoniafocusreports.com/Motor-Vehicles-United-States-FF85029/?progid=91541
Each month, The Freedonia Group – a division of MarketResearch.com – publishes over 20 new or updated Freedonia Focus Reports, providing fresh, unbiased analysis on a wide variety of markets and industries. Published in 20-30 pages, Focus Report coverage ranges from raw materials to finished manufactured goods and related services such as freight and construction. Additional Services & Industries reports can be purchased at Freedonia Focus Reports or MarketResearch.com.
Analysis is intended to guide the busy reader through pertinent topics in rapid succession, including:
- total historical market size and industry output
- segmentation by products and markets
- identification of market drivers, constraints, and key indicators
- segment-by-segment outlook in five-year forecasts
- a survey of the supply base
- suggested resources for further study
Press Contact:
Corinne Gangloff
+1 440.842.2400
cgangloff@freedoniagroup.com
View original content to download multimedia:
SOURCE The Freedonia Group
|
https://www.whsv.com/prnewswire/2022/04/08/supply-chain-constraints-semiconductor-shortage-boost-motor-vehicle-prices-sales-values-near-term/
| 2022-04-08T18:59:25Z
|
Michelle Miller to Serve as UNO Spring Commencement Speaker
NEW ORLEANS (press release) — CBS News journalist and University of New Orleans alumna Michelle Miller will serve as the principal speaker at the university’s spring 2022 undergraduate commencement ceremony.
The university will hold two commencement ceremonies in the UNO Lakefront Arena on Saturday, May 21: a graduate student ceremony at 10 a.m. and an undergraduate student ceremony at 2:30 p.m.
UNO will also award New Orleans attorney and former University of Louisiana System Board of Supervisors chair James Carter with an honorary doctorate during the graduate school ceremony.
Miller is a co-host of “CBS Saturday Morning.” Her work regularly appears on “CBS Mornings,” “CBS Sunday Morning” and the CBS Evening News. She also files reports for “48 Hours” and anchors Discovery’s “48 Hours on ID” and “Hard Evidence.”
“We are so excited to welcome Michelle back to campus,” said UNO president John Nicklow. “She has traveled the country and the globe, reporting on some of the most important news events of our lifetime. Our graduates will benefit from her experience and insight. As an alumna of the university, she is a fantastic role model for all privateers.”
Miller’s reporting has earned her several prestigious journalism awards including an Emmy for her series of reports on the National Guard’s Youth Challenge Academy, an Edward R. Murrow for her coverage of a day care center stand-off in New Orleans, and she was part of the Alfred I. duPont – Columbia Award winning team for coverage of the Newtown, Conn., school shooting. In 2019, Miller won a Gracie award for her reporting on the hidden world of sex trafficking in “‘48 Hours’: Live to Tell: Trafficked.”
Miller is well-acquainted with New Orleans. She previously worked at WWL-TV, the local CBS affiliate. She earned a bachelor’s degree in journalism from Howard University and a master’s degree in urban studies from the University of New Orleans.
|
https://www.bizneworleans.com/michelle-miller-to-serve-as-uno-spring-commencement-speaker/
| 2022-04-08T18:59:27Z
|
SOUTH SAN FRANCISCO, Calif., April 8, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced new nonclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) STRO-002, in an e-poster session, at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans from April 8-13, 2022.
STRO-002 is an ADC designed to target FolRα, which is currently in Phase 1 clinical trials for the treatment of ovarian and endometrial cancers. In the e-poster session presented at AACR, studies in vitro demonstrate STRO-002's ability to induce hallmarks of immunogenic cell death. Studies in vivo show that pre-administration of STRO-002 to FolRα-expressing tumor cells confers anti-tumor immunity as demonstrated by both rejection of the primary tumor and significant protection after a tumor re-challenge. Further, in vivo induction of immunogenic cell death extended to a complementary anti-tumor mechanism in combination with a checkpoint inhibitor (avelumab) in re-challenged animals. Additionally, when STRO-002 was administered in combination with an anti-VEGF antibody (bevacizumab), the tumor growth was significantly inhibited.
Nonclinical studies using endometrial and non-small cell lung cancer (NSCLC) patient derived xenograft models with diverse levels of FolRα expression demonstrated robust STRO-002 activity, with the degree of efficacy correlating with FolRα levels. Similar activity was also seen in cells with moderate to low levels of FolRα expression. In the NSCLC model, a STRO-002 dose of 10 mg/ml resulted in significant and long-term responses.
"These nonclinical data provide insight into STRO-002's immunogenic cell death properties and reveal its potential to elicit host immune system engagement and potentiate efficacy in a targeted and dependent manner," said Trevor Hallam, Ph.D., President of Research and Chief Scientific Officer at Sutro. "The potent cytotoxic and immune stimulatory properties of STRO-002 through immunogenic cell death may also enhance activity in indications that are thought to have lower levels of FolRα such as in non-small cell lung cancer and endometrial cancers."
The data is being presented as an e-poster at the AACR Annual Meeting, with details as follows:
The poster is accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company's website at www.sutrobio.com.
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies and was granted Orphan Drug Designation by the FDA for multiple myeloma. STRO-002, a folate receptor alpha (FolRα)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. A third product candidate, CC-99712, a BCMA-targeting ADC, which is part of Sutro's collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR, bispecific ADC, which is part of Sutro's collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. These four product candidates resulted from Sutro's XpressCF® and XpressCF+™ technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro's platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies to discover and develop novel, next-generation therapeutics.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of announcements of clinical results or nonclinical results, potential benefits of STRO-002 and the Company's other product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for STRO-002 and the Company's other product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates and the Company's ability to successfully leverage Fast Track designation, the market size for the Company's product candidates to be smaller than anticipated, the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the Company's ability to protect intellectual property, the value of the Company's holdings of Vaxcyte common stock, and the Company's commercial collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com
Media Contact
Maggie Beller
Russo Partners
(646) 942-5631
Maggie.beller@russopartnersllc.com
View original content:
SOURCE Sutro Biopharma
|
https://www.whsv.com/prnewswire/2022/04/08/sutro-biopharma-presents-nonclinical-data-antibody-drug-conjugate-stro-002-aacr-annual-meeting-2022/
| 2022-04-08T18:59:32Z
|
Second Chance Virtual Job Fair to be Held April 27
NEW ORLEANS (press release) — The Office of Workforce Development, in partnership with the State of Louisiana, Louisiana Department of Public Safety & Corrections, and the Louisiana Workforce Commission is hosting a Second Chance Virtual Virtual Career & Resource Expo for justice-involved/returning citizens on Wednesday, April 27 from 1p.m. – 3p.m.
The expo will help assist qualified and professional candidates who are returning citizens seeking employment.
|
https://www.bizneworleans.com/second-chance-virtual-job-fair-to-be-held-april-27/
| 2022-04-08T18:59:33Z
|
The Spa at Four Seasons Announces Opening Date
NEW ORLEANS (press release) — The newly opened Four Seasons Hotel and Private Residences New Orleans announced the April 20, 2022 opening of its beauty atelier Spa. The Spa at Four Seasons Hotel New Orleans is the first establishment in Louisiana to offer products and treatments from acclaimed French skincare brand Biologique Recherche.
“We are thrilled to welcome guests and locals to experience the highly anticipated Spa at Four Seasons Hotel New Orleans—the final complement to the hotel’s luxury offerings,” said Mali Carow, general manager for Four Seasons Hotel New Orleans. “In our concept, we drew inspiration from the city itself. New Orleans is a city known for indulgence and celebration.”
Taking a cue from the destination, The Spa offers thoughtfully curated treatments to erase the effects of a late night out on the town and have guests looking and feeling their best. Après-treatment, enjoy a lagniappe of bubbles and nibbles in the relaxation lounge overlooking the Crescent City and the Mississippi River. Guests can choose from a selection of massages, facials, wraps, skin treatments, brow and lash treatments.
At 5,525 square feet (513 square meters), The Spa offers eight treatment rooms, including a couple’s room with a soaking tub. A Relaxation Lounge, steam room, and cool mist experience, as well as his and her locker rooms complete the space. The boutique offers favorites from Biologique Recherche, along with stylish new lifestyle products. A quarterly program of visiting experts will welcome the most sought-after aestheticians and wellness therapists from across the United States.
Spa reservations are available beginning April 20, 2022 by calling 504-434-5108 or by email Spa.NewOrleans@fourseasons.com. For more information on The Spa and for a complete listing of services, visit fourseasons.com/neworleans/spa.
|
https://www.bizneworleans.com/the-spa-at-four-seasons-announces-opening-date/
| 2022-04-08T18:59:40Z
|
LOUISVILLE, Ky., April 8, 2022 /PRNewswire/ -- Swashbockler, the first beer brewed to pair perfectly with Long John Silver's seafood, took its maiden voyage on April 4, 2022 at Shippingport Brewing Company just ahead of National Beer Day. Starting today, Long John Silver's fans in Louisville, KY can get a pint of the beer to commemorate the Lenten season.
Filled with notes of fresh bread, mild honey, and a hint of lemon, rounded out with the light, malted sweetness of Long John Silver's malt vinegar, the German-style Helles Bock beer serves as the perfect companion to wash down your crispy, crunchy, and fresh seafood dish.
"Safe to say when first hearing of Long John Silver's creating a beer with its malt vinegar, there were some initial reservations. But truthfully, after the first sip, they were all washed aside," said Josh Johnson, The Kentucky Gent on Instagram. "The beer sips incredibly clean and refreshing with a slight acidic kick that makes it more of a robust beer than a traditional bock beer. And the tartness of the lemon makes for a refreshing sip – solo or alongside a fresh and crispy piece of Long John Silver's fish."
"For over 50 years, Long John Silver's has provided fries, hushpuppies, and coleslaw that pairs perfectly with our hand battered Alaskan pollock. We're happy to add beer to that list as well," said Bentley McBentleson, Director of Marketing at Long John Silver's. "We're thrilled to have the opportunity to partner with a local brewery to create the Swashbockler beer for Long John Silver's fans and we hope this is just the start of several sea-themed beverages."
Swashbockler is available now on draft at Shippingport Brewing Company and Sallyforth Taproom in Louisville and can be found in select bars throughout Kentucky. Swashbockler is only available for a limited time, so set sail today to try this treasure of a beer.
About Long John Silver's
Long John Silver's was founded in 1969 and has grown into the nation's largest quick-service seafood chain. With restaurants nationwide and delivery available from sea to mouth-watering sea, Long John Silver's continues building on a belief that the unique seafood experience from the coasts should be accessible to all. Learn more at www.ljsilvers.com or join the conversation via social media on Twitter, Facebook, or Instagram.
About Shippingport Brewing Company
Shippingport Brewing Company and Sallyforth Taproom opened in 2021, becoming the only taproom and brewpub currently operating in the West End of Louisville, Ky. Founder and brew master Amelia Pillow was inspired to bring a taste of the Portland culture she fell in love with to the heart of Louisville. Today, Shippingport Brewing Company manufactures and sells a variety of house beers and collaborations with local makers and features deli-style sandwiches with warm sides and plant-based options. For more information, visit www.shippingportbrewing.com.
View original content to download multimedia:
SOURCE Long John Silver's
|
https://www.whsv.com/prnewswire/2022/04/08/swashbockler-sets-sail-shippingport-brewing-company/
| 2022-04-08T18:59:39Z
|
April 28, 2022, 8:30 a.m. Central time
DALLAS, April 8, 2022 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) will hold its annual meeting of stockholders on Thursday, April 28, at 8:30 a.m. Central time in Dallas. The audio webcast of the meeting can be heard live through the Investor Relations section of the company's website at www.ti.com/ir. An archived copy of the webcast will also be available shortly after the end of the meeting.
About Texas Instruments
Texas Instruments Incorporated (Nasdaq: TXN) is a global semiconductor company that designs, manufactures, tests and sells analog and embedded processing chips for markets such as industrial, automotive, personal electronics, communications equipment and enterprise systems. Our passion to create a better world by making electronics more affordable through semiconductors is alive today, as each generation of innovation builds upon the last to make our technology smaller, more efficient, more reliable and more affordable – making it possible for semiconductors to go into electronics everywhere. We think of this as Engineering Progress. It's what we do and have been doing for decades. Learn more at TI.com.
TXN-G
View original content to download multimedia:
SOURCE Texas Instruments Incorporated
|
https://www.whsv.com/prnewswire/2022/04/08/texas-instruments-webcast-its-2022-annual-meeting-stockholders/
| 2022-04-08T18:59:48Z
|
USPS Honors Author and Illustrator Shel Silverstein
CHICAGO, April 8, 2022 /PRNewswire/ -- The Shel Silverstein Forever stamp — featuring artwork from one of his most famous books, "The Giving Tree" — was dedicated today at Darwin Elementary, one of the schools he attended as a child.
The extraordinarily versatile Silverstein (1930–1999) was one of the 20th century's most imaginative authors and illustrators.
"He could be silly or serious — and anything in between. With his witty rhymes and whimsical, nonsensical verse, it was clear that he loved to play with language. It was also clear that his many readers — young and old alike — loved him for his clever word play. His books are bestsellers, with more than 20 million copies sold in more than 47 languages," said Judy de Torok, the Postal Service's vice president of corporate affairs and dedicating official.
Artist and author Dmitry Samarov, who was the featured speaker, said of Silverstein:
"I was 7 years old when my family moved to this country from the Soviet Union, so I didn't grow up with Silverstein's pictures and words. Nevertheless, I was predisposed to appreciate Silverstein's type of poetry because in the Soviet Union many of the best writers found their only means of expression through children's literature. His wit, playfulness and melancholy were felt instantly familiar — as if I'd always known them. … Silverstein never set out to write for children. He worked for Playboy and wrote raunchy songs for rock bands. He only turned to art and writing at all once it became clear he wouldn't be in the starting lineup for his beloved White Sox."
The Shel Silverstein Forever stamps are issued in panes of 20 and will always be equal in value to the current First-Class Mail 1-ounce price. News of the Shel Silverstein stamps is being shared with the hashtag #GivingTreeStamps.
Silverstein's "The Giving Tree," published in 1964 by Harper & Row, is about a friendship between a motherly tree and a boy. As the child grows older, the tree gives him its shade, apples, branches and trunk. The story ends with the boy returning as an old man to rest against the tree's stump. The bestselling tale of selflessness, which is accompanied by the author's elegantly simple black-and-white illustrations, is considered a classic of children's literature.
Silverstein's zany, self-illustrated books of poetry are similarly revered. "Where the Sidewalk Ends" (1974), "A Light in the Attic" (1981), "Falling Up" (1996) and "Every Thing On It" (2011) feature clever and, at times, playfully nonsensical verse that is adored by young people all over the world.
Children are enthralled by Silverstein's poetry, which is full of fantastical imagery and often deals with the joys and fears of childhood. The four distinctive collections of poetry were bestsellers. The New York Times named "Where the Sidewalk Ends" an Outstanding Book of 1974; Silverstein's album version of the book earned a Grammy Award for Best Recording for Children.
The multi-talented Silverstein also wrote and illustrated books for adult readers. He recorded his own songs in addition to writing hits for other artists. Silverstein's music has appeared in many films. In the 1980s, he wrote plays performed off-Broadway in New York. He died in May 1999 at his home in Key West, FL.
In 2002, Silverstein was inducted into the Nashville Songwriters Hall of Fame. Three of Silverstein's books have been published posthumously: "Runny Babbit" (2005), "Every Thing On It" and "Runny Babbit Returns" (2017). His diverse body of work remains beloved by adults and children alike.
Postal Products
Customers may purchase stamps and other philatelic products through the Postal Store at usps.com/shopstamps, by calling 844-737-7826, by mail through USA Philatelic or at Post Office locations nationwide.
A video of the ceremony will be available on facebook.com/usps. Information for ordering first-day-of-issue postmarks and covers is at usps.com/shop.
Please Note: For U.S. Postal Service media resources, including broadcast-quality video and audio and photo stills, visit the USPS Newsroom. Follow us on Twitter, Instagram, Pinterest and LinkedIn. Subscribe to the USPS YouTube channel, like us on Facebook and enjoy our Postal Posts blog. For more information about the Postal Service, visit usps.com and facts.usps.com.
National: James McKean
202.268.2380
jim.mckean@usps.gov
Local: Timothy Norman
312.983.8371
timothy.j.norman@usps.gov
usps.com/news
View original content to download multimedia:
SOURCE U.S. Postal Service
|
https://www.whsv.com/prnewswire/2022/04/08/the-giving-tree-forever-stamp/
| 2022-04-08T18:59:54Z
|
Poster presentation details lead compounds demonstrating activity against EGFR variants that are resistant to all approved EGFR inhibitors
Nomination of development candidate expected in Q3 2022; IND expected in 2023
CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced preclinical data characterizing next-generation pan-variant EGFR inhibitors that will be detailed in a live poster presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana. The poster highlights advanced lead compounds for use in non-small cell lung cancer (NSCLC) that have been observed to potently inhibit the kinase activity, both in vitro and in vivo, of all major single-, double-, and triple-mutant EGFR variants, including T790M and C797S, with selectivity over wild-type EGFR and the ability to penetrate the central nervous system (CNS).
"Up to half of all non-small cell lung cancer tumors are driven by activating mutations (single-mutants) in EGFR and up to 90 percent of those mutations are found in exons 19 and 21. Furthermore, as patients progress through lines of treatment, a substantial percentage of patients' tumors may develop one or more additional EGFR mutations (double- and triple-mutants) that cause resistance to treatment," said William Shakespeare, Ph.D., President of Research and Development at Theseus. "At Theseus, we have developed a series of potent and selective, single molecule, fourth-generation EGFR inhibitors that are designed to inhibit all major classes of EGFR activating and resistance mutations that contribute to later-line clonal heterogeneity in patients who have been failed by current approved therapies. We are finalizing preclinical studies to characterize our lead compounds and look forward to designating a development candidate in the third quarter of this year."
The preclinical data presented at AACR demonstrates that pan-variant EGFR inhibition of all major single-, double-, and triple-mutants, including T790M and C797S, with selectivity over wild-type, is achievable with a single molecule. Detailed findings show that:
- Theseus' lead compounds potently inhibited all major single-, double-, and triple-mutant EGFR variants in vitro, demonstrating cellular IC50 values between 2-12 nM.
- Lead compounds displayed favorable selectivity over wild-type EGFR, with ratios between 11- to 88-fold.
- An advanced lead compound demonstrated tumor regressions in mice against variants associated with both 1st and 2nd line osimertinib clinical failure – i.e., C797S double- and triple-mutants – at well-tolerated doses.
Studies to further characterize lead compounds are under way, with additional data expected to be presented at a scientific conference in the second half of 2022.
Presentation details:
Poster Number: 3342
Presenter: Wei-Sheng Huang, Ph.D., Vice President of Chemistry
Session Date and Time: Live presentation on Tuesday, April 12TH, 1:30pm - 5pm CT
About NSCLC
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85 percent of the estimated 2.2 million cases of lung cancer diagnosed in 2020. Up to half of NSCLC patients have tumors that are driven by activating mutations in the epidermal growth factor receptor (EGFR) and up to 90 percent of those mutations are found in exons 19 and 21. [Most] patients' tumors, in response to treatment, develop one or more additional EGFR mutations, causing resistance and rendering current therapies ineffective.
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.
Cautionary Statement Regarding Forward Looking Statements
Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Theseus' strategy, future operations, prospects and plans, the structure and timing of its planned preclinical studies and clinical trials, expected milestones, market opportunity and sizing and objectives of management, including in relation to the EGFR inhibitor program and the conclusions derived from preclinical data and the expected designation of a development candidate in respect thereof.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, such as those described from time to time in the reports Theseus files with the Securities and Exchange Commission (SEC), including Theseus' Form 10-K for the year ended December 31, 2021 filed with the SEC on March 10, 2022. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Theseus' management team and speak only as of the date hereof, and Theseus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contact
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
View original content:
SOURCE Theseus Pharmaceuticals
|
https://www.whsv.com/prnewswire/2022/04/08/theseus-pharmaceuticals-announces-preclinical-data-characterizing-next-generation-epidermal-growth-factor-receptor-egfr-inhibitors-2022-american-association-cancer-research-aacr-annual-meeting/
| 2022-04-08T19:00:01Z
|
NEW YORK, April 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BCRX, XCUR, UEC, PSFE, and BILI.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- BCRX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BCRX&prnumber=040820225
- XCUR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=XCUR&prnumber=040820225
- UEC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=UEC&prnumber=040820225
- PSFE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=PSFE&prnumber=040820225
- BILI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BILI&prnumber=040820225
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver
|
https://www.whsv.com/prnewswire/2022/04/08/thinking-about-buying-stock-biocryst-pharmaceuticals-exicure-uranium-energy-paysafe-or-bilibili/
| 2022-04-08T19:00:08Z
|
NEW YORK, April 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBFM, NILE, HOOD, MNTS, and NAT.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- SBFM: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=SBFM&prnumber=040820226
- NILE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=NILE&prnumber=040820226
- HOOD: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=HOOD&prnumber=040820226
- MNTS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=MNTS&prnumber=040820226
- NAT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=NAT&prnumber=040820226
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver
|
https://www.whsv.com/prnewswire/2022/04/08/thinking-about-buying-stock-sunshine-biopharma-bitnile-robinhood-markets-momentus-or-nordic-american-tanker/
| 2022-04-08T19:00:15Z
|
NEW YORK, April 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TWTR, TSLA, KR, UPS, and SYY.
Click a link below then choose between in-depth options trade idea report or a stock score report.
Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.
Stock Report - Measures a stock's suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street's opinion including a 12-month price forecast.
- TWTR: https://www.investorsobserver.com/lp/pr-options-lp-2/?symbol=TWTR&prnumber=040820227
- TSLA: https://www.investorsobserver.com/lp/pr-options-lp-2/?symbol=TSLA&prnumber=040820227
- KR: https://www.investorsobserver.com/lp/pr-options-lp-2/?symbol=KR&prnumber=040820227
- UPS: https://www.investorsobserver.com/lp/pr-options-lp-2/?symbol=UPS&prnumber=040820227
- SYY: https://www.investorsobserver.com/lp/pr-options-lp-2/?symbol=SYY&prnumber=040820227
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver
|
https://www.whsv.com/prnewswire/2022/04/08/thinking-about-trading-options-or-stock-twitter-tesla-kroger-united-parcel-service-or-sysco/
| 2022-04-08T19:00:22Z
|
CHEYENNE, Wyo., April 8, 2022 /PRNewswire/ -- U.S. Gold Corp. ("U.S. Gold," the "Company," "we," "our" or "us") (NASDAQ: USAU), today announced that its advanced stage gold and copper project, the CK Gold Project, was featured in a recent article, "Gold and copper mine could generate hundreds of jobs and millions in revenue, report suggests", in the Casper Star-Tribune.
As stated in the article, a new analysis conducted by University of Wyoming researchers cited that the CK Gold Project would bring an economic boost to the state of Wyoming, estimating that the mine would directly employ 324 long-term workers and generate $75 million in tax revenue during its expected 13-year lifetime, including construction and closure.
The article further states that U.S. Gold Corp. is on track to and anticipates completing its feasibility study, securing the necessary permits, and building the mine to be fully operational by 2024. The Company also anticipates reclaiming the land between 2034 and 2035. Additionally, the article states that "in total, the mine would generate roughly $39 million in tax revenue during construction, $34 million during operations and $2 million during reclamation".
"The article provided us with great visibility and the near-term goals that we have in developing a new mine in Wyoming," said George Bee, President, Chief Executive Officer and Chairman of U.S. Gold Corp. "This project would help to provide local jobs and help toward education funding."
To read the article, please use this link: https://trib.com/business/energy/gold-and-copper-mine-could-generate-hundreds-of-jobs-and-millions-in-revenue-report-suggests/article_95a10484-23dd-5022-8e3f-54665acfa0cb.html
About U.S. Gold Corp
U.S. Gold Corp. is a publicly traded, U.S. focused gold exploration and development company. U.S. Gold Corp. has a portfolio of exploration properties. The CK Gold Project is located in Southeast Wyoming and has a Preliminary Feasibility Study (PFS) technical report, which was completed by Gustavson Associates, LLC. Keystone and Maggie Creek are exploration properties on the Cortez and Carlin Trends in Nevada. The Challis Gold Project is located in Idaho. For more information about U.S. Gold Corp., please visit www.usgoldcorp.gold.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These statements include the projected economic impact of the CK Gold project, including employment and projected tax benefits. These forward-looking statements are estimates based on third party projections and actual results could differ materially from such statements. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks arising from: market and other conditions, the prevailing market conditions for metal prices and mining industry cost inputs, environmental and regulatory risks, COVID-19 uncertainties, risks faced by junior companies generally engaged in exploration activities, whether U.S. Gold Corp. will be able to raise sufficient capital to develop the CK Gold Project, the success or failure of future drilling programs, delays in obtaining the necessary permits for the CK Gold Project, and other factors described in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov. The Company has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company's control. The Company undertakes no duty to correct or update any information contained herein.
For additional information, please contact:
U.S. Gold Corp. Investor Relations:
+1 800 557 4550
ir@usgoldcorp.gold
www.usgoldcorp.gold
View original content:
SOURCE U.S. Gold Corp.
|
https://www.whsv.com/prnewswire/2022/04/08/us-gold-corps-advanced-stage-gold-copper-project-ck-gold-project-featured-casper-star-tribune/
| 2022-04-08T19:00:29Z
|
Bipartisan action requires use of Task Force on Climate-Related Financial Disclosures for annual state-led survey to protect consumers starting this year
KANSAS CITY, Mo., April 8, 2022 /PRNewswire/ -- A bipartisan group of state insurance regulators led by Insurance Commissioners Ricardo Lara of California and David Altmaier of Florida adopted a new standard for insurance companies to report their climate-related risks, in alignment with the international Task Force on Climate-Related Financial Disclosures (TCFD). The TCFD standard is the international benchmark for climate risk disclosure and will help insurance regulators and the public to better understand the climate-related risks to the U.S. insurance market, which is the largest in the world. This announcement during the National Association of Insurance Commissioners' (NAIC) spring meeting in Kansas City, Missouri, puts U.S. state insurance regulators on the forefront of climate risk disclosure to protect consumers.
Commissioners Lara and Altmaier are co-chairs of the NAIC Climate Risk & Resiliency Task Force (Task Force), which was established in 2020 to coordinate all of the NAIC's domestic and international efforts on climate-related risk and resiliency issues. The Task Force developed the new TCFD-aligned survey over a 14-month public participation process led by Oregon Insurance Commissioner Andrew Stolfi and Rhode Island Superintendent Elizabeth Dwyer in coordination with Commissioners Lara and Altmaier, and marks the first update to the NAIC's Climate Risk Disclosure Survey approach since it was created in 2010.
The Task Force determined that implementing a TCFD-aligned disclosure framework would enhance transparency about how insurance companies manage climate-related risks and opportunities and incorporate international best practices, among other benefits that the Task Force identified in the new standard. Insurance regulators from France, Switzerland, and the United Kingdom currently require TCFD-aligned reports. U.S. financial regulators such as the U.S. Securities and Exchange Commission are also taking steps toward requiring TCFD-aligned disclosures for other financial institutions.
Under the new standard, insurance companies required to respond to the annual NAIC Climate Risk Disclosure Survey will need to comply with TCFD reporting by November 2022. Fifteen states – including California, Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, Minnesota, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, Vermont, and Washington – have committed to utilize the NAIC survey in 2022 for insurance companies licensed in their jurisdictions, representing nearly 80 percent of the U.S. insurance market. While 28 insurance companies provided TCFD-compliant reports in 2021, this list will grow to nearly 400 insurance companies and groups as a result of the consensus demonstrated today.
"Our global climate crisis affects every state, requiring us to reach across partisan divides to find solutions that protect all people," said California Insurance Commissioner Ricardo Lara. "By holding insurance companies to this global standard for climate disclosure, insurance regulators are showing the power of united leadership in our efforts to address climate change and reduce the negative impacts on insurance consumers."
"The NAIC's action shows that our system of state-based insurance regulation remains strong and flexible in responding to changing conditions in our markets and our world," said Florida Insurance Commissioner David Altmaier. "Thank you to my fellow regulators for your commitment to work together to protect consumers."
"We have all been affected by climate-related events, including wildfires, floods, and increased extreme weather. The first NAIC climate risk survey, created more than 10 years ago, led the way at the time, and it's great to see the NAIC lead again by being the first U.S. financial system regulator to adopt TCFD-aligned disclosure requirements," said Oregon Insurance Commissioner Andrew Stolfi. "I'm grateful for the robust participation in this process over the past year and the strong support to adopt internationally aligned climate risk disclosures, and I look forward to continuing our work by supporting insurers in shifting to this new reporting framework."
"Enacting the TCFD standard will give insurance regulators greater oversight of insurance companies' strategies for addressing climate change through investments, board governance, and all areas of their operation, helping us to protect consumers in the future by reducing climate risks," said Elizabeth Dwyer, Superintendent of Banking and Insurance for Rhode Island.
"Our bipartisan action to endorse a common standard for disclosing insurance companies' climate risks shows progress is possible on protecting consumers from the threats of a warming planet," said Maryland Insurance Commissioner Kathleen Birrane. "Through our collective state level actions we are protecting consumers from climate risks that affect our whole nation."
"I am delighted that the NAIC has adopted changes to our NAIC Climate Risk Disclosure Survey. Participating insurers will now disclose their climate change exposure using the internationally accepted TCFD," said Mike Kreidler, Insurance Commissioner of Washington and member of the Sustainable Insurance Forum. "Nearly 20 years ago I was privileged to start creating the Survey with my then-Climate Change Committee co-chair from Nebraska. I'm pleased that the Survey is now updated to reflect state-of-the-art disclosure requirements in line with international standards."
"Few regulators have more experience and insight into the macroeconomic effects of climate risk than insurance regulators," said Mike Consedine, Chief Executive Office of the National Association of Insurance Commissioners. "By modernizing the NAIC climate disclosure survey for the first time since its inception, participating members are taking a comprehensive and unified approach to protecting consumers through our state-based system of insurance regulation."
International regulators and climate groups who have called for compliance with TCFD disclosures welcomed the news.
"With insurance companies' investments and underwriting reaching around the globe, it is critical that insurance regulators speak the same language as we seek to protect markets from climate risks," said Anna Sweeney, who supervises the United Kingdom's insurance sector and serves as Chair of the UNDP Sustainable Insurance Forum. "With this landmark action by U.S. regulators, alongside the work of a number of leading jurisdictions, we are well on our way to holding the global insurance sector to the same standard, allowing nations and states to work across borders like never before."
"By putting U.S. insurance companies on the same level of accountability and transparency with other global sectors and insurance markets in terms of managing and disclosing climate risks, U.S. state insurance regulators are showing the kind of leadership on a national scale that will help meet the global goals of climate-resilient communities and net-zero economies," said Butch Bacani, who leads the U.N.'s Principles for Sustainable Insurance Initiative, the largest collaboration between the U.N. and the global insurance industry.
"Aligning U.S. insurance companies' climate disclosures with the global norm is a major step forward to protect financial markets and consumers who rely on insurance for safety and security," said Steven Rothstein, Managing Director, Ceres Accelerator for Sustainable Capital Markets "The bipartisan leadership of Commissioner Lara of California and Commissioner Altmaier of Florida is in short supply around the globe. It is needed more than ever before as we address climate-related financial risks across investment portfolios and global supply chains."
Media notes:
- The Task Force for Climate-Related Financial Disclosures released the standards in 2017. The Task Force consists of 31 members from G-20 nations. Click here to read more: https://www.fsb-tcfd.org/
- TCFD reporting includes sections on governance, strategy, risk management, investments, and metrics, requiring companies to measure their progress and commit to reducing climate risks across all areas of their business.
View original content:
SOURCE National Association of Insurance Commissioners
|
https://www.whsv.com/prnewswire/2022/04/08/us-insurance-commissioners-endorse-internationally-recognized-climate-risk-disclosure-standard-insurance-companies/
| 2022-04-08T19:00:36Z
|
Prevalence of leasing among younger consumers, preference for CUVs, SUVs, and trucks to drive value gains
CLEVELAND, April 8, 2022 /PRNewswire/ -- US consumer spending on motor vehicle (MV) leases is forecast to rise 1.3% per year in nominal dollars through 2025, according to Motor Vehicle Leasing: United States, a report recently released by Freedonia Focus Reports. Increased consumer leasing of crossover utility vehicles (CUVs), sports utility vehicles (SUVs), and trucks – which generally lease at a higher price point – will drive growth over the forecast period. Furthermore, those aged 18–34 years – the population cohort most likely to lease a car – will continue to fuel replacement demand for car leases, especially as they begin to start families, which often requires upsizing a vehicle to accommodate more passengers and luggage. Those in the 18-34 cohort will also be attracted to car leases due to the relatively low monthly payments compared to those of car loans, as this generation sustained long-term harm to wealth formation due to the 2007-2009 recession. People of this age group also tend to be technologically minded, making leasing more attractive for those seeking new MV features. Finally, with manufacturers continually expanding and improving the features installed in these vehicles, some consumers will choose the short term commitment of leasing so that they can more quickly update to the newest technology.
These and other key insights are featured in Motor Vehicle Leasing: United States. This report forecasts to 2021 and 2025 US personal consumption expenditures (PCE) on motor vehicle leases in nominal and real (inflation-adjusted) US dollars. Expenditures are segmented by vehicle type in terms of:
- automobiles
- CUVs, SUVs, and trucks
To illustrate historical trends, total PCE, the various segments, and price indexes by segment are provided in annual series from 2010 to 2020.
For the purpose of this report, trucks include light vehicles such as CUVs, pickup trucks, SUVs, and vans. Motorcycles are excluded from the scope of this report, as are medium- and heavy-duty trucks, and RVs (recreational vehicles).
PCE data include spending by nonprofit institutions serving households (e.g., the value of education services provided by nonprofit colleges or medical care provided by nonprofit hospitals). Consequently, the spending by such parties on motor vehicle leases is included.
More information about the report is available at:
https://www.freedoniafocusreports.com/Motor-Vehicle-Leasing-United-States-FF95043/?progid=91541
Each month, The Freedonia Group – a division of MarketResearch.com – publishes over 20 new or updated Freedonia Focus Reports, providing fresh, unbiased analysis on a wide variety of markets and industries. Published in 20-30 pages, Focus Report coverage ranges from raw materials to finished manufactured goods and related services such as freight and construction. Additional Services & Industries reports can be purchased at Freedonia Focus Reports or MarketResearch.com.
Analysis is intended to guide the busy reader through pertinent topics in rapid succession, including:
- total historical market size and industry output
- segmentation by products and markets
- identification of market drivers, constraints, and key indicators
- segment-by-segment outlook in five-year forecasts
- a survey of the supply base
- suggested resources for further study
Press Contact:
Corinne Gangloff
+1 440.842.2400
cgangloff@freedoniagroup.com
View original content to download multimedia:
SOURCE The Freedonia Group
|
https://www.whsv.com/prnewswire/2022/04/08/us-spending-mv-leases-rise-consumers-opt-larger-pricier-vehicles/
| 2022-04-08T19:00:43Z
|
DALLAS, April 8, 2022 /PRNewswire/ -- Vertical Capital Income Fund (NYSE: VCIF) today announced a distribution of $0.0742 per share pursuant to the Fund's managed distribution plan (the "Plan"), payable as follows:
Declaration – 4/8/2022 Ex-Date – 4/18/2022 Record Date – 4/19/2022 Payable – 4/29/2022
Pursuant to the Plan, the Fund pays a minimum monthly distribution to shareholders at a stated annual rate as a percentage of the 3-month average net asset value ("NAV") of the Fund's shares prior to the month of distribution. The distribution is calculated as 8% of the previous three-month average NAV, divided by 12. The primary purpose of the Plan is to provide investors with consistent, but not guaranteed, periodic distributions from the Fund, regardless of when or whether income is earned or capital gains are realized. Distributions under the Plan may consist of (i) net investment income, (ii) net realized short-term capital gains, (iii) net realized long-term capital gains and, to the extent necessary, (iv) return of capital (or other capital sources). With each distribution that does not consist solely of net investment income, the Fund will issue a notice to shareholders and an accompanying press release that will provide detailed information regarding the amount and composition of the distribution, as well as certain other related information. The Fund expects to issue any such notice and press release on or about the distribution payment date.
The Fund had approximately $2.9 million in cash as of March 31, 2022. Approximately $8.25 million was committed as of the same date in the acquisition pipeline to loans that have already been awarded to the Fund and were either in due diligence or through due diligence and awaiting closing. Pending acquisitions are subject to various closing conditions, and the Fund cannot guarantee that those acquisitions will close.
A new monthly net asset value per share of $10.97 was produced on March 31, 2022. For information on the Fund's current net asset value per share, please visit the Fund's website at vcif.us.
The Plan will be subject to periodic review by the Board, and the Board may amend the terms of the Plan including amending the annual rate of payment or may terminate the Plan at any time without prior notice to the Fund's shareholders. The Fund's distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors. There can be no assurance that an unanticipated change in market conditions or other unforeseen factors will not result in a change in the Fund's distribution rate at a future time. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund's shares. The public health crises caused by the COVID-19 outbreak may exacerbate other pre-existing political, social and economic risks to which the Fund is exposed. The duration of the COVID-19 outbreak and its effects cannot be determined with certainty. In order to comply with the requirements of Section 19 of the Investment Company Act of 1940, and an exemptive order received by the Fund from the Securities and Exchange Commission, the Fund will provide its shareholders of record on each distribution date with a 19(a) Notice and issue an accompanying press release disclosing the sources of its distribution payment when a distribution includes anything other than net investment income. This information will be forthcoming later this month.
The amounts and sources of distributions reported in 19(a) Notices are only estimates and are not provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its full fiscal year and may be subject to changes based on tax regulations. The Fund will send shareholders a Form 1099-DIV for the calendar year that will tell them how to report these distributions for federal income tax purposes. Information on the Fund's 19(a) Notices, if any, can be found at www.vcif.us. The final determination of the source and tax characteristics of all distributions in 2022 will be made after the end of the year.
Shares of closed-end funds often trade at a discount from their net asset value. The market price of Fund shares may vary from net asset value based on factors affecting the supply and demand for shares, such as Fund distribution rates relative to similar investments, investors' expectations for future distribution changes, the clarity of the Fund's investment strategy and future return expectations, and investors' confidence in the underlying markets in which the Fund invests. Fund shares are subject to investment risk, including possible loss of principal invested. No Fund is a complete investment program and you may lose money investing in a Fund. An investment in the Fund may not be appropriate for all investors. Before investing, prospective investors should consider carefully the Fund's investment objective, risks, charges and expenses. For further details, please visit Vertical Capital Income Fund's website at vcif.us.
This release contains forward-looking statements relating to the business and financial outlook of Vertical Capital Income Fund that are based on the Fund's current expectations, estimates, forecasts and projections and are not guarantees of future performance. There is no assurance that the Fund will achieve its investment objective. Actual results may differ materially from those expressed in these forward-looking statements, and you should not place undue reliance on any such statements. A number of important factors could cause actual results to differ materially from the forward-looking statements contained in this release.
Vertical Capital Income Fund (VCIF) is an NYSE-listed closed-end fund that seeks monthly income by investing primarily in performing non-agency residential whole loans secured by real estate. As a secondary strategy the Fund aims to provide total return by acquiring performing residential loans at a discount to the unpaid principal balance (UPB). VCIF realizes capital gains as loans are paid off before maturity. For more information visit VCIF.us and connect with the Fund on Twitter.
Oakline Advisors, LLC is the adviser to Vertical Capital Income Fund. Founded in 2013, Oakline Advisors, LLC is an SEC-registered investment adviser that specializes in the residential whole loan market. It is a wholly owned subsidiary of Dallas, TX-based Behringer. Since its inception in 1989, Behringer, together with its affiliates, has raised equity of more than $6 billion in assets through public and private fund structures. For more information about Oakline and Behringer please visit their respective websites at oaklineadvisors.com and behringerinvestments.com.
Fund shares are identified by CUSIP 92535C104
View original content to download multimedia:
SOURCE Vertical Capital Income Fund
|
https://www.whsv.com/prnewswire/2022/04/08/vertical-capital-income-fund-vcif-declares-april-2022-distribution/
| 2022-04-08T19:00:50Z
|
Keep pets safe on the road this National Pet Day
AUCKLAND, New Zealand, April 8, 2022 /PRNewswire/ -- New Zealand pets will soon be seen in all the right places after dark, as Southern Cross Pet Insurance collaborates with international designer to the stars, Matthew Adams Dolan on an exclusive range of high-fashion hi-vis dog wear. Dolan first shot to fashion fame when superstar Rihanna modelled one of his signature oversized jackets. He's since gone on to dress the likes of Lady Gaga and Gigi Hadid, so his unique range for New Zealand's furry fashionistas means lucky recipients will be more than ready for the 'dogwalk'.
'VIS - The Road Safety Collection' comprises eight couture hi-vis pieces including stylish reflective puffers, vests, sweaters and bandanas, created to support the Live Your Pet Life campaign; a project designed by advertising agency TBWA\New Zealand to help New Zealand's pets live happier and healthier lives, for longer.
Dolan says he was thrilled to create the collection on behalf of New Zealand's dogs. "As a dog-lover and owner of Maisie, I was delighted to receive such an exciting brief. To save lives and be fashionable with it, I've been on an amazing journey working with the Southern Cross team to highlight road safety issues for pets and make products which can be integrated so easily into everyday situations.
"While some owners will love the full couture look, others will appreciate the simplicity of a reflective bandana which can be worn regardless of the type of leash or harness they use when walking their pup after dark. To be safe, we just need our furbabies to be seen, but by all means let's make them look good too. Our next step may be better looking road-safety gear for humans!"
Anthony McPhail, GM Southern Cross Pet Insurance says, "We'd much rather help prevent beloved pets needing care with top-notch protective gear, than have to treat a painful injury. I'm excited to see how New Zealand responds to the VIS Collection. The hi-vis fashion collection helps highlight the ways in which owners can ensure their pets' wellbeing, including being careful while out walking at night.
"We wanted a fun way to show pet owners how important it is to keep our beloved pups safe while they're out for their walk, especially as we head into the shorter days and colder weather."
"So, we were thrilled when Matthew Adams Dolan agreed to design this range of hi-vis wear. Some very lucky, and very safe, pooches are certainly going to be turning heads on their evening walks this winter."
Southern Cross Pet Insurance customers will have a chance to win one of five exclusive VIS items, while one dog owner will also have the very special opportunity to win a bespoke piece for their pooch via an online auction. Profits from that auction will be donated to charity partner, Pet Refuge. Other pet owners will also be in to win one of many special Matthew Adams Dolan-designed VIS pet bandanas. Details can be found on Southern Cross Pet Insurance's website.
The Live Your Pet Life campaign aims to ultimately raise the average life expectancy of New Zealand's cats and dogs.
To watch the 2-minute interview with Matthew Adams Dolan click here.
For hi-res imagery click here.
To watch the AV click here.
To download VIS - The Road Safety Collection official look book click here
About Southern Cross Pet Insurance:
Southern Cross Pet Insurance helps New Zealanders care for their pets, currently looking after the health of over 54,000 domestic animals. In FY21, the business paid out more than $18.21 million in claims (including GST). It also sponsors Pet Refuge, which provides shelter for pets affected by domestic violence, and is also a trusted partner of the New Zealand Veterinary Association. Southern Cross is a group of independent businesses united by a shared brand with an interest in the health and wellbeing of New Zealanders. With a range of products and services and a not-for-profit ethos, Southern Cross is New Zealand's leading independent provider and funder of healthcare.
About TBWA\New Zealand
TBWA is The Disruption® Company. We use creativity to help businesses challenge the status quo and capture an unfair share of the future. Named one of the World's Most Innovative Companies by Fast Company in 2022, 2021, 2020 and 2019, and Adweek's 2021 and 2018 Global Agency of the Year, we are a creative company that uses trademarked Disruption® methodologies to help businesses address their challenges and achieve transformative growth. Our collective has 10,000+ creative minds in 41 countries, and TBWA\NZ Group includes The Digital Arts Network and Eleven PR. Local clients include ANZ Bank NZ, 2degrees, The Warehouse Group, Southern Cross, Anchor, Asahi Beverages NZ Ltd, Sony PlayStation, South Australian Tourism among others. Follow us on Twitter LinkedIn and Instagram, and like us on Facebook.
View original content to download multimedia:
SOURCE TBWA\Worldwide
|
https://www.whsv.com/prnewswire/2022/04/08/vis-pet-road-safety-collection-by-celeb-fashion-designer-matthew-adams-dolan/
| 2022-04-08T19:00:56Z
|
MEXICO CITY, April 8, 2022 /PRNewswire/ -- Volaris* (NYSE: VLRS and BMV: VOLAR), announces a summons for the general ordinary annual shareholders' meeting to be held on April 26, 2022.
Under Mexican law Volaris needs to hold a general ordinary shareholders' meeting at least once a year in respect of general corporate matters. A courtesy English translation of this year's shareholders' meeting agenda is attached as exhibit.
The information included in this report has not been audited and it does not provide information on the company's future performance. Volaris' future performance depends on many factors and it cannot be inferred that any period's performance or its comparison year over year will be an indicator of a similar performance in the future.
About Volaris:
Controladora Vuela Compañía de Aviación, S.A.B. de C.V. ("Volaris" or the "Company") (NYSE: VLRS and BMV: VOLAR), is an ultra-low-cost carrier, with point-to-point operations, serving Mexico, the United States, Central and South America. Volaris offers low base fares to build its market, providing quality service and extensive customer choice. Since the beginning of operations in March 2006, Volaris has increased its routes from 5 to more than 188 and its fleet from 4 to 105 aircraft. Volaris offers more than 500 daily flight segments on routes that connect 44 cities in Mexico and 27 cities in the United States, Central and South America with one of the youngest fleet in Mexico. Volaris targets passengers who are visiting friends and relatives, cost-conscious business and leisure travelers in Mexico, the United States, Central and South America. Volaris has received the ESR Award for Social Corporate Responsibility for eleven consecutive years. For more information, please visit: www.volaris.com.
CALL TO
A GENERAL ORDINARY ANNUAL SHAREHOLDERS MEETING
CONTROLADORA VUELA COMPAÑÍA DE AVIACIÓN, S.A.B. DE C.V.
By resolution of the Board of Directors of CONTROLADORA VUELA COMPAÑÍA DE AVIACIÓN, S.A.B. DE C.V. (the "Company"), and pursuant to articles 179, 180, 181, 183, 186 and other applicable articles of the General Law of Commercial Companies and clauses Seventeenth, Eighteenth and Nineteenth and other applicable clauses of the corporate by-laws, holders of Series "A" and Series "B" shares of the capital stock of the Company, are hereby summoned to a general ordinary annual shareholders meeting to be held on April 26, 2022 at 10:00 (ten) hours, in the corporate domicile of the Company located at Avenida Antonio Dovalí Jaime No. 70, Building B, Floor 13, Colonia Zedec Santa Fe, Alcaldía Álvaro Obregón, C.P. 01210, Mexico City, Mexico in order to deal with the subject-matters contained in the following:
AGENDA
I. Presentation and, if applicable, approval of the reports referred to article 28, section IV, of the Securities Market Law including the presentation of the consolidated financial statements for the year ended on December 31, 2021, and resolutions regarding the performance of the Board of Directors, Committees and Chief Executive Officer of the Company.
II. Resolutions regarding the allocation of the results for the fiscal year ended on December 31, 2021.
III. Resolutions of (i) the amount that could be allocated to the purchase of Company´s shares in accordance with article 56, section IV, of the Securities Market Law; and (ii) the report regarding the policies and resolutions adopted by the Board of Directors of the Company, regarding the purchase and sale of such shares.
IV. Appointment and/or ratification of the members of the Board of Directors, of the secretary, prosecretary and principal officers of the Company.
V. Appointment and/or ratification of the chairman of the Audit and Corporate Practices Committee of the Company.
VI. Resolutions regarding the compensation to the members of the Board of Directors, Audit and Corporate Practices Committee, Compensations and Nominations Committee and the secretary of the Board of Directors of the Company.
VII. Appointment of delegates who will carry out and formalize the resolutions adopted by this meeting.
Pursuant to clause Nineteenth of the corporate by-laws, in order to have the right to attend the meeting, shareholders must be registered in the Stock Registry Book of the Company and present the corresponding admission card, which must be requested no later than forty-eight hours prior to the start of the shareholders meeting at the domicile of the secretary of the Company located at Javier Barros Sierra 540, Building 1, Floor 4, Col. Santa Fe, 01210, Mexico City, Mexico, by depositing the corresponding share certificates or provide evidence of the corresponding deposit certificates of such shares issued by S.D. Indeval Institución para el Depósito de Valores, S.A. de C.V., by a Mexican credit or foreign institution, or by an authorized brokerage firm. In order to obtain the above-mentioned admission card, the depositors with S.D. Indeval Institución para el Depósito de Valores, S.A. de C.V., must enclose to the statements issued by such institution, the lists that identify the names of the corresponding shareholders.
Shareholders or holders of other securities referred to Series "A" and "B" of the Company, may be represented by attorneys-in fact who must evidence their authority by means of a power-of-attorney granted in terms of the form prepared by the Company in compliance with paragraph III of Article 49 of the Mexican Securities Market Law and the corporate by-laws. Additionally, shareholders of Series "A" shares not held in the neutral investment trust established by the Company must prove their status as Mexican Investors (as such term is defined below), either directly or through the aforementioned forms, in order for the Company to verify their status.
Pursuant to Clause Six of the Company's by-laws, the Series A shares may be subscribed and paid for or acquired exclusively by Mexican individuals or Mexican legal entities with a foreigner exclusion clause or with a majority of Mexican capital and controlled by Mexican capital (any of them, a "Mexican Investor" and, collectively, the "Mexican Investors"), in accordance with the applicable legislation regarding foreign investment in Mexico.
Any person who is not a Mexican Investor and who participates directly or indirectly in the capital stock of the Company will maintain his or her participation through Ordinary Participation Certificates ("CPOs") and/or through American Depositary Shares ("ADSs") and/or American Depositary Receipts ("ADRs"), as applicable, and in any case, neither the CPOs and/or ADSs and/or ADRs grant any voting rights.
The Series A shares held in the neutral investment trust executed by the Company with Nacional Financiera, Sociedad Nacional de Crédito, Institución de Banca de Desarrollo, Dirección Fiduciaria will be voted in the same manner as the Series A Shares not held in the, that is, in the same manner as the majority of the Mexican Investors. Pursuant to Clause Nineteenth of the Company's Bylaws, attendance and the exercise of voting rights are subject to the proper and sufficient accreditation of the Mexican Investment, on the understanding that, in the event that the information is insufficient or not proper, or the forms do not comply with the forms prepared by the Company and authorized by the Secretary of Economy, the Secretary of the Shareholder Meeting will not recognize or give any value to such forms, or the forms do not comply with the forms prepared by the Company and authorized by the Ministry of Economy, the Secretary of the Shareholders Meeting will not recognize or give any value to such forms, and therefore the Series A shares in question will not be counted for purposes of the quorum for installation or voting at the Shareholders Meeting.
The abovementioned forms and admission cards may be requested at the above-mentioned Secretary's domicile, within the fifteen days prior to the date on which the meeting will be held, from 10:00 to 14:00 hours and from 16:00 to 18:00 hours. Likewise, the information related to the agenda will be available to the shareholders or their representatives, at the above-mentioned hours and domicile, within at least fifteen days prior to the date of the meeting.
DUE TO THE NATIONAL CONTINGENCY DERIVED FROM COVID-19, IT IS HEREBY INFORMED THAT THE LOCATION WHERE THE MEETING WILL TAKE PLACE WILL BE LARGE ENOUGH TO COMPLY WITH THE REQUIRED DISTANCE PROTOCOLS. LIKEWISE, OTHER HEALTH AND SANITATION PROTOCOLS WILL BE FULFILLED FOR THE SAFETY OF THOSE PRESENT AT THE MEETING. IN THE CASE OF ISSUANCE OF ANY RULING OR DISPOSITION THAT REQUIRES US TO MAKE ANY AMENDMENTS TO THIS CALL, WE WILL INFORM SHAREHOLDERS IN DUE TIME.
Mexico City, on April 8, 2022.
_________________________________
Jaime Esteban Pous Fernández
Secretary of the Board of Directors
Investor Relations Contact
Félix Martínez / Naara Cortés Gallardo / ir@volaris.com
Media Contact
Gabriela Fernández / gabriela.fernandez@volaris.com
View original content to download multimedia:
SOURCE Volaris
|
https://www.whsv.com/prnewswire/2022/04/08/volaris-announces-summons-general-ordinary-annual-shareholders-meeting/
| 2022-04-08T19:01:03Z
|
Betty White’s personal possessions to go up for auction
(CNN) - Fans of the famous actress Betty White will have a chance to own several keepsakes from her lustrous career as the first lady of television.
Julien’s Auctions in Beverly Hills, California, is putting 1,500 of her treasured possessions on the auction block this fall.
The items include everything from her award show gowns to her jewelry, home furnishings and even her “Golden Girls” director’s chair.
The collection also includes certificates for her 21 Emmy nominations and rare photos of her personal life and work on behalf of animal rights.
With all the memorabilia spanning White’s eight-decade career in entertainment, the auction is scheduled to take three days starting Sept. 23.
Fans will also be able to make their bids remotely, according to Julien’s Auctions.
Copyright 2022 via CNN Newsource. All rights reserved.
|
https://www.wvva.com/2022/04/08/betty-whites-personal-possessions-go-up-auction/
| 2022-04-08T20:14:22Z
|
Homeless teen surrenders dog because he can no longer care for her, shelter says
SENATOBIA, Miss. (Gray News) - A homeless teenager surrendered his dog to an animal shelter because he could no longer provide proper care to the animal, according to the shelter.
The Senatobia-Tate County Animal Shelter in Mississippi said a 17-year-old surrendered his dog to the shelter Tuesday.
In a Facebook post, the shelter said that the teen lives under a bridge and walked all the way to the shelter, where he asked the staff to please take his dog because he couldn’t afford to keep her.
The shelter said the dog is about 4 months old and stayed pinned to her owner’s legs while he dropped her off. A photo of the dog lying in the shelter’s lobby went viral.
“This is where she laid after her owner surrendered her today with her plastic bag of dog food and a blanket. She is devastated,” the caption reads.
The shelter received an outpouring of interest on how to help both the dog and the homeless teen. On Friday, the shelter said the teen now has a place to stay and will soon be getting his dog back.
The shelter is hoping to get the dog spayed and get enough flea, tick and heartworm prevention to last at least a year.
If you would like to help the dog and her owner, you can donate through PayPal to the user account fosasenatobia@gmail.com, and mention “Jada” in your comment.
“I hope his selfless actions have made people think about the animals in this community - they deserve a chance, they don’t deserve to be dumped anywhere,” the shelter’s Facebook post reads. “Thanks everyone for your concern for both of them - the response from people everywhere has been touching.”
Copyright 2022 Gray Media Group, Inc. All rights reserved.
|
https://www.wvva.com/2022/04/08/homeless-teen-surrenders-dog-because-he-can-no-longer-care-her-shelter-says/
| 2022-04-08T20:14:28Z
|
WATCH: Bear smashes through windshield after destroying inside of N.C. family’s SUV
ASHEVILLE, N.C. (WHNS/Gray News) - A black bear in North Carolina was caught on camera attempting to get out of a family’s SUV through the windshield after being stuck inside overnight.
Ashley McGowin said she went to walk her dogs at 6:30 a.m. on Friday when she saw the hazard lights on her SUV blinking, WHNS reported.
When she went to see what it was, she discovered a bear trapped inside the vehicle.
The family believes the bear was able to open an unlocked door to get inside. It then destroyed the inside of the car before smashing the windshield in order to get back out.
The family recorded the bear while it was stuck trying to climb through the windshield.
McGowin said along with the damage to the car, the bear also urinated on her son’s homework that was in the SUV.
After making its escape, the bear was reunited with its two cubs.
The family reported it had a tracker on its ear.
Neighbors told McGowin they heard honking around midnight so she believes the bear was trapped in the SUV for more than six hours.
McGowin said they see bears around their house four to five times a week, but never in a situation like this before.
Copyright 2022 WHNS via Gray Media Group, Inc. All rights reserved.
|
https://www.wvva.com/2022/04/08/watch-bear-smashes-through-windshield-after-destroying-inside-nc-familys-suv/
| 2022-04-08T20:14:36Z
|
Will Smith gets 10-year Oscars ban for Chris Rock slap
LOS ANGELES (AP) — The motion picture academy on Friday banned Will Smith from attending the Oscars or any other academy event for 10 years following his slap of Chris Rock at the Academy Awards.
The move comes after a meeting of the academy’s Board of Governors to discuss a response to Smith’s actions.
“The 94th Oscars were meant to be a celebration of the many individuals in our community who did incredible work this past year; however, those moments were overshadowed by the unacceptable and harmful behavior we saw Mr. Smith exhibit on stage,” the academy said in a statement.
Smith pre-emptively resigned from the academy last week during the run-up to the meeting and said he would accept any punishment the academy handed down.
“I accept and respect the Academy’s decision,” Smith said in a statement.
The academy also apologized for its handling of the situation and allowing Smith to stay and accept his best actor award for “King Richard.”
“During our telecast, we did not adequately address the situation in the room. For this, we are sorry,” the academy said. “This was an opportunity for us to set an example for our guests, viewers and our Academy family around the world, and we fell short — unprepared for the unprecedented. "
In a statement in the days following the Oscars, the academy said Smith was asked to leave the ceremony but refused.
But it’s not clear how the message was delivered to Smith or what form it took, and several media outlets reported that he was never formally told to leave the Dolby Theatre. The Los Angeles Times reported in a story Thursday that Oscars producer Will Packer told Smith: “Officially, we don’t want you to leave. We want you to stay.”
The ban means Smith will not be presenting one of the major awards at next year’s Oscars, as is tradition for the best actor winner.
The academy in its Friday statement also expressed “deep gratitude to Mr. Rock for maintaining his composure under extraordinary circumstances.”
The academy’s statement did not address whether Smith could be nominated for Oscars during his 10-year ban. Nor did it take any action to revoke Smith’s Academy Award.
The academy has not revoked Oscars from expelled members Harvey Weinstein or Roman Polanski.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wvva.com/2022/04/08/will-smith-banned-oscars-10-years-slapping-chris-rock/
| 2022-04-08T20:14:45Z
|
Woman might need third amputation after surviving vicious dog attack, family says
ABBEVILLE COUNTY, S.C. (WHNS/Gray News) - A South Carolina woman who remains in the hospital weeks after being seriously injured by several dogs might need additional surgery.
WHNS reports Kyleen Waltman was mauled by three dogs, two of which were pit bulls, outside a home on Ball Road in Honea Path last month.
Her family said the recent grandmother had both of her arms amputated after the attack. Since then, she has been fighting for her life in the ICU.
Earlier this week, Waltman’s family said she has to be sedated often due to her spinal cord injury and breathing and blood pressure issues. Doctors did wake her up on March 29 so she could talk to her daughters and mother.
Waltman’s family said she had a skin graft on her right leg on Thursday, and her left leg might have to be amputated if it doesn’t heal.
The family has asked the community to continue to pray for her recovery.
Waltman recently underwent her 10th surgery since the attack.
A GoFundMe for Waltman’s medical expenses has raised more than $190,000.
Copyright 2022 WHNS via Gray Media Group, Inc. All rights reserved.
|
https://www.wvva.com/2022/04/08/woman-might-need-third-amputation-after-surviving-vicious-dog-attack-family-says/
| 2022-04-08T20:14:52Z
|
2 men arrested with enough fentanyl to kill 4.7 million people, officials say
BUENA PARK, Calif. (Gray News) - Officials in Southern California report police have taken two men into custody with hundreds of pounds of drugs, which has resulted in the biggest bust in the last 16 years in Orange County.
According to the Orange County District Attorney’s Office, a lethal dose of fentanyl is as little as 2 milligrams, and authorities recovered nearly 21 pounds of fentanyl pills after Buena Park police pulled over a minivan leaving a house on March 17.
Police also said they found about 821 pounds of methamphetamine and 190 pounds of cocaine.
Edgar Alfonso Lamas, 36, and Carlos Raygozaparedes, 53, were the men arrested in the drug bust. The district attorney’s office reports the two face several felony charges, including possession of a controlled substance and the sale or transportation of a controlled substance.
Police said the alleged two drug dealers were also charged with felony enhancements that the controlled substances exceeded 80 and 20 kilograms by weight or 400 liters by liquid volume.
“Millions of unsuspecting people have the grim reaper looking over their shoulder. They have no idea how close they actually are to dying from taking a single pill,” said Orange County District Attorney Todd Spitzer. “Fentanyl is cheap, it’s easy to get, and it is killing our children, our co-workers, and tens of thousands of innocent Americans who don’t have to die. Drug dealers don’t care about you or your loved ones – they only care about their bottom line and making as much money as possible.”
Lamas and Raygozaparedes face a maximum sentence of 37 years and four months in jail if convicted on all charges. According to the district attorney’s office, the two have pled not guilty and remain in custody on a $5 million bail.
According to court records, a preliminary hearing is scheduled for the two men on June 7 in Fullerton, California.
“With fentanyl in an estimated 40 percent of street drugs, it’s not a matter of if but when someone you know, and love dies from fentanyl. We have to continue to do everything we can to combat this deadly drug epidemic and save lives,” Spitzer said.
Copyright 2022 Gray Media Group, Inc. All rights reserved.
|
https://www.whsv.com/2022/04/07/2-men-arrested-with-enough-fentanyl-kill-47-million-people-officials-say/
| 2022-04-08T20:33:05Z
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.